

STIC Database Tracking Number: 295297

**To: Ken Nguyen**  
**Location: Hoteling**  
**Art Unit: 3626**  
**Date: 05/19/09**  
**Case Serial Number: 10/813421**

**From: Eileen Patton**  
**Location: EIC3600**  
**KNX 2D08A**  
**Phone: (571) 272-3413**  
**eileen.patton@uspto.gov**

## Search Notes

Dear Examiner Nguyen:

Please find attached the results of your search for the above-referenced case. The search was conducted in Dialog, ProQuest, EBSCOhost, and the internet.

I have listed *potential* references of interest in the first part of the search results. However, please be sure to scan through the entire report. There may be additional references that you might find useful.

If you have any questions about the search, or need a refocus, please do not hesitate to contact me.

Thank you for using the EIC, and we look forward to your next search!

I.	POTENTIAL REFERENCES OF INTEREST .....	3
A.	Dialog .....	3
B.	Additional Resources Searched.....	10
II.	INVENTOR SEARCH RESULTS FROM DIALOG .....	18
III.	TEXT SEARCH RESULTS FROM DIALOG .....	25
A.	Patent Files, Abstract.....	25
B.	Patent Files, Full-Text.....	41
IV.	TEXT SEARCH RESULTS FROM DIALOG .....	57
A.	NPL Files, Abstract.....	57
B.	NPL Files, Full-text .....	80
V.	ADDITIONAL RESOURCES SEARCHED .....	106
A.	Google: .....	106
B.	ProQuest .....	106

*\*EIC-Searcher identified “potential references of interest” are selected based upon their apparent relevance to the terms/concepts provided in the examiner’s search request.*

## **I. Potential References of Interest**

### **A. Dialog**

25/3,K/26 (Item 21 from file: 149)  
DIALOG(R)File 149: TGG Health&Wellness DB(SM)  
(c) 2009 Gale/Cengage. All rights reserved.

01526822 **Supplier Number:** 08096369 (USE FORMAT 7 OR 9 FOR FULL TEXT )  
**Allergy testing.**

Sobel, David S.; Ferguson, Tom  
The People's Book of Medical Tests , p371(3)  
Edition 1 ,  
1985

**Publication Format:** Reference Book

**Language:** English

**Record Type:** Fulltext **Target Audience:** Consumer

**Word Count:** 1071 **Line Count:** 00087

...location, habits, or exposures can provide essential clues. Seasonal variations suggest pollen allergy. Symptoms that occur repeatedly after eating certain foods point to a food **allergy**. If avoiding these **suspected allergens results** in an improvement of symptoms, this helps confirm your suspicions. **It may be useful to keep a journal of allergic symptoms for several weeks to...** ...taking does not suggest the substance or substances responsible, allergy testing may be helpful.

Skin tests (scratch and intradermal injection) are most often done to **identify** inhaled **allergens** which may be **causing** the sneezing, runny nose, and nasal congestion of hay fever or the wheezing of asthma. Skin tests are occasionally performed for evaluation of hives or...

25/3,K/28 (Item 23 from file: 149)  
DIALOG(R)File 149: TGG Health&Wellness DB(SM)  
(c) 2009 Gale/Cengage. All rights reserved.

01057140 **Supplier Number:** 02903960 (USE FORMAT 7 OR 9 FOR FULL TEXT )  
**Skin perfect.**

Health , v15 , p46(4)  
Sept ,  
1983

**Publication Format:** Magazine/Journal

ISSN: 0279-3547

**Language:** English

**Record Type:** Fulltext **Target Audience:** Consumer

**Word Count:** 1587 **Line Count:** 00155

...you have a certain set of symptoms and use a certain set of cosmetics. Using the computer to match information, the physician narrows down the list of potential allergy-causing substances. Then, for each ingredient, the computer spells out the patch testing technique (for instance, what concentration of the ingredient to use and where to place...

21/3K/12 (Item 6 from file: 349)

DIALOG(R)File 349: PCT FULLTEXT

(c) 2009 WIPO/Thomson. All rights reserved.

01058481

**LOW ALLERGEN PLANT AND ANIMAL GENOTYPES**

GENOTYPES ANIMAUX ET VEGETAUX PEU ALLERGENES

**Patent Applicant/Patent Assignee:**

**THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;** 1111 Franklin Street, 12th floor, Oakland, CA 94607-5200  
US; US (Residence); US (Nationality)  
(For all designated states except: US)

**Patent Applicant/Inventor:**

**BUCHANAN Robert B**

19 Tamalpais Road, Kensington, CA 94708; US; US (Residence); US (Nationality); (Designated only for: US)

**LEMAUX Peggy G**

253 Corlis Drive, Moraga, CA 94556; US; US (Residence); US (Nationality); (Designated only for: US)

**WONG J H**

55 Sylvan Drive, San Francisco, CA 94132; US; US (Residence); US (Nationality); (Designated only for: US)

**CHO Myeong-Je**

c/o The Regents of the University of California, 1111 Franklin Street, 12th Floor, Oakland, CA 94607-5200; US; US (Residence); -- (Nationality); (Designated only for: US)

**FRICK Oscar L**

370 Parnassus Avenue, San Francisco, CA 94117; US; US (Residence); US (Nationality); (Designated only for: US)

**Legal Representative:**

**LITTLEFIELD Otis B et al(agent)**

Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105-2482; US;

	Country	Number	Kind	Date
Patent	WO	200386052	A2-A3	20031023
Application	WO	2003US10910		20030411
Priorities	US	2002372253		20020411

**Detailed Description:**

...tiny amount of allergen under the skin, usually on the upper arms or the abdomen of dogs.

#### ORAL CHALLENGE TESTS

Challenge tests involve having a **patient inhale** or swallow a very small amount of the **suspected allergen**, such as milk or an antibiotic. If there is no reaction, the dose may be slowly increased. Since challenge tests may induce severe allergic reactions...see footnote to Table 2). In this case,, Yecora Rojo appeared to be the highest by a narrow margin. The differences among these lines were **statistically significant** (p value=0.0285). Again, the allergenicity of the other lines was intermediate.

Table 2. Skin test response to gliadin fraction from different wheat lines.

Yecora Ward... ..concentration giving a reaction among the wheat lines could be applied to an authentic population of wheat-sensitive dogs (Table 4). To this end, we **calculated** the **probability** of an **allergenic response** induced within a given line relative to the response of the strongest line. We based the calculation on the lowest amount...a reaction between homozygote and the null segregant could be applied to an authentic population of wheat-sensitive dogs (Table 10). To this end, we **calculated** the **probability** of an allergenic response induced within a given homozygote relative to the response of the null segregant. We based the calculation on the lowest amount...

39/3,K/1 (Item 1 from file: 350)

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0014469970 *Drawing available*

WPI Acc no: 2004-661414/200464

XRPX Acc No: N2004-523720

**Skin allergic reaction inspecting apparatus, has microcomputer calculating relative values of respective bloodstreams at measured portions to be tested for allergic reaction or subjected to patch test**

Patent Assignee: FUJII H (FUJI-I); UNIV KYUSHU (UYKY-N)

Inventor: FUJII H

Patent Family ( 4 patents, 2 countries )

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20040176701	A1	20040909	US 2003654325	A	20030902	200464	B
JP 2004267308	A	20040930	JP 200359345	A	20030306	200464	E
JP 4048274	B2	20080220	JP 200359345	A	20030306	200816	E
US 7351209	B2	20080401	US 2003654325	A	20030902	200825	E

Priority Applications (no., kind, date): JP 200359345 A 20030306; US 2003654325 A 20030902

**Skin allergic reaction inspecting apparatus, has microcomputer calculating relative values of respective bloodstreams at measured portions to be tested for allergic reaction or subjected to patch test ...Original Titles:**Apparatus for inspecting **allergic** reaction... ..Apparatus for inspecting **allergic** reaction **Alerting Abstract**

...NOVELTY - The apparatus has a microcomputer calculating relative values of respective bloodstreams at measured portions to be tested for an **allergic** reaction or subjected to a patch test. The calculation is done based on an average value of the bloodstreams measured at portions of a skin... DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of inspecting an **allergic** reaction of a skin after subjected to a patch test for checking an **allergen**. ... ..USE - Used for inspecting an **allergic** reaction of a skin by a substance e.g. cosmetics, fibers, metals and itching or inflammation, after subjected to a patch test for checking an **allergen** before treatment or surgery... ..ADVANTAGE - The **allergens** can be specified with a small number of inspection and

high precision when a **calculating** unit for obtaining a **correlation coefficient** between the obtained results, i.e., measured values, and a contained amount of the respective components in a specimen solution used for the measurement are ...

**Original Abstracts:** Disclosed are an apparatus for inspecting an **allergic** reaction comprising a light-projecting device for projecting a laser light upon an object having a bloodstream; a light-receiving device for receiving laser beams... ... the information in a map state, wherein the calculating means comprises calculating relative values of the respective bloodstreams at measured portions to be tested the **allergic** reaction or subjected to a patch test based on an average value of the bloodstreams measured at portions other than the portion to be tested... ... test as a standard value, and the display device comprises plotting the relative values obtained in the calculating device, and a method of inspecting an **allergic** reaction of a skin after subjected to a patch test for checking an **allergen**(s)... ... An apparatus for inspecting an **allergic** reaction projects laser light onto an object having a bloodstreams and receives, using a light sensor, light rays scattered by blood cells at the surface... ... on signals output from the light sensor, the apparatus calculates respective relative values of the bloodstreams at a portion of the object subjected to an **allergic** reaction test, wherein the relative values are relative to an average value of the bloodstreams measured at a portion of the object other than the portion subjected to the **allergic** reaction test which is not affected by the **allergic** reaction test. The apparatus displays the obtained relative values. **Claims:**It is an apparatus for measuring the skin **allergic** reaction in a patch test quantitatively,Comprising:The irradiation means for irradiating a laser beam to a test subject,A light reception means to detect... ... to image-form and display a calculation resultThe blood-flow status display apparatus which comprises theseWHEREIN:(1) Calculating means calculates blood-flow state of skin **allergic**-reaction region/part in laser spot, and region/part of other than that, respectively,(2) Display means displays value of ratio of each said calculation... ... 1. An apparatus for inspecting an **allergic** reaction comprising a light-projecting means for projecting a laser light upon an object having a bloodstream; a light-receiving means for receiving a plurality... ... the information in a map state, wherein the calculating means comprises calculating relative values of the respective bloodstreams at measured portions to be tested the **allergic** reaction or subjected to a patch test based on an average value of the bloodstreams measured at portions other than the portion to be tested... ... The invention claimed is:1. An apparatus for inspecting an **allergic** reaction comprising: light-projecting means for projecting a laser light onto an object having a plurality of bloodstreams and into an area including a portion subjected to an **allergic** reaction test;light-receiving means for receiving light rays scattered by blood cells at a plurality of points at a surface of the object;memory... ... based on the output signals stored in the memory means, respective relative values of the bloodstreams at the portion of the object subjected to the **allergic** reaction test, said relative values being relative to an average value of the bloodstreams measured at a portion of the object other than the portion subjected to the **allergic** reaction test which is not affected by the **allergic** reaction test; anddisplay means for displaying the relative values obtained by the calculating means;wherein the calculating means is arranged to: calculate an average... ... higher than the average value Bv1; anddivide the average bloodstream value Bv2 by the average bloodstream value Bv3 to calculate a degree of the **allergic** reaction;wherein the display means is arranged to further display the calculated degree of the **allergic** reaction at least as a numerical value; andwherein the **allergic** reaction test is a patch test.

39/3,K/3 (Item 3 from file: 350)

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0011240199 *Drawing available*

WPI Acc no: 2002-179839/200223

XRAM Acc no: C2002-055932

XRPX Acc No: N2002-136706

**Processing subject (S) characteristic by remote data service which processes electronic information representing sample characteristics of S, transmitted by testing kit, to provide electronically-transmittable results**

Patent Assignee: ACOSTA G F (ACOS-I); BLACKWELL E S (BLAC-I); COLE A (COLE-I); FERRANS R H (FERR-I); LABNETICS INC (LABN-N); MCMORRIS J A (MCMO-I); MULLINS G A (MULL-I); OTWORTH

M J (OTWO-I); PACKARD M J (PACK-I); SCOTT J S (SCOT-I)  
 Inventor: ACOSTA G F; BLACKWELL E S; COLE A; FERRANS R H; MCMORRIS J A; MULLINS G A;  
 OTWORTH M J; PACKARD M J; SCOTT J S

Patent Family ( 3 patents, 94 countries )

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2002007064	A2	20020124	WO 2001US22300	A	20010717	200223	B
AU 200173486	A	20020130	AU 200173486	A	20010717	200236	E
US 20020059030	A1	20020516	US 2000218583	P	20000717	200237	E
			US 2000218584	P	20000717		
			US 2000218585	P	20000717		
			US 2001906005	A	20010717		

Priority Applications (no., kind, date): US 2000218585 P 20000717; US 2000218584 P 20000717; US 2000218583 P 20000717; US 2001906005 A 20010717

**Technology Focus** ...which includes comparing present data with prior data for the subject. The defined test kit used in the method provides for the testing for an **allergic** or interaction to a particular substance, where a screening-effective quantity of the substance is introduced to the subject prior to obtaining the sample by... ..of acceptable values and notifying at least one of the subject, the provider, and the third party if the test results lie within a pre- **determined** range of acceptable **values**. The **correlation** step further involves electronic transmitting of the correlation information generated to at least one of the subject, the provider, and the third party. The correlating... **Extension Abstract Class Codes** International Patent Classification IPC Class Level Scope Position Status Version Date **A61B-0005/00...** ...**A61B-0005/117** **A61B-0005/00...** ...**A61B-0005/117**

22/3,K/6 (Item 6 from file: 350) **Bad Date??**

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0015535219 *Drawing available*

WPI Acc no: 2006-099369/200610

XRAM Acc no: C2006-035387

XRPX Acc No: N2006-086229

**Diagnostic method for identifying food allergies in human subjects, by identifying subjects with specific ABO/Rh blood types, generating immune response test scores on subjects to foods, correlating blood types and interpreting data**

Patent Assignee: POWER L W (POWE-I)

Inventor: POWER L W

Patent Family ( 1 patents, 1 countries )

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20060013773	A1	20060119	US 2004587827	P	20040715	200610	B
			US 2005178666	A	20050712		

Priority Applications (no., kind, date): US 2004587827 P 20040715; US 2005178666 A 20050712

**Alerting Abstract** ... to foods in human subjects, and uses the identification to formulate a "Food-Allergy-Typing System" or "Food Allergy Index", for the purpose of predicting **potential** food **allergens** in future subjects, involves identifying human subjects with specific ABO or Rh blood types, and optionally gender, and selecting for at least two of these... ... responses to foods in human subjects, and for identification to formulate a "Food-Allergy-Typing System" or "Food Allergy Index", for the purpose of predicting **potential** food **allergens** in future subjects. (**Technology Focus** ...identifying patterns in food allergies relative to blood types or gender by determining the strength of **the** reactions (using test **scores**) and by **statistical significance** (p **values**); **estimating the degree of** human clinical **immune** reactivity to foods (for IgE, IgG, and T-cells) by applying standard deviations to the distribution of test scores in the study, where the lower... ... The step of formulating a "Food-Allergy-Typing System" which identifies food allergies for different types of subjects, then uses these to predict **potential** food **allergens** for other people of the same types, involves categorizing **the** allergenic **foods** to produce six food-allergy lists, each containing one set of foods for each blood type (A1, A2, B, O, A1B, A2B), or optionally five... **Extension Abstract** Original Publication Data by AuthorityArgentina**Publication No.** ...**Claims:**responses to foods in human subjects, and uses this to formulate a "Food-Allergy-Typing System" or "Food Allergy Index", for the purpose of predicting **potential** food **allergens** in future subjects, wherein said method **comprises**:(a): **Identifying** human subjects with specific ABO or Rh blood types, and optionally gender,

42/3,K/5 (Item 5 from file: 350) **Bad Date??**

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0016922455

WPI Acc no: 2007-637521/200760

Related WPI Acc No: 2006-116409; 2006-298524; 2007-131059; 2007-585636; 2007-700407; 2008-F34174

XRPX Acc No: N2007-497751

**Migraine variables determination method for diagnosis and treatment of diseases triggering migraine, involves determining statistical relationship between one or more temporal onsets to derive variables**

Patent Assignee: CARPENTER C (CARP-I); LANCKRIET G (LANC-I); NEWMAN L (NEWM-I); STUPP S E (STUP-I)

Inventor: CARPENTER C; LANCKRIET G; NEWMAN L; STUPP S E

Patent Family ( 1 patents, 1 countries )



Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20070179354	A1	20070802	US 2004587003	P	20040710	200760	B
			US 2004591300	P	20040727		
			US 2004601480	P	20040814		
			US 2005177063	A	20050708		
			US 2006604494	A	20061127		

Priority Applications (no., kind, date): US 2004587003 P 20040710; US 2004591300 P 20040727; US 2004601480 P 20040814; US 2005177063 A 20050708; US 2006604494 A 20061127

**Migraine variables determination method for diagnosis and treatment of diseases triggering migraine, involves determining statistical relationship between one or more temporal onsets to derive variables**

**Original Titles:** Apparatus for **determining association** variables **Alerting Abstract ...NOVELTY** - The statistical relationship between one or more temporal onsets corresponding to one or more events e.g. **allergens** and a pattern of occurrence of a compound variable is determined, where pattern of occurrence is contributed by presence and absence of the compound variable... **USE** - For determining migraine variables associated with migraine triggering events such as tension head aches, **allergens**, weather changes, compounds containing phenol, pollution, hormonal fluctuations, etc., and diseases such as arthritis, auto-immune disorders, diabetes, inflammatory diseases, gastro-intestinal diseases, thyroid diseases... **Class Codes** International Patent Classification IPC Class Level Scope Position Status Version Date **A61B-0019/00... ..A61B-0005/00 A61B-0019/00... ..A61B-0005/00** Original Publication Data by Authority Argentina **Publication No. Original Abstracts:** An apparatus, and related method, for **determining** one or more **association** variables is described. The apparatus includes at least one processor, at least one memory, and at least one program module. The program module is stored in the memory and is configurable to be executed by the processor. The program module includes instructions for **determining** a statistical **relationship** between one or more temporal onsets corresponding to one or more events and a pattern of occurrence of a compound variable. The compound variable corresponds... **Claims:** 1. A method of determining one or more migraine variables associated with migraines, comprising: **determining** a statistical **relationship** between one or more temporal onsets corresponding to one or more events and a pattern of occurrence of a compound variable, wherein the compound variable...

35/3,K/5 (Item 4 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

13024967 **Biosis No.:** 199598492800

**Comparison of multiple-antigen simultaneous test and CAP systems for diagnosis of nasal allergy**

**Author:** Ogino Satoshi; Kawashima Kayoko; Nibu Mariko; Irifune Morihiro

**Author Address:** Dep. Otolaryngology, Osaka Univ. Med. Sch., 2-2 Yamadaoka, Suita-shi, Osaka 565, Japan\*\*Japan

**Journal:** ORL (Basel) 57 ( 4 ): p 210-213 1995 1995

**ISSN:** 0301-1569

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Abstract:** ...The MAST and CA-P were used for 7 inhaled allergens: house dust, Dermatophagoides farinae,

Japanese cedar, timothy, sweet vernal grass, ragweed and mugwort. The **correlation coefficients** found for MAST and CAP were significant for all the allergens tested. In addition, high values for sensitivity, specificity and efficiency were obtained for all... ..results may clinically be false-positive. We believe that the MAST and CA-P are both useful for the detection of allergens but that the **diagnosis of allergy** must be based on **results** of detailed examinations such as use of the skin test, the nasal provocation test and clinical symptoms.

42/3,K/2 (Item 1 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

16787707 **Biosis No.:** 200200381218

### **Some immunological aspects of patients with rhinitis in Lebanon**

**Author:** Abdelnoor Alexander M (Reprint); Kobeissy Firas; Farhat Daad; Hadi Usama

**Author Address:** Department of Microbiology/Immunology, Faculty of Medicine, American University of Beirut, Riad el Solh, P. O. Box 110236, Beirut, 11072020, Lebanon\*\*Lebanon

**Journal:** Immunopharmacology and Immunotoxicology 24 ( 2 ): p 289-301 May, 2002 2002

**Medium:** print

**ISSN:** 0892-3973

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Abstract:** Background: Hitherto immunological determinates in Lebanese patients with rhinitis have not been investigated. Objective: To **identify causative allergens** in Lebanese **patients** with **allergic** rhinitis and **determine** possible **correlation's among** serum **allergen** specific antibody, polyclonal IgE, IL-4, IL-5 and peripheral eosinophil levels. Methods: One hundred and thirteen patients with a long lasting history of nasal obstruction, rhinorrhea, sneezing and nasal itching were investigated. Serum allergen specific antibodies using a panel of 10 **potential allergens**, IL-4 and IL-5 levels were determined by enzyme immunoassays. Polyclonal IgE levels were estimated by an immunochromatographic assay and eosinophil counts by a...

## **B. Additional Resources Searched**

### **ProQuest:**

#### **Diagnosis of allergic reactions to food**

Wesley Burks. Pediatric Annals. Thorofare: Dec 2000. Vol. 29, Iss. 12; pg. 744, 12 pgs

A variety of terms have been used to characterize **adverse food reactions**, and their use has allowed clearer communication regarding various reactions to food components.<sup>1</sup> An adverse food reaction is a general term that can be applied to a clinically abnormal **response** to an **ingested** food or food additive. Adverse food reactions may be secondary to food hypersensitivity (allergy) or food intolerance.

Food hypersensitivity (**allergy**) is an immunologic reaction resulting from the ingestion of a food or food additive. This reaction occurs only in some patients, may occur after only a small amount is ingested, and is unrelated to any physiologic effect of the food or food additive. To most physicians, the term is synonymous with reactions that involve the IgE mechanism, of which anaphylaxis is the classic example.

Food intolerance is a general term describing an abnormal physiologic response to an ingested food or food additive. The reaction is not considered immunologic in nature and may be caused by many factors, including toxic contaminants (eg, histamine in scombroid fish poisoning and toxins secreted by *Salmonella*, *Shigella*, and *Campylobacter*), pharmacologic properties of the food (eg, caffeine in coffee and tyramine in aged cheeses), characteristics of the host such as metabolic disorders (eg, lactase deficiency or nontropical spore), and idiosyncratic responses. The term food intolerance has often been overused and, similar to the term food allergy, has been applied incorrectly to any adverse reaction to foods.

IgE-mediated (type I) hypersensitivity accounts for most well-characterized allergic reactions to foods, although non-IgE-mediated immune mechanisms are believed to be responsible for a variety of non-IgE hypersensitivity disorders.

## CLINICAL MANIFESTATIONS OF FOOD HYPERSENSITIVITY IgE-Mediated Hypersensitivity

The signs and symptoms of food-induced, IgE-mediated gastrointestinal allergy in humans may be secondary to the oral allergy syndrome, immediate gastrointestinal hypersensitivity, or a small subgroup, allergic eosinophilic gastroenteritis.

The oral allergy syndrome (Table 1) is considered a form of contact urticaria that is confined almost exclusively to the oropharynx and rarely involves other target organs. Symptoms include rapid onset of pruritus and angioedema of the lips, tongue, palate, and throat. Generally, these symptoms resolve rapidly. This syndrome is most commonly associated with the ingestion of fresh fruits and vegetables. Interestingly, patients with allergic rhinitis secondary to certain airborne pollens (especially ragweed and birch pollens) are frequently afflicted with this syndrome. Patients sensitive to ragweed may experience these symptoms following contact with bananas and certain melons (eg, watermelon, cantaloupe, and honeydew). Likewise, patients with birch sensitivity often have symptoms following the ingestion of raw potatoes, carrots, celery, apples, and hazelnuts.

The **diagnosis** of this syndrome is made after a suggestive history and positive results on prick skin tests with the implicated fresh fruits or vegetables.<sup>2</sup> The confounder in this syndrome is that the commercially available allergen extracts for fresh fruits and vegetables are often not as reliable as those for other foods. It may be necessary to use the "prick-by-prick" method, where the device used for introducing the allergen into the skin may have to first be "pricked" into the food.

Immediate gastrointestinal hypersensitivity (Table 2) is a form of IgE-mediated gastrointestinal hypersensitivity that may accompany allergic manifestations in other target organs.<sup>3</sup> Symptoms vary, but may include nausea, abdominal pain, abdominal cramping, vomiting, diarrhea, anaphylaxis, or all of these. In studies of children with atopic dermatitis and food allergy, the frequent ingestion of a food allergen appears to induce partial desensitization of gastrointestinal mast cells, resulting in less pronounced gastrointestinal symptoms.

This diagnosis is made by a suggestive clinical history, positive results on prick skin tests, complete elimination of the suspected food allergen for up to 2 weeks with resolution of symptoms, and an oral food challenge. After avoidance of a particular food for 10 to 14 days, it is not unusual for symptoms of vomiting to occur during a challenge, although the patient was previously ingesting the food without vomiting each time.

[illegible]

TABLE 1

[illegible]

TABLE 2

Allergic eosinophilic gastroenterocolitis (Tables 3 and 4) is characterized by infiltration of the gastric walls, intestinal walls, or both with eosinophils, absence of vasculitis, and, frequently, a peripheral eosinophilia.<sup>4</sup> The eosinophilic infiltrate may involve the mucosa layer, the muscular layer, the serosal layer, or all three of the stomach or small intestine. Patients presenting with this syndrome frequently have postprandial nausea and vomiting, abdominal pain, diarrhea, occasionally steatorrhea, and failure to thrive (in young infants) or weight loss (in adults). A subset of patients with allergic eosinophilic gastroenteritis appear to have symptoms secondary to foods. They generally have the mucosal form with cells that stain for IgE in the jejunum, plus elevated IgE in duodenal fluids, a history of other atopic disease, elevated serum IgE concentrations, positive results on prick skin tests to a variety of foods and inhalants, an elevated peripheral blood eosinophil count, iron deficiency anemia, and hypoalbuminemia.

TABLE 3

TABLE 4

The diagnosis of this entity is based on an appropriate history and a gastrointestinal biopsy demonstrating the characteristic eosinophilic infiltration. Multiple sites (up to 8) may need to be biopsied to effectively exclude eosinophilic gastroenteritis because the eosinophilic infiltrates may be patchy.<sup>5</sup> Patients with the mucosal form of the disease may have atopic symptoms, food allergy, elevated serum IgE concentrations, positive results on skin tests or radioallergosorbent tests (RASTs), and peripheral eosinophilia. Other laboratory findings consistent with this disease include Charcot-Leyden crystals in the stool, anemia, hypoalbuminemia, and abnormal results on D-xylose tests. An elimination diet of up to 12 weeks may be necessary before complete resolution of symptoms and normalization of intestinal histology are observed.

These disorders lack clear evidence that they are mediated by classic (IgE-related) allergy. Clues as to etiology may be found in the tables, but, in most cases, an exact mechanism of disease has not been established.

Dietary protein enterocolitis (also known as protein intolerance; Table 5) is a disorder that presents most commonly between 1 week and 3 months of age. The symptoms are isolated to the gastrointestinal tract and typically consist of recurrent vomiting, diarrhea, or both.<sup>6</sup> These can be severe enough to cause dehydration. Cow's milk, soy protein (particularly in infant formulas), or both are most often responsible, although egg sensitivity has been reported in older patients. The children will often have stools that contain occult blood, polymorphonuclear neutrophils, eosinophils, and reducing substances (indicating malabsorbed sugars). Results of prick skin tests for the putative food protein are characteristically negative. Jejunal biopsies classically reveal flattened villi, edema, and increased numbers of lymphocytes, eosinophils, and mast cells. **A food challenge** with the responsible protein generally results in vomiting,

diarrhea, or both within minutes to several hours, and will occasionally lead to shock. It is not uncommon to find children who are sensitive to both cow's milk and soy protein. This disorder tends to remit by 18 to 24 months of age.

[illegible]

TABLE 5

Elimination of the offending allergen generally will result in improvement or resolution of the symptoms within 72 hours, although secondary disaccharidase deficiency may persist longer.<sup>6</sup> Oral food challenges, which should be done in a medical setting (because they can induce severe vomiting, diarrhea, dehydration, or hypotension), consist of administering 0.6 g/kg body weight of the suspected food allergen.<sup>6</sup> This disorder appears to be mediated by T cells.

Dietary protein proctitis generally presents in the first few months of life and is often secondary to cow's milk or soy protein hypersensitivity (Table 6).<sup>7</sup> Most infants with this disorder do not appear ill and have normally formed stools, but are given this diagnosis because of blood (gross or occult) in their stools. Gastrointestinal lesions are confined to the small bowel and consist of mucosal edema with eosinophils in the epithelium and lumina propria. If lesions are severe with crypt destruction, polymorphonuclear neutrophil leukocytes are also prominent.<sup>8</sup> It is thought that colitis induced by cow's milk and soy protein resolves by 6 months to 2 years of allergen avoidance, but there are not many well-controlled studies to support this.

Elimination of the offending food allergen leads to resolution of hematochezia within 72 hours, but the mucosal lesions may take up to 1 month to disappear and range from patchy mucosal injection to severe friability with small aphthoid ulcerations and bleeding. Colonic biopsy reveals a prominent eosinophilic infiltrate in the surface and crypt epithelia and the lumina propria. This disorder appears to be T-cell mediated.

Celiac disease (Table 7) is an extensive enteropathy leading to malabsorption. Total villous atrophy and an extensive cellular infiltrate are associated with sensitivity to gliadin, the alcohol-soluble portion of gluten found in wheat oat, rye, and barley. The general incidence is thought to be 1 in 4,000, but has been reported to be as high as 1 in 500 in Ireland.<sup>9</sup> Patients appear to have a genetic predisposition to this disease, because approximately 90% have the HLA-B8 antigen and nearly 80% have the HLA-DW3 antigen. Patients often present with diarrhea or frank steatorrhea, abdominal distention and flatulence, weight loss, and, occasionally, nausea and vomiting. Other extraintestinal symptoms and oral ulcers secondary to malabsorption are not common.<sup>10</sup> This also appears to be primarily a Tcell-mediated disorder.

## DIAGNOSING ADVERSE FOOD REACTIONS

As with all medical disorders, the diagnostic approach to the patient with a **suspected adverse food reaction** begins with the medical history and physical examination. Based on the information derived from these initial steps, various laboratory studies may be ordered.

## History

The true value of the medical history is largely dependent on the patient's recollection of symptoms and the physician's ability to differentiate disorders provoked by food hypersensitivity and other possible etiologies. The history may be used to diagnose a food allergy in acute events (eg, systemic anaphylaxis following the ingestion of fish). However, in many series, less than 50% of reported food allergy reactions could be substantiated by the gold standard, a double-blind, placebo-controlled food challenge.<sup>11,12</sup> Several pieces of information are important in establishing a food allergic reaction: (1) the food suspected to have provoked the reaction; (2) the quantity of the food ingested; (3) the length of time between ingestion and development of symptoms; (4) a description of the symptoms provoked; (5) whether similar symptoms developed on other occasions when the food was eaten; (6) whether other factors (eg, exercise) are necessary; and (7) the length of time since the last reaction. Any food may cause an allergic reaction, although 90% of these reactions are caused by only a few foods. In children, these foods are eggs, milk, peanuts, soy, and wheat (and fish in Scandinavian countries). In chronic disorders such as atopic dermatitis, the history is often an unreliable indicator of the offending allergen.

History: Food Allergy Reaction
<p> <input type="checkbox"/> Suspected food(s)  <input type="checkbox"/> Time of day  <input type="checkbox"/> Amount of food  <input type="checkbox"/> Location of reaction  <input type="checkbox"/> Time of onset  <input type="checkbox"/> Symptoms  <input type="checkbox"/> Duration of symptoms  <input type="checkbox"/> Response to treatment  <input type="checkbox"/> Recurrence of symptoms  <input type="checkbox"/> Other factors (eg, exercise)  <input type="checkbox"/> Family history  <input type="checkbox"/> Previous allergic reactions  <input type="checkbox"/> Other medical conditions  <input type="checkbox"/> Medications  <input type="checkbox"/> Other allergies  <input type="checkbox"/> Other symptoms  <input type="checkbox"/> Other tests  <input type="checkbox"/> Other treatments  <input type="checkbox"/> Other notes </p>

Enlarge 200%

Enlarge 400%

TABLE 6

## Diet Diary

A **diet diary** has been frequently used as an adjunct to the medical history. Patients (or parents) are asked to keep a **chronological record of all foods ingested during a specified period of time and to record any symptoms they experience during this time. The diary can then be reviewed at a visit to determine whether there is any relationship between the foods ingested and the symptoms experienced.** This method will rarely detect an unrecognized association between a food and a patient's symptoms. However, as opposed to the medical history, information can be collected on a prospective basis instead of being dependent on a patient's or a parent's memory.

## Elimination Diet

An elimination diet is frequently used in both diagnosis and management of adverse food reactions. If a certain food is suspected of provoking a reaction, it is completely eliminated from the diet. The success of an elimination diet depends on the correct identification of the allergen(s) involved, the ability of the patient to maintain a diet completely free of all forms of the possible offending allergen, and the assumption that other factors will not provoke similar symptoms during the study period. The likelihood of meeting all of these conditions is often slim. For example, in a young infant reacting to cow's milk formula, resolution of symptoms following substitution of cow's milk formula with a soy formula or casein hydrolysate is highly suggestive of cow's milk allergy, but the problem could also be due to lactose intolerance. Avoidance of suspected food allergens prior to blinded challenge is recommended so that any positive reactions are heightened. Elimination diets are rarely diagnostic of food allergy, particularly in chronic disorders such as atopic dermatitis or asthma.



## Double-Blind, Placebo-Controlled Food Challenge

The "gold standard" for the diagnosis of food allergies, the double-blind, placebo-controlled **food challenge**, has been used successfully to examine a wide variety of food-related complaints in both children and adults.<sup>17</sup> The selection of the foods for the oral challenge test is based on history, prick skin test or RAST results, or both. Foods thought unlikely to provoke a food allergic reaction may be screened in open or single-blind challenges. However, it is necessary (except for very young infants) to confirm a positive reaction by double-blind, placebo-controlled food challenge. Prior to undertaking this, several requirements should be met: (1) suspect foods should be eliminated from the diet for 7 to 14 days prior to challenge; (2) antihistamines should be discontinued long enough to establish a normal result on histamine skin test; (3) other medications should be minimized to levels that will prevent breakthrough of acute symptoms; and (4) in some patients with asthma, short bursts of corticosteroids may be necessary to ensure adequate pulmonary reserve for testing (forced expiratory volume 1 second > 70% of predicted).

The food challenge should be administered with the patient in a fasting state, starting the challenge with a dose of food unlikely to provoke symptoms (generally 125 to 500 mg of lyophilized food). This dose is then doubled every 15 to 60 minutes, depending on the type of reaction that was suspected to have occurred. Reactivity is generally ruled out clinically when the patient has tolerated 10 g of lyophilized food blinded by placement in capsules or liquid. If the blinded portion of the challenge is negative, however, it must be confirmed by an open feeding under observation to rule out the rare false-negative challenge. The foods are dehydrated for blinding, whereas openly they are given in a normal fashion.

The order of administration of the food antigen and placebo challenge should be randomized by a noninterested third party (eg, a dietitian), and an equal number of food antigen and placebo challenges are necessary." A standardized scoring system should be used for all challenges. The length of observation of the patient is dependent on the type of reaction suspected. In IgE-mediated reactions, this is generally up to 2 hours. When testing for protein-induced enterocolitis, the time would be at least 4 to 8 hours. When only objective signs and symptoms are scored, the results of blinded challenges are rarely equivocal. The objectivity is enhanced by monitoring a variety of laboratory parameters, such as plasma histamine, pulmonary function tests, and nasal airway resistance.

A double-blind, placebo-controlled food challenge is the best means of controlling for the variability of chronic disorders (eg, chronic urticaria and atopic dermatitis), any extraneous, time-related effects, and acute exacerbations secondary to reducing or discontinuing medications. Psychogenic factors and observer bias are particularly eliminated.

There are rare false-negative results when performing a double-blind, placebo-controlled food challenge, such as when a patient receives insufficient challenge material to provoke the reaction, or lyophilization of the food has altered the relevant allergenic epitopes (eg, fish). Currently, overall, the double-blind, placebo-controlled food challenge has proven to be the most accurate means of diagnosing food allergy.'

In general, double-blind, placebo-controlled food challenges should be conducted in a clinic or hospital setting, especially if an IgE-mediated reaction is suspected.<sup>19</sup> Trained personnel and equipment for treating systemic anaphylaxis should be present. If life-threatening anaphylaxis is suspected and the causative agent cannot be identified conclusively by history, a challenge may be conducted in the intensive care unit of a center that frequently deals with food allergic reactions. The evaluation of suspected "delayed" reactions can be conducted safely on an outpatient basis, provided the symptoms have not been severe and there is no concern about the patient's breaking the blinding by opening capsules. There are some possible adverse food reactions where the proposed symptoms are largely subjective: three crossover trials with reactions developing only during the allergen challenge are necessary to conclude that there exists a cause-and-effect relationship in this situation.'

## PRACTICAL APPROACH TO DIAGNOSING FOOD ALLERGY

The **diagnosis** of food **allergy** remains a clinical exercise that uses a careful history, selective prick skin tests or RASTs (if an IgE-mediated disorder is suspected), appropriate exclusion diet, and blinded provocation. The evaluation of food-specific IgG or IgG4 antibody levels, food-- antigen-antibody complexes, evidence of lymphocyte activation (3H uptake, IL-2 production, and leukocyte inhibitory factor), and sublingual or intracutaneous provocation appear not to be of significant value. Blinded challenges may not be necessary in suspected gastrointestinal disorders, as prechallenge and postchallenge laboratory values and biopsies are often used.



An exclusion diet eliminating all foods suspected by history or prick skin testing (or RASTs for IgE-mediated disorders) should be conducted for at least 1 to 2 weeks. Some gastrointestinal disorders may need to have the exclusion diet extended for up to 12 weeks following appropriate biopsies. This is especially true for celiac disease, and this delay makes a biopsy more valuable. If no improvement is noted following the change in diet, it is unlikely that food allergy is involved. In the case of some chronic diseases, such as atopic dermatitis or chronic asthma, other precipitating factors (eg, exercise, upper respiratory tract infections, or irritants) may be difficult to distinguish from the effects of the food allergen.

Single-blind challenges in a clinic setting may be helpful to screen for suspected food allergens. Positive results should be confirmed by a doubleblind, placebo-controlled food challenge unless a single "major" allergen (egg, milk, soy, or wheat) provoked classic allergic symptoms. Patients with multiple food allergies are rare. When suspected, this should be confirmed by double-blind, placebo-controlled food challenge. For the latter, many dried foods can be obtained through grocery stores, health food stores, and camping outlets. Additionally, several companies in Europe and the United States are starting to make food capsules available to physicians.

## CONCLUSION

A presumptive diagnosis of food allergy, based on a patient's history and the results of prick skin tests or RASTs, is no longer acceptable, in this author's opinion. There are exceptions to this, such as patients who had severe anaphylaxis following the isolated ingestion of a specific food. However, it is important that the physician make unequivocal diagnoses of food allergy. If the current, more lax approach to making this diagnosis continues, more than one-fourth of the population will continue to alter their eating habits based on a misconception of food allergy.

## II. Inventor Search Results from Dialog

**File 347:JAPIO Dec 1976-2009/Jan(Updated 090503)**

(c) 2009 JPO & JAPIO

**File 348:EUROPEAN PATENTS 1978-200920**

(c) 2009 European Patent Office

**File 349:PCT FULLTEXT 1979-2009/UB=20090514|UT=20090507**

(c) 2009 WIPO/Thomson

**File 350:Derwent WPIX 1963-2009/UD=200929**

(c) 2009 Thomson Reuters

Set	Items	Description
S1	194	AU=(HARTER, M? OR HARTER, R? OR HARTER, T? OR HARTER M? OR HARTER R? OR HARTER T? OR HARTER(2N)M? OR HARTER(2N)R? OR HARTER(2N)T?)
S2	4	S1 AND (ALLERG? OR HYPERSENSITIVIT? OR (INFLUENCING OR ATO-PIC) () (AGENT? ? OR SUBSTANCE? ?))
S3	0	S2 AND IC=(G06Q OR A61B)

2/3K/1 (Item 1 from file: 348)

DIALOG(R)File 348: EUROPEAN PATENTS

(c) 2009 European Patent Office. All rights reserved.

01774337

### **ISOPHTALIC ACID DERIVATIVES**

ISOPHTHALSAUREDERIVATE

DERIVES D'ACIDE ISOPHTALIQUE

#### **Patent Assignee:**

**Bayer HealthCare AG;** (4574411)

51368 Leverkusen; (DE); (Proprietor designated states: all)

#### **Inventor:**

**HARTER, Michael**

**Ernst-Ludwig-Kirchner-Str. 56; 51375 Leverkusen; (DE)**

	Country	Number	Kind	Date	
Patent	EP	1572628	A1	20050914	(Basic)
	EP	1572628	B1	20070725	
	WO	2004052839		20040624	
Application	EP	2003782248		20031128	
	WO	2003EP13433		20031128	
Priorities	DE	10257785		20021211	

**Specification:** ...Ansatz fur die Behandlung von kardiovaskularen Erkrankungen.

In <PATCIT ID=PCIT0001 DNUM=EP516069A> EP-A 516 069 </PATCIT> sind Leukotrien B4-Antagonisten zur Behandlung von **allergischen** und antiinflammatorischen Erkrankungen beschrieben. <PATCIT

ID=PCIT0002 DNUM=EP791576A> EP-A 791 576 </PATCIT> und <PATCIT ID=PCIT0003 DNUM=EP341551A> EP-A 341 551 </PATCIT...

2/3K/2 (Item 1 from file: 349)  
DIALOG(R)File 349: PCT FULLTEXT  
(c) 2009 WIPO/Thomson. All rights reserved.

01295144

**PHENYL ACETAMIDES**  
**PHENYLACETAMIDES**  
**PHENYLACETAMIDE**

**Patent Applicant/Patent Assignee:**

**BAYER HEALTHCARE AG; 51368 Leverkusen**  
DE; DE(Residence); DE(Nationality)  
(For all designated states except: US)

**HARTER Michael; Ernst-Ludwig-Kirchner-Str. 56, 51375 Leverkusen**  
DE; DE(Residence); DE(Nationality)  
(Designated only for: US)

**Patent Applicant/Inventor:**

**HARTER Michael**  
Ernst-Ludwig-Kirchner-Str. 56, 51375 Leverkusen; DE; DE(Residence); DE(Nationality);  
(Designated only for: US)

**WUNDER Frank**  
Schwarzer Weg 251, 42117 Wuppertal; DE; DE(Residence); DE(Nationality); (Designated only for: US)

**BARFACKER Lars**  
Walter-Flex-Str. 29, 46047 Oberhausen; DE; DE(Residence); DE(Nationality); (Designated only for: US)

**Legal Representative:**

**BAYER HEALTHCARE AG(commercial rep.)**  
Law and Patents, Patents and Licensing, 51368 Leverkusen; DE;

	Country	Number	Kind	Date
Patent	WO	2005103001	A1	20051103
Application	WO	2005EP3926		20050414
Priorities	DE	102004019472		20040422

In EP-A 516 0693.US 43826e9903 US 4,942.236 und US 5,103,014 sind Leukotrien-Antagonisten zur Behandlung von **allergischen** und antiinflanunatorischen Erkrankungen beschrieben. EP-A 791 -576 und EP-A 341 551 offenbaren Leukotrien-Antagonisten zur Behandlung von Asthma.

01262157

**TRICYCLIC BENZAZEPINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS USED FOR THE TREATMENT OF CARDIOVASCULAR DISEASES**

**Patent Applicant/Patent Assignee:**

**BAYER HEALTHCARE AG;** 51368 Leverkusen

DE; DE(Residence); DE(Nationality)

(For all designated states except: US)

**WOLTERING Elisabeth;** Eichenstr. 116, 40721 Hilden

DE; DE(Residence); DE(Nationality)

(Designated only for: US)

**HARTER Michael; Ernst-Ludwig-Kirchner-Str. 56, 51375 Leverkusen**

DE; DE(Residence); DE(Nationality)

(Designated only for: US)

**Patent Applicant/Inventor:**

**WOLTERING Elisabeth**

Eichenstr. 116, 40721 Hilden; DE; DE(Residence); DE(Nationality); (Designated only for: US)

**HARTER Michael**

Ernst-Ludwig-Kirchner-Str. 56, 51375 Leverkusen; DE; DE(Residence); DE(Nationality);

(Designated only for: US)

**FLESSNER Timo**

Egenstr. 64, 42113 Wuppertal; DE; DE(Residence); DE(Nationality); (Designated only for: US)

**Legal Representative:**

**BAYER HEALTHCARE AG(commercial rep.)**

Law and Patents, Patents and Licensing, 51368 Leverkusen; DE;

	Country	Number	Kind	Date
Patent	WO	200568472	A1	20050728
Application	WO	2004EP14871		20041231
Priorities	DE	102004001871		20040114

**Detailed Description:**

...Tierfutterzusatz. Die Verwendung bestimmter Azepin-Derivate zur Kontrolle der Blutplasma-Spiegel von Lipoproteinen wird in EP 875 247 beansprucht. Triazolooxazepine zur Behandlung von Entzündungszuständen und **Allergien** sind in JP 345 785 offenbart. In EP 638 560 wird die Verwendung von Azepin-Derivaten zur Behandlung von Osteoporose beansprucht.

01132042

**ISOPHTHALIC ACID DERIVATIVES**  
**DERIVES D'ACIDE ISOPHTALIQUE**  
**ISOPHTHALSAUREDERIVATE**

**Patent Applicant/Patent Assignee:**

**BAYER HEALTHCARE AG**; 51368 Leverkusen  
DE; DE(Residence); DE(Nationality)  
(For all designated states except: US)

**Patent Applicant/Inventor:**

**HARTER Michael**

Ernst-Ludwig-Kirchner-Str. 56, 51375 Leverkusen; DE; DE(Residence); DE(Nationality);  
(Designated only for: US)

**ERGUDEN Jens**

Bertolt-Brecht-Str. 2, 42489 Wulfrath; DE; DE(Residence); DE(Nationality); (Designated only for:  
US)

**WUNDER Frank**

Schwarzer Weg 251, 42117 Wuppertal; DE; DE(Residence); DE(Nationality); (Designated only for:  
US)

**Legal Representative:**

**BAYER HEALTHCARE AG**(commercial rep.)

Law & Patents, Patents and Licensing, 51368 Leverkusen; DE;

	Country	Number	Kind	Date
Patent	WO	200452839	A1	20040624
Application	WO	2003EP13433		20031128
Priorities	DE	10257785		20021211

**Detailed Description:**

...Cystelnyl-Leukotrien Rezeptoren einen therapeutischen Ansatz für die Behandlung von kardiovaskulären Erkrankungen.

In EP-A 516 069 sind Leukotrien B<sub>4</sub>-Antagonisten zur Behandlung von **allergischen** und entzündlichen Erkrankungen beschrieben. EP-A 791 576 und EP-A 341 551 offenbaren Leukotrien-Antagonisten zur Behandlung von Asthma.

**File 35:Dissertation Abs Online 1861-2009/Apr**

(c) 2009 ProQuest Info&Learning

**File 583:Gale Group Globalbase(TM) 1986-2002/Dec 13**

(c) 2002 Gale/Cengage

**File 65:Inside Conferences 1993-2009/May 15**

(c) 2009 BLDSC all rts. reserv.

**File 2:INSPEC 1898-2009/May W2**

(c) 2009 The IET

**File 474:New York Times Abs 1969-2009/May 15**

(c) 2009 The New York Times

**File 475:Wall Street Journal Abs 1973-2009/May 15**

(c) 2009 The New York Times

**File 99:Wilson Appl. Sci & Tech Abs 1983-2009/Apr**  
 (c) 2009 The HW Wilson Co.  
**File 256:TecInfoSource 82-2009/Mar**  
 (c) 2009 Info.Sources Inc  
**File 5:Biosis Previews(R) 1926-2009/May W2**  
 (c) 2009 The Thomson Corporation  
**File 73:EMBASE 1974-2009/May 13**  
 (c) 2009 Elsevier B.V.  
**File 155:MEDLINE(R) 1950-2009/May 14**  
 (c) format only 2009 Dialog  
**File 34:SciSearch(R) Cited Ref Sci 1990-2009/May W2**  
 (c) 2009 The Thomson Corp  
**File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec**  
 (c) 2006 The Thomson Corp  
**File 74:Int.Pharm.Abs 1970-2009/Feb B1**  
 (c) 2009 The Thomson Corporation  
**File 42:Pharm. News Index 1974-2009/Apr W3**  
 (c) 2009 ProQuest Info&Learning  
**File 156:ToxFile 1965-2009/May W2**  
 (c) format only 2009 Dialog  
**File 51:Food Sci.&Tech.Abs 1969-2009/May W2**  
 (c) 2009 FSTA IFIS Publishing  
**File 53:FOODLINE(R): Science 1972-2009/May 14**  
 (c) 2009 LFRA

Set	Items	Description
S1	1419	AU=(HARTER, M? OR HARTER, R? OR HARTER, T? OR HARTER M? OR HARTER R? OR HARTER T? OR HARTER(2N)M? OR HARTER(2N)R? OR HARTER(2N)T?)
S2	6	S1 AND (ALLERG? OR HYPERSENSITIVIT? OR (INFLUENCING OR ATO-PIC)() (AGENT? ? OR SUBSTANCE? ?))
S3	6	S2 NOT PY>2004
S4	2	RD (unique items)

4/3,K/1 (Item 1 from file: 5)  
 DIALOG(R)File 5: Biosis Previews(R)  
 (c) 2009 The Thomson Corporation. All rights reserved.

10487464 Biosis No.: 199141000090

## ALLERGY TO SULFONYLUREA HYPOGLYCEMIC DRUGS ARE THERE CROSS-REACTIONS?

**Author:** CHICHMANIAN R M (Reprint); PAPASSEUDI G; HIERONIMUS S; GUEDJ A M; MIGNOT G; SPREUX A; FREYCHET P; **HARTER M**

**Author Address:** CENTRE PHARMACOVIGILANCE, HOPITAL PASTEUR, BP 69, 06002 NICE CEDEX, FR\*\* FRANCE

**Journal:** Therapie (London/Paris) 46 ( 2 ): p 163-167 1991

**ISSN:** 0040-5957

**Document Type:** Article

**Record Type:** Citation

**Language:** FRENCH

## ALLERGY TO SULFONYLUREA HYPOGLYCEMIC DRUGS ARE THERE CROSS-REACTIONS?

**Author:** ...HARTER M

**DESCRIPTORS:**

**Major Concepts:** Allergy--

**Biosystematic Names:**

4/3,K/2 (Item 1 from file: 155)  
DIALOG(R)File 155: MEDLINE(R)  
(c) format only 2009 Dialog. All rights reserved.

09942509 **PMID:** 1828914

**[Hypersensitivity to hypoglycemic sulfonylurea compounds. Are there cross-reactions?]**

**Allergies** aux sulfonylurees hypoglycemiantes. Les reactions croisees existent-elles?

Chichmanian R M; Papasseudi G; Hieronimus S; Guedj A M; Mignot G; Spreux A; Freychet P; **Harter M**  
Centre Regional de Pharmacovigilance, Nice.

Therapie ( FRANCE ) Mar-Apr 1991 , 46 (2) p163-7 , **ISSN:** 0040-5957--Print **Journal Code:** 0420544

Publishing Model Print

**Document type:** Case Reports; English Abstract; Journal Article; Review

**Languages:** FRENCH

**Main Citation Owner:** NLM

**Record type:** MEDLINE; Completed

**[Hypersensitivity to hypoglycemic sulfonylurea compounds. Are there cross-reactions?]**

**Allergies** aux sulfonylurees hypoglycemiantes. Les reactions croisees existent-elles?

Chichmanian R M; Papasseudi G; Hieronimus S; Guedj A M; Mignot G; Spreux A; Freychet P; **Harter M**

We describe 5 observations of cutaneous reactions or immediate **hypersensitivity** with different hypoglycemic sulfonylurea: Quincke's oedema with glibornuride, three urticaria (one was followed by bronchospasm and collapsus) with glibenclamide, one bullous dermatitis with carbutamide ... (

**Descriptors:** \*Drug **Hypersensitivity**--immunology--IM; \***Hypersensitivity**, Immediate--chemically induced--CI; \*Hypoglycemic Agents--immunology--IM; \*Sulfonylurea Compounds--immunology--IM

**File 15:ABI/Inform(R) 1971-2009/May 14**  
(c) 2009 ProQuest Info&Learning  
**File 9:Business & Industry(R) Jul/1994-2009/May 14**  
(c) 2009 Gale/Cengage  
**File 610:Business Wire 1999-2009/May 15**  
(c) 2009 Business Wire.  
**File 810:Business Wire 1986-1999/Feb 28**  
(c) 1999 Business Wire  
**File 275:Gale Group Computer DB(TM) 1983-2009/Apr 21**  
(c) 2009 Gale/Cengage  
**File 624:McGraw-Hill Publications 1985-2009/May 15**  
(c) 2009 McGraw-Hill Co. Inc  
**File 621:Gale Group New Prod.Annou. (R) 1985-2009/Apr 10**  
(c) 2009 Gale/Cengage  
**File 636:Gale Group Newsletter DB(TM) 1987-2009/Apr 24**  
(c) 2009 Gale/Cengage  
**File 613:PR Newswire 1999-2009/May 15**  
(c) 2009 PR Newswire Association Inc  
**File 813:PR Newswire 1987-1999/Apr 30**  
(c) 1999 PR Newswire Association Inc  
**File 16:Gale Group PROMT(R) 1990-2009/Apr 24**  
(c) 2009 Gale/Cengage  
**File 160:Gale Group PROMT(R) 1972-1989**  
(c) 1999 The Gale Group  
**File 634:San Jose Mercury Jun 1985-2009/May 14**  
(c) 2009 San Jose Mercury News  
**File 148:Gale Group Trade & Industry DB 1976-2009/May 01**  
(c) 2009 Gale/Cengage  
**File 20:Dialog Global Reporter 1997-2009/May 15**

(c) 2009 Dialog  
**File 149:TGG Health&Wellness DB(SM) 1976-2009/Apr W2**  
(c) 2009 Gale/Cengage  
**File 444:New England Journal of Med. 1985-2009/May W2**  
(c) 2009 Mass. Med. Soc.  
**File 129:PHIND(Archival) 1980-2009/Feb W3**  
(c) 2009 Informa UK Ltd  
**File 130:PHIND(Daily & Current) 2009/May 15**  
(c) 2009 Informa UK Ltd  
**File 455:Drug News & Perspectives 1992-2005/Aug**  
(c) 2005 Prous Science

Set	Items	Description
S1	60	AU=(HARTER, M? OR HARTER, R? OR HARTER, T? OR HARTER M? OR HARTER R? OR HARTER T? OR HARTER(2N)M? OR HARTER(2N)R? OR HAR- TER(2N)T?)
S2	0	S1 AND (ALLERG? OR HYPERSENSITIVIT? OR (INFLUENCING OR ATO- PIC)() (AGENT? ? OR SUBSTANCE? ?))



### III. Text Search Results from Dialog

#### A. Patent Files, Abstract

**File 347:JAPIO Dec 1976-2009/Jan(Updated 090503)**

(c) 2009 JPO & JAPIO

**File 350:Derwent WPIX 1963-2009/UD=200930**

(c) 2009 Thomson Reuters

Set	Items	Description
S1	883	(ALLERGEN? ? OR ALLERGIN? ? OR (INFLUENCING OR ATOPIC OR TRIGGERING)() (AGENT? ? OR SUBSTANCE? ?) OR TRIGGER OR TRIGGERS-)(3N) (POTENTIAL? OR CANDIDATE OR SUSPECT??? OR LIKELY OR PROBABLE)
S2	68	S1(3N) (PLURALITY OR GROUP? ? OR NUMBER OR COMBINATION? ? OR SEVERAL OR MANY OR LIST? ? OR MULTIPLE OR NUMEROUS OR MULTITUDE OR SET OR SETS)
S3	27550	(PATIENT OR PATIENTS OR SUBJECT OR SUBJECTS OR INPATIENT? ? OR OUTPATIENT? ? OR PERSON? ? OR INDIVIDUAL? ? OR USER? ?) (3N) (EXPOSURE? ? OR EXPOSED OR EXPOSING OR EXPERIENC??? OR CONSUMPTION OR CONSUMED OR CONSUMING OR INHALE OR INHALES OR INHALING OR INHALATION OR INJECT??? OR EAT OR EATS OR EATING OR ATE)
S4	2038	(TRIGGER??? CAUSE? ? OR CAUSING OR CAUSAL OR (LEAD? ? OR LEADING OR LED)() TO OR RESULT???) (4N) ((ALLERGIC OR ADVERSE OR PHYSICAL OR PHYSIOLOGICAL OR BODILY)() (REACTION? ? OR RESPONSE? ? OR EFFECT? ?) OR ATOPY OR ATOPIC OR HYPERSENSITIVITY OR ANAPHYLAXIS OR ANAPHYLACT?)
S5	24097	((CORRELATION? ? OR STATISTICAL??) SIGNIFICAN??? OR PROBABILITY OR PROBABILITIES OR LIKELIHOOD OR CONFIDENCE OR (STRENGTH OR LINEAR OR MAGNITUDE OR DEGREE OR EXTENT) (2N) (ASSOCIATION? ? OR RELATIONSHIP? ?)) (3N) (COEFFICIENT? ? OR VALUE OR VALUES OR NUMBER? ? OR PERCENTAGE? ? OR SCORE? ?))
S6	8314	S5 (3N) (DETERMIN??? OR CALCULAT???? OR COMPUTE OR COMPUTES OR COMPUTING OR (FIGUR??? OR WORK)() OUT OR ASCERTAIN??? OR IDENTIF? OR ESTIMATE? ? OR ESTIMATING)
S7	65180	(CORRELATION? ? OR CONFIDENCE OR STATISTICAL??) SIGNIFICAN??? OR PROBABILITY OR PROBABILITIES OR LIKELIHOOD OR ASSOCIATION? ? OR RELATIONSHIP? ?) (5N) (DETERMIN? OR CALCULAT???? OR COMPUTE OR COMPUTES OR COMPUTED OR COMPUTING OR COMPUTATION? ? OR (FIGUR??? OR WORK)() OUT OR ASCERTAIN??? OR IDENTIF? OR ESTIMATE? ? OR ESTIMATING)
S8	13435	S7 (3N) (COEFFICIENT? ? OR VALUE OR VALUES OR NUMBER? ? OR PERCENTAGE? ? OR SCORE? ? OR SCORING)
S9	28	S4(5N) (IDENTIF? OR DIAGNOS? OR PINPOINT? OR PIN() POINT OR ISOLATE OR ISOLATES OR ISOLATING OR DISTINGUISH??? OR PRONOUNCE? ? OR PRONOUNCING OR INTERPRET???)
S10	0	(S5 OR S8) (10N) (FOOD? ? OR ALLERG?) (2N) (CHALLENGE() TEST??? OR ELIMINATION() DIET? ? OR CAUSE(1W) EFFECT)
S11	0	(CORRELAT? OR PROBABILITY OR LIKELIHOOD OR CONFIDENCE) (5N) - (ALLERG? OR TRIGGER?) (5N) (REACTION? ? OR RESPONSE? ? OR HYPERSENSITIVIT? OR ATOPY OR ATOPIC) (5N) (PATIENT? ? (2N) (EXPOS? OR CONSUM? OR INHAL? OR INJECT? OR EAT???) (5N) (DIAGNOS? OR IDENTIF? OR PINPOINT? OR ISOLAT?)
S12	41	IC=G06Q-010/00
S13	373588	IC=A61B
S14	1	S2 AND S3
S15	7	S1 AND S3
S16	0	S2 AND S4
S17	4	S1 AND S4
S18	2	S1 AND S6
S19	3	S1 AND S5

S20 2 S1 AND S8  
S21 8 S1 AND S7  
S22 17 (S14 OR S15 OR S17 OR S18 OR S19 OR S20 OR S21)  
S23 0 S4 AND (S6 OR S8)  
S24 4 S4 AND (S5 OR S7)  
S25 4 S24 NOT S22  
S26 2 S3 AND S9  
S27 2 S26 NOT (S22 OR S25)  
S28 32 S3 AND S4  
S29 1 S28 AND (CORRELATION? ? OR CONFIDENCE OR STATISTICAL??())SI-  
GNIFICAN??? OR PROBABILITY OR PROBABILITIES OR LIKELIHOOD OR -  
ASSOCIATION? ? OR RELATIONSHIP? ?)  
S30 2 S28 AND (S12 OR S13)  
S31 3 (S29 OR S30) NOT (S22 OR S25 OR S27)  
S32 26 S22 OR S25 OR S27 OR S31  
S33 6 ((S2 OR S9) AND S13) NOT S32  
S34 0 S9 AND (S6 OR S8)  
S35 0 S9 AND (S5 OR S7)  
S36 2 S12 AND S13  
S37 554 (S6 OR S8) AND S13  
S38 3 S37 AND (ALLERG? OR (PHYSICAL OR PHYSIOLOGICAL OR BODILY) (-  
) (REACTION? ? OR RESPONSE? ? OR EFFECT? ?) OR ATOPY OR ATOPIC  
OR HYPERSENSITIVITY OR ANAPHYLAXIS OR ANAPHYLACT?)  
S39 3 S38 NOT (S32 OR S33 OR S36)  
S40 3031 (S5 OR S7) AND S13  
S41 21 S40 AND (ALLERG? OR (PHYSICAL OR PHYSIOLOGICAL OR BODILY) (-  
) (REACTION? ? OR RESPONSE? ? OR EFFECT? ?) OR ATOPY OR ATOPIC  
OR HYPERSENSITIVITY OR ANAPHYLAXIS OR ANAPHYLACT?)  
S42 18 S41 NOT (S32 OR S33 OR S36 OR S39)

22/3,K/2 (Item 2 from file: 350)

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0018006184 *Drawing available*

WPI Acc no: 2008-J26505/200853

XRPX Acc No: N2008-664936

**Illness e.g. migraine headache, potential trigger identifying method for patient, involves receiving illness data from subject, and identifying potential trigger for illness based on food consumption data**

Patent Assignee: GERACI A P (GERA-I); GRZESKOWIAK M (GRZE-I)

Inventor: GERACI A P; GRZESKOWIAK M

Patent Family ( 3 patents, 121 countries )

***Bad Date***

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20080183047	A1	20080731	US 2007668774	A	20070130	200853	B
WO 2008094843	A2	20080807	WO 2008US52152	A	20080128	200854	E
WO 2008094843	A3	20081120	WO 2008US52152	A	20080128	200879	E

Priority Applications (no., kind, date): US 2007668774 A 20070130

NOVELTY - The method involves receiving food **consumption** data from a **subject** e.g. personal information, where the food consumption data includes information relating to food e.g. chocolate, **consumed** by the **subject**. Illness data is received from the subject, where the illness data identifies an illness i.e. migraine, **experienced** by the **subject**. A **potential trigger** i.e. food, is identified for the illness based on the food consumption data. The

food includes a medicine **consumed** by the **subject**. A report indicates a probability that the food/food element triggers the illness. A system and method for identifying a **potential trigger** of an illness. Subject data including information about a **subject**, food **consumption** data including information about food **consumed** by the **subject**, and illness data including information about an illness **experienced** by the **subject** are forwarded to a server. The server also retrieves reference data indicating nutrient information for particular foods. The server determines the nutrients in each consumed... **Claims:**What is claimed is:1. A method for identifying a **potential trigger** of an illness, the method comprising:receiving food **consumption** data from a **subject**, the food **consumption** data including information relating to food **consumed** by the **subject**;receiving illness data from the subject, the illness data identifying an illness **experienced** by the **subject**; andidentifying a **potential trigger** for the illness based on the food consumption data.

22/3,K/3 (Item 3 from file: 350)  
DIALOG(R)File 350: Derwent WPIX  
(c) 2009 Thomson Reuters. All rights reserved.

0017694905  
WPI Acc no: 2008-F15355/200835  
XRAM Acc no: C2008-170234  
XRPX Acc No: N2008-406748

**Anti-allergen solid substance of allergen reduction composition, inactivates allergic substance and allergen e.g. mites and pollen existing in dust absorbed in vacuum cleaner bag or dust collection cup of vacuum cleaner**

Patent Assignee: MARUTO KK (MARU-N)  
Inventor: IOKA H; MIHARA R

Patent Family ( 1 patents, 1 countries )

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
JP 2008088268	A	20080417	JP 2006269947	A	20060929	200835	B

Priority Applications (no., kind, date): JP 2006269947 A 20060929

Original Publication Data by AuthorityArgentina**Publication No. ...Original Abstracts:**exhaustion effectively by setting it as a particulate material.The allergen substance accumulatelstored into the vacuum cleaner can be inactivated.Therefore, it can prevent **exposing** a cleaning **person** to a dust disposal time at an allergen substance.Furthermore, since the anti- allergen solid substances of this invention are a vacuum cleaner bag or a dust-collection cup, and a different body, they are user-friendly.The removal **candidate** of an **allergen** substance can injectlthrow-in a necessary amount suitably, before cleaning up into a vacuum cleaner bag or a dust-collection cup.Regardless of the...

22/3,K/12 (Item 12 from file: 350)  
DIALOG(R)File 350: Derwent WPIX  
(c) 2009 Thomson Reuters. All rights reserved.

0010792736  
WPI Acc no: 2001-408258/200143  
Related WPI Acc No: 2001-381378; 2001-589915; 2003-018765; 2003-875632  
XRAM Acc no: C2001-123594

**Preventing allergic response against antigens, e.g. food and environmental allergens such as peanut allergen or grass pollen, latex or drug, comprises administering agent, e.g. a peptide, that blocks antigen**

**binding sites on offending IgE**

Patent Assignee: CAPLAN M J (CAPL-I); PANACEA PHARM LLC (PANA-N)

Inventor: CAPLAN M; CAPLAN M J

Patent Family ( 3 patents, 92 countries )

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2001039799	A2	20010607	WO 2000US33125	A	20001206	200143	B
AU 200120658	A	20010612	AU 200120658	A	20001206	200154	E
US 20020018778	A1	20020214	US 1999455294	A	19991206	200214	E
			US 2000213765	P	20000623		
			US 2000235797	P	20000927		
			US 2000731221	A	20001206		

Priority Applications (no., kind, date): US 1999455294 A 19991206; US 2000213765 P 20000623; US 2000235797 P 20000927; US 2000731221 A 20001206

**Original Abstracts:**from binding. These agents typically have up to one IgE binding site present per molecule so as prevent any cross-linking of IgE which could **lead to an allergic reaction**. Methods of using these novel IgE blocking agents include administering the agents to alleviate or prevent allergic reactions as well as administering the agents to... .. binding. These agents typically have up to one IgE binding site present per molecule so as to prevent any cross-linking of IgE which could **lead to an allergic reaction**. Methods of using these novel IgE blocking agents include administering the agents to alleviate or prevent allergic reactions as well as administering the agents to...

22/3,K/13 (Item 13 from file: 350)

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0010389216 *Drawing available*

WPI Acc no: 2000-273592/200024

XRAM Acc no: C2000-083610

XRPX Acc No: N2000-205094

**Determining an allergic response of an individual, using an improved skin test, comprises protease-digestion of potential allergens to specifically determine their allergenic potential**

Patent Assignee: HALMON LAB BEHEER BV (HALM-N)

Inventor: AALBERSE R C; VAN REE R

Patent Family ( 4 patents, 24 countries )

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
EP 994353	A1	20000419	EP 1998203472	A	19981015	200024	B
EP 994353	B1	20030502	EP 1998203472	A	19981015	200330	E
DE 69814078	E	20030605	DE 69814078	A	19981015	200345	E
			EP 1998203472	A	19981015		
ES 2198645	T3	20040201	EP 1998203472	A	19981015	200414	E

Priority Applications (no., kind, date): EP 1998203472 A 19981015

**Determining an allergic response of an individual, using an improved skin test, comprises protease-digestion of potential allergens to specifically determine their allergenic potential** Alerting Abstract ... potential, and subsequently determining the formation of IgE/antigen complexes, characterized in that IgE antibodies, preferably a serum sample containing IgE antibodies, obtained from the **individual** are **exposed** to... **Extension Abstract** ...food creations) using both digested and undigested extracts. Here there was no significant decrease in IgE binding after pepsin treatment. This confirmed the stability and **potential** allergenicity of food **allergens** occurring in shrimp and in related invertebrates alike.

31/3,K/1 (Item 1 from file: 350)

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0016554905

WPI Acc no: 2007-269842/200726

XRAM Acc no: C2007-098198

XRPX Acc No: N2007-200396

**Treatment of obesity in mammal comprises applying sodium channel blocker, e.g. lidocaine, to mammal intranasally and administering second compound, e.g. energy expenditure drug, to mammal**

Patent Assignee: COWLEY M A (COWL-I); GREENWAY F L (GREE-I); YOUNG L R D (YOUN-I)

Inventor: COWLEY M A; GREENWAY F L; YOUNG L R D

Patent Family ( 1 patents, 1 countries )

*Bad Date*

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20070020195	A1	20070125	US 2005689009	P	20050608	200726	B
			US 2006449418	A	20060608		

Priority Applications (no., kind, date): US 2005689009 P 20050608; US 2006449418 A 20060608

**Alerting Abstract** ... wished over a 20-minute period, and there were more chicken pieces than they could reasonably be expected to eat at one sitting. The four **subjects consumed** 15 %, 11 %, 27 % and 33 % less on the lidocaine week compared to the placebo week. The overall reduction in food intake 21.5 %±10.2 % was **statistically significant** (p is less than 0.02). Sibutramine, an obesity drug, gives an 8 % weight loss at 6 months and causes a 12 % decrease in food... ... olfactory cells to ions and inhibiting olfactory nerve impulses. Appetite is suppressed through the inhibition of olfactory neurosensory perception, thus the subject exhibits a reduced **physiological response** which **results** in lower food intake. The sodium channel blockers have very few side

effects and have been used with relatively little risk.

31/3,K/2 (Item 2 from file: 350)

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0010626904

WPI Acc no: 2001-233450/200124

XRAM Acc no: C2001-069930

XRPX Acc No: N2001-166700

**Method for individually selecting optimum nutrition of human beings**

Patent Assignee: KAMAKIN V V (KAMA-I); KAMAKINA M V (KAMA-I); MAKLAKOV V V (MAKL-I); MAKLAKOVA N N (MAKL-I)

Inventor: KAMAKIN V V; KAMAKINA M V; MAKLAKOV V V; MAKLAKOVA N N

Patent Family ( 2 patents, 21 countries )

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
RU 2162297	C1	20010127	RU 1999124506	A	19991125	200124	B
WO 2001037736	A1	20010531	WO 2000RU10	A	20000119	200132	E

Priority Applications (no., kind, date): RU 1999124506 A 19991125

**Alerting Abstract** ...NOVELTY - Method involves individually selecting food stuff items. Protein product cultured on living tissue by culturing cells taken from the **person consuming** the food stuff. **Class Codes** International Patent Classification IPC Class Level Scope Position Status Version Date ...**A61B-0010/00** ...**A61B-0010/00** Original Publication Data by AuthorityArgentina**Publication No. ...Original Abstracts:**a human being. The invention is based on the task of creating an optimal organization of and to optimize human nutrition whereby the possibility of **allergic reactions resulting from the consumption of** food proteins is excluded. Said aim is achieved by developing a method for individual selection of the optimal nutrition for a human being by defining...

33/3,K/1 (Item 1 from file: 350)

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0018953545 *Drawing available*

WPI Acc no: 2009-H36634/200929

**FAtopy diagnosing method for patient, involves searching images similar to affected part image among stored atopy images, and clipping affected part domain in input image for taking photograph of affected part of diagnostic object person**

Patent Assignee: KUMOH NAT INST TECHNOLOGY (KUMO-N)

Inventor: BYUN Y; KIM E; KO J

Patent Family ( 1 patents, 1 countries )

*Bad Date*

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
KR 2009002123	A	20090109	KR 200759496	A	20070618	200929	B

Priority Applications (no., kind, date): KR 200759496 A 20070618

**Alerting Abstract** ...ADVANTAGE - The method helps for automatically searching the collected atopy images and providing the **diagnosis result** of the searched **atopy** image and the **diagnosis** information toward atopy symptom of the patient, thus being helpful for right diagnosis toward the symptom of the corresponding patient...

**Class Codes** International Patent Classification IPC Class Level Scope Position Status Version Date **A61B-0010/00...** **A61B-0010/00...** Original Publication Data by Authority Argentina **Publication No. ...Original**

**Abstracts:**the searched similar images as described above is analyzed and the atopic symptom of the diagnostic object person is diagnosed. In order to provide the **diagnosis result** and the **atopic** symptom **diagnosis** of patient is helped the tag is implemented. The atopia, SIFT, image, tagging, the feature extraction, search, the invention relates to the atopia diagnosis support

33/3,K/2 (Item 2 from file: 350)

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0013746704

WPI Acc no: 2003-845242/200378

XRAM Acc no: C2003-237526

XRFX Acc No: N2003-675579

**Selecting genotypes within a species inducing a reduced allergic reaction in an allergy test, comprises testing genotypes for an allergic reaction in an allergy test and selecting a genotype exhibiting reduced allergic reaction**

Patent Assignee: UNIV CALIFORNIA (REGC); BUCHANAN B B (BUCH-I); CHO M (CHOM-I); FRICK O L (FRIC-I); KIM H (KIMH-I); LEMAUX P (LEMA-I); WONG J H (WONG-I)

Inventor: BUCHANAN R B; CHO M; FRICK O L; LEMAUX P G; WONG J H; BUCHANAN B B; KIM H; LEMAUX P

Patent Family ( 4 patents, 29 countries )

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2003086052	A2	20031023	WO 2003US10910	A	20030411	200378	B
AU 2003226032	A1	20031027	AU 2003226032	A	20030411	200436	E
US 20060090215	A1	20060427	US 2002372253	P	20020411	200629	E
			WO 2003US10910	A	20030411		
			US 2005510325	A	20050822		
AU 2003226032	A8	20061109	AU 2003226032	A	20030411	200724	E

Priority Applications (no., kind, date): US 2002372253 P 20020411; US 2005510325 A 20050822

**Extension Abstract** ...methods of **identifying** growth conditions that **lead to** a reduced **allergic reaction** an allergy test compared to the same species or preferably a genotype growth under different conditions; food and food products produced from low allergic reaction... **Extension Abstract Image Class Codes** International Patent Classification IPC Class Level Scope Position Status Version Date ...**A61B-0010/00**

33/3,K/3 (Item 3 from file: 350)  
 DIALOG(R)File 350: Derwent WPIX  
 (c) 2009 Thomson Reuters. All rights reserved.

0010754268  
 WPI Acc no: 2001-367584/200138  
 XRAM Acc no: C2001-112763  
 XRPX Acc No: N2001-268192

**Rapid and reliable diagnosis of allergies and intolerance reactions, e.g., coeliac disease, with minimal patient discomfort, using nitric oxide concentrations in the rectum as a marker**

Patent Assignee: AEROCRINE AB (AERO-N)

Inventor: ALVING K; LUNDBERG J; NORDVALL L; WEITZBERG E

Patent Family ( 4 patents, 93 countries )

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2001036969	A1	20010525	WO 2000SE2253	A	20001116	200138	B
AU 200119072	A	20010530	AU 200119072	A	20001116	200152	E
EP 1255992	A1	20021113	EP 2000981993	A	20001116	200282	E
			WO 2000SE2253	A	20001116		
US 6511425	B1	20030128	US 1997849282	A	19970530	200311	E
			US 1999273514	A	19990322		
			US 2000712262	A	20001115		

Priority Applications (no., kind, date): SE 19994137 A 19991116; SE 19994138 A 19991116

**Class Codes** International Patent Classification IPC Class Level Scope Position Status Version Date **A61B-0005/00... A61B-0005/00...** Original Publication Data by AuthorityArgentina**Publication No. ...Original Abstracts:**to normal levels, obtained from healthy controls, are taken as an indication of allergy or a predisposition for allergy. One or several repeated measurements after **elimination** of the **suspected allergen** from the **patient's** diet can be used to confirm the diagnose and to check patient compliance

33/3,K/5 (Item 5 from file: 350)  
 DIALOG(R)File 350: Derwent WPIX  
 (c) 2009 Thomson Reuters. All rights reserved.

0007148975 *Drawing available*  
 WPI Acc no: 1995-184696/199524  
 XRPX Acc No: N1995-144617

**Electronic allergic sensitivity test appts - has pair of electrodes attached at separate locations of body and are connected to signal amplification unit and A-D converter**

Patent Assignee: MILNE R D (MILN-I)

Inventor: MILNE R D

Patent Family ( 7 patents, 63 countries )



Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 5413113	A	19950509	US 1994215358	A	19940321	199524	B
WO 1996035471	A1	19961114	WO 1995US5824	A	19950508	199651	NCE
CA 2146227	A	19961004	CA 2146227	A	19950403	199705	NCE
AU 199524798	A	19961129	AU 199524798	A	19950508	199712	NCE
			WO 1995US5824	A	19950508		
AU 691287	B	19980514	AU 199524798	A	19950508	199831	NCE
EP 1007141	A1	20000614	EP 1995919111	A	19950508	200033	NCE
			WO 1995US5824	A	19950508		
CA 2146227	C	20001010	CA 2146227	A	19950403	200056	NCE

Priority Applications (no., kind, date): US 1994215358 A 19940321; CA 2146227 A 19950403; WO 1995US5824 A 19950508; AU 199524798 A 19950508; EP 1995919111 A 19950508

**Class Codes** International Patent Classification IPC Class Level Scope Position Status Version Date **A61B-0005/053...** ...**A61B-0005/103 A61B-0005/053...** ...**A61B-0005/103** Original Publication Data by

Authority Argentina **Publication No. Original Abstracts:** A device and method for testing a patient's sensitivity to a **plurality of potential allergens** is disclosed **using the** galvanometric skin response of the patient's body to determine the same. A pair of electrodes (10, 12) are attached at separate locations on the... ... A device and method for testing a patient's sensitivity to a **plurality of potential allergens** is disclosed using the galvanometric skin response **of the** patient's body to determine the same. A pair of electrodes are attached at separate locations of the body and are connected to a signal... ... A device and method for testing a patient's sensitivity to a **plurality of potential allergens** is disclosed using the galvanometric skin response of the patient's body **to determine** the same. A pair of electrodes (10, 12) are attached at separate locations on the body and are connected to a signal amplification unit (20... **Claims:** A testing apparatus to test a patient's sensitivity to a **plurality of potential allergens comprising: electrode** means for measuring directly the galvanometric response of the patient, said electrode means comprising a pair of electrodes attached at different points to said patient...

33/3,K/6 (Item 6 from file: 350)

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0005770957

WPI Acc no: 1991-202385/199128

XRPX Acc No: N1991-154811

**Patches for diagnosing contact dermatitis - each contg. several potential allergens, opt. at different concns.**

Patent Assignee: SHUSTER S (SHUS-I)

Inventor: MCLELLANDK J; SHUSTER S

Patent Family ( 1 patents, 1 countries )

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
GB 2239708	A	19910710	GB 198919209	A	19890824	199128	B
			GB 1989919209	A	19890824		

Priority Applications (no., kind, date): GB 1989919209 A 19890824

...each contg. several potential allergens, opt. at different concns. Class Codes International Patent Classification IPC Class Level Scope Position Status Version Date **A61B-0010/00... A61B-0010/00...**

36/3,K/2 (Item 2 from file: 350)

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0012315391 *Drawing available*

WPI Acc no: 2002-256955/200230

Related WPI Acc No: 2002-328612; 2002-329175; 2004-280298; 2004-340779; 2004-364972; 2005-202350; 2005-295672; 2005-314903; 2005-713762; 2006-432366; 2007-071661; 2007-557340; 2007-749613; 2008-M29153

XRPX Acc No: N2002-198929

**Human physiological information detecting, monitoring and reporting system using internet, transmits analytical status data generated from detected physiological parameters to user**

Patent Assignee: BODYMEDIA INC (BODY-N); KASABACH C D (KASA-I); LIDEN C B (LIDE-I); MCCORMACK M A (MCCO-I); MOSS J L (MOSS-I); PACIONE C D (PACI-I); STIVORIC J M (STIV-I); TELLER E (TELL-I)

Inventor: KASABACH C D; LIDEN C B; MCCORMACK M A; MOSS J L; PACIONE C D; STIVORIC J M ; TELLER E; KASABACH D; LIDEN B; MOSS L; PACIONE D; STIVORIC M

Patent Family ( 18 patents, 93 countries )

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2001096986	A2	20011220	WO 2001US40958	A	20010613	200230	B
AU 200167083	A	20011224	AU 200167083	A	20010613	200231	E
EP 1292217	A2	20030319	EP 2001944698	A	20010613	200322	E
			WO 2001US40958	A	20010613		
KR 2003015281	A	20030220	KR 2002717160	A	20021216	200340	E
JP 2004512061	W	20040422	JP 2002511050	A	20010613	200428	E
			WO 2001US40958	A	20010613		
BR 200111995	A	20050628	BR 200111995	A	20010613	200545	E
			WO 2001US40958	A	20010613		
MX 2002012482	A1	20041101	MX 200212482	A	20021216	200558	E
			WO 2001US40958	A	20010613		
AU 2001267083	A8	20050915	AU 2001267083	A	20010613	200569	E
EP 1292217	B1	20051123	EP 2001944698	A	20010613	200577	E
			WO 2001US40958	A	20010613		
DE 60115234	E	20051229	DE 60115234	A	20010613	200603	E
			EP 2001944698	A	20010613		
			WO 2001US40958	A	20010613		
US 20060031102	A1	20060209	US 2000595660	A	20000616	200612	E
			US 2005247049	A	20051011		
EP 1639939	A1	20060329	EP 2001944698	A	20010613	200623	E
			EP 200577625	A	20010613		
ES 2253393	T3	20060601	EP 2001944698	A	20010613	200638	E
DE 60115234	T2	20060810	DE 60115234	A	20010613	200654	E
			EP 2001944698	A	20010613		
			WO 2001US40958	A	20010613		
MX 236870	B	20060515	MX 200212482	A	20021216	200670	E
			WO 2001US40958	A	20010613		
CA 2413220	C	20071113	CA 2413220	A	20010613	200779	E
			WO 2001US40958	A	20010613		
EIC3600 SEARCH RESULTS						5/19/2009	
US 20080177158	A1	20080724	US 2000595660	A	20000616	200851	E
			US 2007930405	A	20071031		

Priority Applications (no., kind, date): US 2000595660 A 20000616; US 2005247049 A 20051011; US 2007930405 A 20071031

42/3,K/4 (Item 4 from file: 350)

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0017255059 *Drawing available*

WPI Acc no: 2008-A75490/200805

XRAM Acc no: C2008-019423

XRPX Acc No: N2008-059261

**Correlation evaluating method for use in medical claims billing and electronic medical record, involves determining correlations between one of clinical conditions and genotypic data and clinical data for subset of patients**

Patent Assignee: GENERAL ELECTRIC CO (GENE)

Inventor: SETTIMI P D

Patent Family ( 4 patents, 4 countries )

*Bad Date*

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20070294113	A1	20071220	US 2006813397	P	20060614	200805	B
			US 2006601358	A	20061117		
FR 2908906	A1	20080523	FR 200756143	A	20070629	200835	E
GB 2443896	A	20080521	GB 200712154	A	20070622	200836	E
CA 2592705	A1	20081221	CA 2592705	A	20070621	200910	NCE

Priority Applications (no., kind, date): US 2006813397 P 20060614; US 2006601358 A 20061117; CA 2592705 A 20070621

**Correlation evaluating method for use in medical claims billing and electronic medical record, involves determining correlations between one of clinical conditions and genotypic data and clinical data for subset of patients** **Alerting Abstract** ...from a user, and a subset of patients is created from the population based on a comparison of the clinical conditions to the clinical data. **Correlations** are **determined** between one of the clinical conditions, the genotypic data and the clinical data for the subset of patients, where the clinical data includes a codified... ... a computer-readable storage medium comprising a set of instructions for normalizing genotypic data and clinical data a method for **determining correlations** between genetic data and medical data... ... g. nucleotide polymorphism, and clinical information such as medical test result, chronic condition and chronic disease e.g. diabetes, heart disease, AIDS, cancer and cataracts, **allergy**, adverse reaction to a medical therapeutic, environmental factor e.g. smoke, dust and animal, and medical problem (claimed) in a medical claims billing and electronic... ... **Claims:**conditions from a user;creating a subset of patients from said population based on a comparison of said clinical conditions to said clinical data; and**determining** one or more **correlations** between at least one of said clinical conditions and one or more of said genotypic data and said clinical data for said subset of patients.

42/3,K/15 (Item 15 from file: 350)  
DIALOG(R)File 350: Derwent WPIX  
(c) 2009 Thomson Reuters. All rights reserved.

0012300138 *Drawing available*  
WPI Acc no: 2002-241332/200229  
XRAM Acc no: C2002-072512  
XRPX Acc No: N2002-186412

**Apparatus for screening olfactory mucosa-stimulating compounds applicable in direct stimulation of human brain cells without side-effects, is useful in neurophysiology, pharmacology, medical science or food science**

Patent Assignee: MATSUSHITA DENKI SANGYO KK (MATU); MATSUSHITA ELECTRIC IND CO LTD (MATU); OGAWA R (OGAW-I); OKA H (OKAH-I); YUKIMASA T (YUKI-I)  
Inventor: OGAWA R; OKA H; YUKIMASA T

Patent Family ( 16 patents, 93 countries )

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2002002009	A1	20020110	WO 2001JP5426	A	20010625	200229	B
AU 200174614	A	20020114	AU 200174614	A	20010625	200237	E
US 20020122770	A1	20020905	WO 2001JP5426	A	20010625	200260	E
			US 200270170	A	20020305		
EP 1234540	A1	20020828	EP 2001941230	A	20010625	200264	E
			WO 2001JP5426	A	20010625		
KR 2002035130	A	20020509	KR 2002702943	A	20020305	200272	E
CN 1383372	A	20021204	CN 2001801924	A	20010625	200322	E
JP 2002506640	X	20030924	WO 2001JP5426	A	20010625	200365	E
			JP 2002506640	A	20010625		
US 20040229345	A1	20041118	WO 2001JP5426	A	20010625	200477	E
			US 200270170	A	20020305		
			US 2004709700	A	20040524		
KR 466954	B	20050126	WO 2001JP5426	A	20010625	200535	E
			KR 2002702943	A	20020305		
JP 3705546	B2	20051012	WO 2001JP5426	A	20010625	200566	E
			JP 2002506640	A	20010625		
JP 2005319316	A	20051117	JP 2002506640	A	20010625	200575	E
			JP 2005167582	A	20050607		
US 6994671	B2	20060207	WO 2001JP5426	A	20010625	200611	E
			US 200270170	A	20020305		
CN 1235543	C	20060111	CN 2001801924	A	20010625	200655	E
EP 1234540	B1	20070321	EP 2001941230	A	20010625	200723	E
			WO 2001JP5426	A	20010625		
DE 60127376	E	20070503	DE 60127376	A	20010625	200731	E
			EP 2001941230	A	20010625		
			WO 2001JP5426	A	20010625		
DE 60127376	T2	20070712	DE 60127376	A	20010625	200746	E
EIC3600 SEARCH RESULTS			EP 2001941230	A	20010625	5/19/2009	
			WO 2001JP5426	A	20010625		

Priority Applications (no., kind, date): JP 2000204411 A 20000705

**Original Abstracts:**in an olfactory bulb of the rat for measuring an electrical signal generated in the olfactory bulb. Efficacy of the olfactory mucosa stimulating compound is **determined** based on a **correlation** between an electrical signal measured by the measuring electrode portion **10** when the olfactory mucosa stimulating compound is sprayed on the olfactory mucosa of the rat and a **physiological response** induced in the rat... ... in an olfactory bulb of the rat for measuring an electrical signal generated in the olfactory bulb. Efficacy of the olfactory mucosa stimulating compound is **determined** based on a **correlation** between an electrical signal measured by the measuring electrode portion **10** when the olfactory mucosa stimulating compound is sprayed on the olfactory mucosa of the rat and a **physiological response** induced in the rat... ... in an olfactory bulb of the rat for measuring an electrical signal generated in the olfactory bulb. Efficacy of the olfactory mucosa stimulating compound is **determined** based on a **correlation** between an electrical signal measured by the measuring electrode portion **10** when the olfactory mucosa stimulating compound is sprayed on the olfactory mucosa of the rat and a **physiological response** induced in the rat... ... **Claims:**measuring electrode portion when the olfactory mucosa stimulating compound is administered to the olfactory mucosa of the test animal by the administration means and a **physiological response** induced in the test animal... ... test animal for measuring an electrical signal generated in the olfactory bulb;a processing means for determining whether the olfactory mucosa stimulating compound induces a **physiological response** from a correlation between an electrical signal measured by the measuring electrode portion when the olfactory mucosa stimulating compound is administered to the olfactory mucosa of the test animal by the administration means and the **physiological response** induced in the test animal, wherein (i) the processing means directly obtains data concerning the **physiological response** from the test animal, so as to determine whether the olfactory mucosa stimulating compound induces the **physiological response** from the correlation between the **physiological response** and the electrical signal obtained by the measuring electrode portion, or(ii) the processing means previously stores data concerning an electrical signal in the olfactory bulb which induces a **physiological response** in the test animal, and determines whether the olfactory mucosa stimulating compound induces the **physiological response** from the data corresponding to the correlation between a **physiological response** and an electrical signal obtained by the measuring electrode portion.... measuring electrode portion when the olfactory mucosa stimulating compound is administered to the olfactory mucosa of the test animal by the administration means and a **physiological response** induced in the test animal... ... measuring electrode portion when the olfactory mucosa stimulating compound is administered to the olfactory mucosa of the test animal by the administration means and a **physiological response** induced in the test animal.

42/3,K/16 (Item 16 from file: 350)

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0010792447

WPI Acc no: 2001-407932/200143

Related WPI Acc No: 2003-362099; 2003-730716; 2005-161641; 2006-212130

XRAM Acc no: C2001-123481

XRPX Acc No: N2001-301854

**Health profiling of animals e.g. horses, by combining genetic data of animals with health assessment data to permit analysis predicting health, disease, disorder probabilities and longevity of animals**

Patent Assignee: DODDS W (DODD-I); DODDS W J (DODD-I); HEMOPET (HEMO-N)

Inventor: DODDS W J

Patent Family ( 11 patents, 93 countries )

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2001028415	A1	20010426	WO 2000US25924	A	20000922	200143	B
AU 200078308	A	20010430	AU 200078308	A	20000922	200148	E
US 6287254	B1	20010911	US 1999432851	A	19991102	200154	E
US 20020022772	A1	20020221	US 1999432851	A	19991102	200221	E
			US 2001908407	A	20010822		
EP 1223852	A1	20020724	EP 2000968382	A	20000922	200256	E
			WO 2000US25924	A	20000922		
US 20030135096	A1	20030717	US 1999419192	A	19991015	200348	E
			US 2003368236	A	20030218		
JP 2003523176	W	20030805	WO 2000US25924	A	20000922	200353	E
			JP 2001531017	A	20000922		
US 6730023	B1	20040504	US 1999419192	A	19991015	200430	E
AU 782474	B2	20050804	AU 200078308	A	20000922	200557	E
AU 2005202664	A1	20050714	AU 2005202664	A	20050617	200562	NCE
US 7134995	B2	20061114	US 1999419192	A	19991015	200675	E
			US 2003368236	A	20030218		

Priority Applications (no., kind, date): US 1999419192 A 19991015; US 1999432851 A 19991102; US 2001908407 A 20010822; US 2003368236 A 20030218; AU 2005202664 A **Class Codes** International Patent Classification IPC Class Level Scope Position Status Version Date ...**A61B-0005/00**... ...**A61B-0005/00**...  
...**A61B-0005/00**... ...**A61B-0005/00** ...**A61B-0005/00**... ...**A61B-0005/00**... ...**A61B-0005/00**... ...**A61B-0005/00**...  
Original Publication Data by AuthorityArgentina**Publication No.** ...**Original Abstracts:**and coagulation function, vaccinal antibody status, adverse and potential adverse vaccine reaction, infectious diseases, pathology, blood typing and bone marrow analysis, cell cytotoxicity, cytokine and **allergy** testing, and markers of neoplastic and paraneoplastic change... ... and coagulation function, vaccinal antibody status, adverse and potential adverse vaccine reaction, infectious diseases, pathology, blood typing and bone marrow analysis, cell cytotoxicity, cytokine and **allergy** testing, and markers of neoplastic and paraneoplastic change... ...**Claims:**ii) phenotype health assessment data of the selected animal;b) using a computer program, combining the genetic data and the phenotype health assessment data to **determine a relationship** between the genetic data and the phenotype health assessment data;c) selecting from b) at least one of:i) the data relating to the temperament ...



## B. Patent Files, Full-Text

**File 348:EUROPEAN PATENTS 1978-200920**

(c) 2009 European Patent Office

**File 349:PCT FULLTEXT 1979-2009/UB=20090514|UT=20090507**

(c) 2009 WIPO/Thomson

Set	Items	Description
S1	534	(ALLERGEN? ? OR ALLERGIN? ? OR (INFLUENCING OR ATOPIC)() (AGENT? ? OR SUBSTANCE? ?) OR ALLERG?(N) (TRIGGER???) (5N) (POTENTIAL? OR CANDIDATE OR SUSPECT??? OR LIKELY OR PROBABLE)
S2	50	S1(5N) (PLURALITY OR GROUP? ? OR NUMBER OR COMBINATION? ? OR SEVERAL OR MANY OR LIST? ? OR MULTIPLE OR NUMEROUS OR MULTITUDE OR SET OR SETS)
S3	79029	(PATIENT OR PATIENTS OR SUBJECT OR SUBJECTS OR INPATIENT? ? OR OUTPATIENT? ? OR PERSON? ? OR INDIVIDUAL? ? OR USER? ?) (3-N) (EXPOSURE? ? OR EXPOSED OR EXPOSING OR EXPERIENC??? OR CONSUMPTION OR CONSUMED OR CONSUMING OR INHALE OR INHALES OR INHALING OR INHALATION OR INJECT??? OR EAT OR EATS OR EATING OR ATE)
S4	5941	(TRIGGER??? CAUSE? ? OR CAUSING OR CAUSAL OR (LEAD? ? OR LEADING OR LED)() TO OR RESULT???) (5N) (ALLERG? OR (PHYSICAL OR - PHYSIOLOGICAL OR BODILY)() (REACTION? ? OR RESPONSE? ? OR EFFECT? ?) OR ATOPY OR ATOPIC OR HYPERSENSITIVITY OR ANAPHYLAXIS - OR ANAPHYLACT?)
S5	46193	((CORRELATION? ? OR STATISTICAL??) SIGNIFICAN??? OR PROBABILITY OR PROBABILITIES OR LIKELIHOOD OR CONFIDENCE OR (STRENGTH OR LINEAR OR MAGNITUDE OR DEGREE OR EXTENT OR MEASUR?) (2N) - (ASSOCIATION? ? OR RELATIONSHIP? ?)) (3N) (COEFFICIENT? ? OR VALUE OR VALUES OR NUMBER? ? OR PERCENTAGE? ? OR SCORE? ?))
S6	10318	S5 (3N) (DETERMIN??? OR CALCULAT???? OR COMPUTE OR COMPUTES OR COMPUTING OR (FIGUR??? OR WORK)() OUT OR ASCERTAIN??? OR IDENTIF? OR ESTIMATE? ? OR ESTIMATING)
S7	104446	(CORRELATION? ? OR CONFIDENCE OR STATISTICAL??) SIGNIFICAN??? OR PROBABILITY OR PROBABILITIES OR LIKELIHOOD OR ASSOCIATION? ? OR RELATIONSHIP? ?) (5N) (DETERMIN? OR CALCULAT???? OR COMPUTE OR COMPUTES OR COMPUTED OR COMPUTING OR COMPUTATION? ? OR (FIGUR??? OR WORK)() OUT OR ASCERTAIN??? OR IDENTIF? OR ESTIMATE? ? OR ESTIMATING)
S8	18873	S7 (3N) (COEFFICIENT? ? OR VALUE OR VALUES OR NUMBER? ? OR PERCENTAGE? ? OR SCORE? ? OR SCORING)
S9	113	S4(5N) (IDENTIF? OR DIAGNOS? OR PINPOINT? OR PIN() POINT OR - ISOLATE OR ISOLATES OR ISOLATING OR DISTINGUISH??? OR PRONOUNCE? ? OR PRONOUNCING OR INTERPRET???)
S10	0	(S5 OR S7) (20N) (FOOD? ? OR ALLERG?) (2N) (CHALLENGE() TEST??? OR ELIMINATION() DIET? ? OR CAUSE(1W) EFFECT)
S11	22	(CORRELAT? OR PROBABILITY OR LIKELIHOOD OR CONFIDENCE) (3N) - (ALLERG? OR HYPERSENSITIV? OR ATOPIC) (2N) (REACTION? ? OR RESPONSE? ?) (3N) (DIAGNOS? OR IDENTIF? OR PINPOINT? OR ISOLAT?)
S12	0	S2 (10N) S3
S13	0	S2 (20N) S3
S14	1	S2 (10N) S4
S15	0	S2 (10N) (S5 OR S7)
S16	0	S2 (20N) (S5 OR S7)
S17	0	S2 (20N) S9
S18	12	S1 (10N) S3
S19	1	S1 (20N) S9

S20 1 S18 AND (S5 OR S7)  
 S21 24 S11 OR S14 OR S20  
 S22 0 S1 (40N) (S6 OR S8)  
 S23 1 S1 (30N) (S5 OR S7)  
 S24 1 S23 NOT S21  
 S25 0 S9 (50N) (S6 OR S8)  
 S26 5 S4 (40N) (S6 OR S8)  
 S27 6 S3 (20N) S9  
 S28 1 S9 (40N) (S5 OR S7)  
 S29 102353 IC=A61B  
 S30 11 IC=G06Q-010/00  
 S31 61 S3 (10N) S4  
 S32 0 S31 (40N) (S5 OR S7)  
 S33 11 S31 AND (S29 OR S30)  
 S34 23 S26 OR S27 OR S28 OR S33  
 S35 23 S34 NOT S21  
 S36 0 S29 AND S30  
 S37 95683 (ALLERG? OR (PHYSICAL OR PHYSIOLOGICAL OR BODILY) ( ) (REACTION? ? OR RESPONSE? ? OR EFFECT? ?) OR ATOPY OR ATOPIC OR HYPERSENSITIVITY OR ANAPHYLAXIS OR ANAPHYLACT?)  
 S38 13 (S6 OR S8) (20N) S37  
 S39 0 S38 AND S29  
 S40 13 S38 NOT (S21 OR S35)  
 S41 138 (S5 OR S7) (15N) S37  
 S42 9 S41 AND S29  
 S43 20 (S42 OR S40) NOT (S21 OR S35)

21/3K/1 (Item 1 from file: 348)

DIALOG(R)File 348: EUROPEAN PATENTS

(c) 2009 European Patent Office. All rights reserved.

01701546

# **Methods of testing for bronchial asthma or chronic obstructive pulmonary disease**

Test-Verfahren für Bronchialasthma oder chronisch-obstruktive-Atemwegserkrankung (COPD)

Méthodes pour tester l'asthme ou la maladie chronique d'obstruction des poumons (COPD)

## **Patent Assignee:**

**Genox Research, Inc.;** (2788270)

5-1-3, Tokodai, Tsukuba-shi,; Ibaraki 300-2635; (JP)

(Applicant designated States: all)

## **Inventor:**

**Ohtani, Noriko**

Kirin Brewery Co. Ltd. 3 Miyahara-cho; Takasaki-shi Gunma 370-1295; (JP)

**Sugita, Yuji**

Yamanouchi Pharm. Co. Ltd. 21 Miyukigaoka; Tsukuba-shi, Ibaraki 305-8585; (JP)

**Yamaya, Mutsuo**

Tohoku Univ. School of Medicine 1-1 Seiryō-cho; Aoba-ku, Sendai-shi, Miyagi 980-8574; (JP)

**Kubo, Hiroshi**

Tohoku Univ. School of Medicine 1-1 Seiryō-cho; Aoba-ku, Sendai-shi, Miyagi 980-8574; (JP)

**Nagai, Hiroichi**

Gifu Pharmaceutical Univ. 5-6-1 Mitahara-Higashi; Gifu-shi Gifu 502-8585; (JP)

**Izuhara, Kenji**

Saga Medical School 5-1-1 Nabeshima; Saga-shi Saga 849-8501; (JP)

## **Legal Representative:**

**Harding, Charles Thomas (70742)**

D. Young & Co. 21 New Fetter Lane; London EC4A 1DA; (GB)

	Country	Number	Kind	Date	
Patent	EP	1394274	A2	20040303	(Basic)
	EP	1394274	A3	20040526	
Application	EP	2003254857		20030804	
Priorities	JP	2002229312		20020806	
	JP	200377212		20030320	

In the present invention, the term "allergic disease" is a general term used for a disease in which an allergic **reaction** is involved. More specifically, for a disease to be considered **allergic**, the **allergen** must be **identified**, a strong **correlation** between exposure to the **allergen** and the onset of a pathological change must be demonstrated, and it should have been proven that an immunological mechanism is behind the pathological change...

21/3K/2 (Item 2 from file: 348)

DIALOG(R)File 348: EUROPEAN PATENTS

(c) 2009 European Patent Office. All rights reserved.

01499979

## METHOD OF EXAMINING ALLERGIC DISEASE

### Patent Assignee:

**Genox Research, Inc.;** (2788271)

5-1-3, Tokodai; Tsukuba-shi Ibaraki 300-2635; (JP)

(Applicant designated States: all)

### Inventor:

**OHTANI, N. Genox Research, Inc.**

Teikyo Univ. Biotech Cntr 907, Nogawa, Miyamae-ku; Kawasaki-shi, Kanagawa 216-0001; (JP)

**MATSUI, K. Genox Research, Inc.**

Teikyo Univ. Biotech Cntr 907, Nogawa, Miyamae-ku; Kawasaki-shi, Kanagawa 216-0001; (JP)

**YOSHIDA, N. Genox Research, Inc.**

Teikyo Univ. Biotech Cntr 907, Nogawa, Miyamae-ku; Kawasaki-shi, Kanagawa 216-0001; (JP)

**SUGITA, Y. Genox Research, Inc.**

Teikyo Univ. Biotech Cntr 907, Nogawa, Miyamae-ku; Kawasaki-shi, Kanagawa 216-0001; (JP)

**IZUHARA, K. Department of Biochemistry**

Saga Medical School 5-1-1, Nabehsima; Saga-shi, Saga 849-8501; (JP)

### Legal Representative:

**Warcoin, Jacques et al (19071)**

Cabinet Regimbeau 20, rue de Chazelles; 75847 Paris cedex 17; (FR)

	Country	Number	Kind	Date	
Patent	EP	1347051	A1	20030924	(Basic)
	WO	2002052006		20020704	

Application	EP	2001272292		20011221	
	WO	2001JP11287		20011221	
Priorities	JP	2000396166		20001226	

**Specification:** ...used as a diagnostic marker for renal cancer and glaucoma.

In the present invention, allergic disease is a general term for diseases in which allergic **reactions** is involved. More specifically, for a disease to be considered **allergic**, the **allergen** must be **identified**, a strong **correlation** between exposure to the **allergen** and the

21/3K/6 (Item 6 from file: 348)

DIALOG(R)File 348: EUROPEAN PATENTS

(c) 2009 European Patent Office. All rights reserved.

00637792

# **VACCINATION WITH PEPTIDE OF MHC CLASS II MOLECULES FOR TREATMENT OF AUTOIMMUNE DISEASE**

## **Patent Assignee:**

**SRIRAM, Subramaniam;** (1819650)

283 Apple Tree Point,; Burlington, VT 05401; (US)

(Proprietor designated states: all)

**NAG, Bishwajit;** (1819660)

465 Lynbrook Drive,; Pacifica, CA 94044; (US)

(Proprietor designated states: all)

**SHARMA, Somesh D.;** (1819690)

44 Stuart Court,; Los Altos, CA; (US)

(Proprietor designated states: all)

## **Inventor:**

**SRIRAM, Subramaniam**

283 Apple Tree Point,; Burlington, VT 05401; (US)

**NAG, Bishwajit**

465 Lynbrook Drive,; Pacifica, CA 94044; (US)

**SHARMA, Somesh D.**

44 Stuart Court,; Los Altos, CA; (US)

## **Legal Representative:**

**Greaves, Carol Pauline et al (50413)**

Mewburn Ellis York House 23 Kingsway; London WC2B 6HP; (GB)

	Country	Number	Kind	Date	
Patent	EP	674526	A1	19951004	(Basic)
	EP	674526	A1	19970115	
	EP	674526	B1	20030507	
	WO	94013320		19940623	

Application	EP	94904861		19931216	
	WO	93US12351		19931216	
Priorities	US	992942		19921217	

**Specification:** ...order to select the MHC molecules for producing peptides of the invention, particular MHC molecules which are involved in the presentation of the antigen are **identified**. In the case of **allergies**, specific **allergic responses** are **correlated** with specific MHC types. For instance, **allergic reactions** to ragweed are known to be associated with DR2 alleles. Marsh et al., (1989) Cold Spring Harb Symp Quant Biol 54:459-70, which is...

21/3K/14 (Item 8 from file: 349)

DIALOG(R)File 349: PCT FULLTEXT

(c) 2009 WIPO/Thomson. All rights reserved.

00990270

# **METHOD OF SCREENING FOR DRUG HYPERSENSITIVITY REACTION**

## **PROCEDE DE DEPISTAGE DES REACTIONS D'HYPERSENSIBILITE A DES MEDICAMENTS**

### **Patent Applicant/Patent Assignee:**

**GLAXO GROUP LIMITED;** Glaxo Group Limited, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 ONN  
GB; GB(Residence); GB(Nationality)  
(For all designated states except: US)

### **Patent Applicant/Inventor:**

#### **HETHERINGTON Seth**

c/o Inhibitex, Inc., 8995 Westside Parkway, Suite 150, Alpharetta, GA 30004; US; US(Residence); US(Nationality); (Designated only for: US)

#### **HUGHES Arlene R**

GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709; US; US(Residence); US(Nationality); (Designated only for: US)

#### **LAI Eric H**

GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709; US; US(Residence); US(Nationality); (Designated only for: US)

#### **MOSTELLER JR Michael**

GlaxoSmithKline, Five Moore Drive, PO Box 1398, Research Triangle Park, NC 27709; US; US(Residence); US(Nationality); (Designated only for: US)

#### **SHORTINO Denise D**

GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709; US; US(Residence); US(Nationality); (Designated only for: US)

### **Legal Representative:**

#### **LEVY David J(et al)(agent)**

GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709; US;

	Country	Number	Kind	Date
Patent	WO	200318745	A2-A3	20030306
Application	WO	2002US24950		20020807

Priorities	US	2001314026		20010821
	US	2001336850		20011030

#### Detailed Description:

...a population of test subjects for at least one polymorphism in the TNFa gene, administering a therapeutic regime of abacavir to each test subject, and **identifying** test subjects that exhibit clinical signs of a **hypersensitivity reaction** to abacavir. **Correlating** TNFu. genotypes with the occurrence of clinical signs of **hypersensitivity reaction**, will determine which genotypes are associated with an increased risk of hypersensitivity reaction to abacavir (compared to the other detected genotypes).

A further aspect of an HLA gene, administering a therapeutic regime of abacavir to each test subject, and **identifying** test subjects that exhibit clinical signs of a **hypersensitivity reaction** to abacavir. **Correlating** HLA genotypes with the occurrence of clinical signs of **hypersensitivity reaction**, will determine which genotypes are associated with an increased risk of hypersensitivity reaction to abacavir (compared to the other detected genotypes).

#### Claims:

...reaction to abacavir, comprising:

a) in a population of test subjects, genotyping each test subject for at least one polymorphism in an HLA gene; b) administering a therapeutic regime of abacavir to each test subject; c) **identifying** test subjects that exhibit clinical signs of a **hypersensitivity reaction** to abacavir; and d) **correlating** the HLA genotypes of the test subjects with the occurrence of clinical signs of hypersensitivity reaction, to determine which genotypes are associated with an increased ...

21/3K/16 (Item 10 from file: 349)

DIALOG(R)File 349: PCT FULLTEXT

(c) 2009 WIPO/Thomson. All rights reserved.

00942706

#### SKIN-TEST REAGENTS AND SERUM SPECIFIC IGE, IGG SUBTYPES DETECTION KITS, COMPRISING CRUDE EXTRACTS OF SPIDER MITES SUCH AS CITRUS RED MITE, TWO-SPOTTED SPIDER MITE AND EUROPEAN RED MITE

##### Patent Applicant/Patent Assignee:

**BIOALLETECH CO LTD**; c/o 7th Floor, Clinical Research Institute, Seoul National University Hospital,  
28 Youngun-dong, Chongno-gu, Seoul 110-744  
KR; KR(Residence); KR(Nationality)  
(For all designated states except: US)

##### Patent Applicant/Inventor:

###### **KIM You-Young**

Hyundai Apt. 108-601, 818 Majang-dong, Seongdong-gu, Seoul 133-753; KR; KR(Residence);  
KR(Nationality); (Designated only for: US)

###### **MIN Kyung-Up**

Seongyeong Apt. 10-702, 506 Daechi-dong, Gangnam-gu, Seoul 135-836; KR; KR(Residence);  
KR(Nationality); (Designated only for: US)

###### **PARK Hae-Sim**

Yangjimaetul Kumho Apt. 109-901, 34 Sunae-dong, Bundang-gu, Gyeonggi-do, Seongnam-si 463-919;  
KR; KR(Residence); KR(Nationality); (Designated only for: US)

**CHO Sang-Heon**

Hyundai Apt. 87-803, 458 Apgujeong-dong, Gangnam-gu, Seoul 135-905; KR; KR(Residence);  
KR(Nationality); (Designated only for: US)

**KIM Yoon-Keun**

Daewoo Apt. 104-703, Jeongneung-dong, Seongbuk-gu, Seoul 136-767; KR; KR(Residence);  
KR(Nationality); (Designated only for: US)

**Legal Representative:****LEE Kuiy Dong(agent)**

Hannuri Bldg., 219 Naeja-dong, Chongno-gu, Seoul 110-053; KR;

	Country	Number	Kind	Date
Patent	WO	200276477	A1	20021003
Application	WO	2002KR534		20020327
Priorities	KR	200115868		20010327

**Detailed Description:**

Ann Allergy Asthmali,nmunol,80:483-8,2000). Further the present inventors studied the levels of two IgG subtypes, namely IgG1 and IgG4, among **allergic reactions** caused by spider mite **allergen**, and **identified** reliable **correlation** between the levels of IgG1 and G4 antibody and the level of IgE antibody. Based on these results, the present inventors concluded that the allergic...

21/3K/18 (Item 12 from file: 349)

DIALOG(R)File 349: PCT FULLTEXT

(c) 2009 WIPO/Thomson. All rights reserved.

00842678

**COMPOSITION FOR TREATMENT OF AUTOIMMUNE DISEASE****Patent Applicant/Patent Assignee:**

**CORIXA CORPORATION**; 1124 Columbia Street, Suite 200, Seattle, WA 98104  
US; US(Residence); US(Nationality)  
(For all designated states except: US)

**Patent Applicant/Inventor:****SOLVASON Nanette Wardy**

1563 El Camino Real, Santa Clara, CA 95050; US; US(Residence); US(Nationality); (Designated only for: US)

**MOCCI Simonetta**

4290 Wilkie Way, Apt. P, Palo Alto, CA 94306; US; US(Residence); IT(Nationality); (Designated only for: US)

**Legal Representative:****PARENT Annette S(et al)(agent)**

Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111-3834; US;

	Country	Number	Kind	Date
Patent	WO	200174375	A1	20011011

Application	WO	2001US11298		20010404
Priorities	US	2000194547		20000404
	US	2000247117		20001110

#### Detailed Description:

...select the MHC molecules for producing peptides of the invention, particular MHC molecules that are involved in the presentation of the antigen of interest are **identified**.

In the case of **allergies**, specific **allergic responses** are **correlated** with specific MHC types. For instance, **allergic reactions** to ragweed are known to be associated with DR2 alleles (see, e.g., Marsh et al., Cold Spring Harb. Symp. Quant. Biol. 54:459-70...

24/3K/1 (Item 1 from file: 349)

DIALOG(R)File 349: PCT FULLTEXT

(c) 2009 WIPO/Thomson. All rights reserved.

00112536

#### A METHOD OF DETECTING OR DETERMINING HISTAMINE IN HISTAMINE CONTAINING MATERIALS, PARTICULARLY BODY FLUIDS AND AN ANALYTICAL MEANS FOR USE IN SUCH METHOD

**Patent Applicant/Patent Assignee:**

**SKOV Per Stahl;**

**NORN Svend;**

**WEEKE Bent;**

	Country	Number	Kind	Date
Patent	WO	8300229	A1	19830120
Application	WO	82DK64		19820706
Priorities	DK	298281		19810706

#### Detailed Description:

...vitro incorporation of radioactively labelled histamine in the basophil cells of the patient, where the release of labelled histamine is determined after provocation with the **suspected allergens**.

However, as illustrated below, a poor **correlation** with the release of histamine **determined** fluorometrically was obtained by this method,

The purpose of the present invention is to provide a method for the detection or determination of histamine, which...



01283644

**METHODS OF MODULATING IMMUNE RESPONSES BY MODULATING TIM-1, TIM-2 AND TIM-4 FUNCTION**

PROCEDES DE MODULATION DE REPONSES IMMUNITAIRES PAR LA MODULATION DE LA FONCTION TIM-1, TIM-2 AND TIM-4

**Patent Applicant/Patent Assignee:**

**THE BRIGHAM AND WOMEN'S HOSPITAL INC;** 75 Francis Street, Boston, MA 02115

US; US (Residence); US (Nationality)

(For all designated states except: US)

**BETH ISRAEL DEACONESS MEDICAL CENTER;** 330 Brookline Avenue, Boston, MA 02214

US; US (Residence); US (Nationality)

(For all designated states except: US)

**Patent Applicant/Inventor:**

**KUCHROO Vijay K**

30 Fairhaven Road, Newton, MA 02459-3424; US; US (Residence); IN (Nationality); (Designated only for: US)

**CHAKRAVARTI Sumone**

32B Gray Street, Cambridge, MA 02138; US; US (Residence); AU (Nationality); (Designated only for: US)

**STROM Terry**

22 Kennard Road, Brookline, MA 02446; US; US (Residence); US (Nationality); (Designated only for: US)

**ZHENG Xin Xiao**

334 Harvard Street, Cambridge, MA 02139; US; US (Residence); CN (Nationality); (Designated only for: US)

**MEYERS Jennifer**

66 Chiswick Road, #15, Brighton, MA 02135; US; US (Residence); US (Nationality); (Designated only for: US)

**Legal Representative:**

**QUISEL John D et al(agent)**

Fish & Neave IP Group of, Ropes & Gray LLP, One International Place, Boston, MA 02110-2624; US;

	Country	Number	Kind	Date
Patent	WO	200590573	A2-A3	20050929
Application	WO	2005US8423		20050314
Priorities	US	2004552523		20040312
	US	2004622559		20041027

**Detailed Description:**

...Atopic diseases are complex genetic traits that develop as a result of environmentally induced immune responses in genetically predisposed individuals. Both atopic and non-atopic **individuals** are **exposed** to the same environmental factors, but genetic differences that **distinguish atopic** from non- **atopic** individuals **result** in

**atopic** disease in some individuals, manifested by **allergic inflammation** in the respiratory tract, skin or gastrointestinal tract, as well as by elevated serum IgE, eosinophilia and...

35/3K/19 (Item 19 from file: 349)  
DIALOG(R)File 349: PCT FULLTEXT  
(c) 2009 WIPO/Thomson. All rights reserved.

01040282

**A METHOD FOR IDENTIFICATION AND DETERMINATION OF HYPERSENSITIVITY OF A PATIENT TO ABACAVIR**  
**PROCEDE D'IDENTIFICATION ET DE DETERMINATION DE L'HYPERSENSIBILITE D'UN PATIENT A L'ABACAVIR**

**Patent Applicant/Patent Assignee:**

**EPIPOP PTY LTD**; 13 Havelock Street, West Perth, Western Australia 6005

AU; AU(Residence); AU(Nationality)

(For all designated states except: US)

**MALLAL Simon**; 53 Gregory Street, Wembley, Western Australia 6014

AU; AU(Residence); AU(Nationality)

(Designated only for: US)

**Patent Applicant/Inventor:**

**MALLAL Simon**

53 Gregory Street, Wembley, Western Australia 6014; AU; AU(Residence); AU(Nationality);

(Designated only for: US)

**Legal Representative:**

**WRAY & ASSOCIATES(agent)**

Level 4, The Quadrant, 1 William Street, Perth, Western Australia 6000; AU;

	Country	Number	Kind	Date
Patent	WO	200368985	A1	20030821
Application	WO	2003AU183		20030212
Priorities	AU	2002464		20020212

**Detailed Description:**

...the study, with abacavir

prescription validated in all cohort cases through the use of the Royal Perth Hospital pharmacy database. The medical records of **abacavir-exposed individuals** were reviewed by a single clinician blinded to HLA typing **results** for evidence of abacavir **hypersensitivity**, utilising standardised **diagnostic** criteria.

Onset of at least two of the following symptoms within 6 weeks of abacavir initiation: fever, rash, gastrointestinal symptoms (nausea, vomiting, diarrhoea or abdominal...

35/3K/23 (Item 23 from file: 349)  
DIALOG(R)File 349: PCT FULLTEXT  
(c) 2009 WIPO/Thomson. All rights reserved.

00776999

**ANAPHYLAXIS SCREENING****TEST DE DEPISTAGE DE L'ANAPHYLAXIE****Patent Applicant/Patent Assignee:**

**NSL HEALTH LIMITED**; Level 5, 415 Burke Street, Melbourne, VIC 3000

AU; AU(Residence); AU(Nationality)

(For all designated states except: US)

**Patent Applicant/Inventor:**

**BALDO Brian**

14 Canisius Close, Pymble, NSW 2073; AU; AU(Residence); AU(Nationality); (Designated only for: US)

**Legal Representative:**

**F B RICE & CO**

605 Darling Street, Balmain, NSW 2041; AU;

	Country	Number	Kind	Date
Patent	WO	200109617	A1	20010208
Application	WO	2000AU908		20000801
Priorities	AU	991997		19990803

**Detailed Description:**

...subjects

assayed correlated to NMBD indicating a likelihood of anaphylaxis to at least one neuromuscular blocking drug.

**DISCUSSION**

One of the major uncertainties in evaluating **diagnostic** test **results** in suspected cases of **anaphylaxis** to anaesthetic drugs is the possibility that a negative result to the suspected drug(s) may occur in a **subject** who **experienced** some or all of the signs associated with an anaphylactic or anaphylactoid reaction due to another, non-allergic, mechanism. In such cases it is difficult...

43/3K/2 (Item 2 from file: 348)

DIALOG(R)File 348: EUROPEAN PATENTS

(c) 2009 European Patent Office. All rights reserved.

01400742

**APPARATUS FOR SCREENING,**

GERAT ZUR ANALYSE

APPAREIL D'ANALYSE

**Patent Assignee:**

**MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD.**; (216883)

1006, Oaza-Kadoma; Kadoma-shi, Osaka 571-8501; (JP)

(Proprietor designated states: all)

**Inventor:**

**OKA, Hiroaki**

913 Hirakata Garden Hills,3-10, Nakamiyakitamachi; Hirakata-shi,Osaka 573-1194; (JP)

**OGAWA, Ryuta**

603, Pareragaru, 1-4-15, Hashibahigashinocho; Moriguchi-shi, Osaka 574-0031; (JP)

**YUKIMASA, Tetsuo**

10-1-206, Nishifunahashi 2-chome; Hirakata-shi, Osaka 573-1122; (JP)

**Legal Representative:**

**Marx, Lothar (8071)**

Patentanwalte Schwabe, Sandmair, Marx Stuntzstrasse 16; 81677 Munchen; (DE)

	Country	Number	Kind	Date	
Patent	EP	1234540	A1	20020828	(Basic)
	EP	1234540	B1	20070321	
	WO	2002002009		20020110	
Application	EP	2001941230		20010625	
	WO	2001JP5426		20010625	
Priorities	JP	2000204411		20000705	

**Specification:** ...the test animal when the olfactory mucosa stimulating compound is administered to the olfactory mucosa of the test animal to obtain an electrical signal pattern: **determining a correlation** between the electrical signal pattern, and the type and level of a **physiological response** induced in the test animal by the electrical signal pattern; and supplying an electrical signal pattern, which is sufficient for generating an intended physiological response ...

**Claims:** ...the test animal when the olfactory mucosa stimulating compound is administered to the olfactory mucosa of the test animal to obtain an electrical signal pattern;

**determining a correlation** between the electrical signal pattern, and the type and level of a **physiological response** induced in the test animal by the electrical signal pattern; and

supplying an electrical signal pattern, which is sufficient for generating an intended physiological response...

43/3K/3 (Item 3 from file: 348)

DIALOG(R)File 348: EUROPEAN PATENTS

(c) 2009 European Patent Office. All rights reserved.

00246092

**Method of measuring antigens or antibodies in biological fluids using ligand labeled antigens or ligand labeled antibodies.**

Verfahren zum Messen von Antigenen oder Antikörpern in biologischen Flüssigkeiten unter Anwendung von Ligand markierten Antigenen oder Ligand markierten Antikörper

Procede pour determiner les antigenes ou les anticorps dans les fluides biologiques utilisant des antigenes ou des anticorps marques avec un ligand.

**Patent Assignee:**

**DIAGNOSTIC PRODUCTS CORPORATION;** (728210)

5700 West 96th Street; Los Angeles California 90045; (US)

(applicant designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

**Inventor:**

**El Shami, A. Said**

29974 Rolling Ridge Drive; Agoura Hills, CA 91301; (US)

**Alaba, Olusola O.**

1411 Mar Vista Boulevard; Pasadena, CA 91104; (US)

**Kasal, Charles A.**

1621 Fair Oaks Avenue; South Pasadena, CA 91030; (US)

**Legal Representative:**

**Myerscough, Philip Boyd et al (34221)**

J.A.Kemp & Co. 14, South Square Gray's Inn; London, WC1R 5EU; (GB)

	Country	Number	Kind	Date	
Patent	EP	245926	A2	19871119	(Basic)
	EP	245926	A3	19880525	
	EP	245926	B1	19920129	
Application	EP	87301978		19870306	
Priorities	US	862123		19860512	

**Specification:** ...with the following regression results: Mean Pharmacia: 89 IU/ml Mean Present Method: 88 IU/ml Present Method = 1.04 Pharmacia - 2.7 IU/ml **Correlation Coefficient** = 0.9690 Example 8

**Determination of IgE Specific Allergens** using the present invention:

The determination of IgE specific **allergens** was conducted using the embodiments of the present invention and assayed according to the following protocol:

43/3K/9 (Item 6 from file: 349)

DIALOG(R)File 349: PCT FULLTEXT

(c) 2009 WIPO/Thomson. All rights reserved.

01286613

**CHEMOKINE CCL18 AS A BIOMARKER**

OUTIL DIAGNOSTIQUE

**Patent Applicant/Patent Assignee:**

**NOVARTIS AG;** Lichstrasse 35, CH-4056 Basel

CH; CH (Residence); CH (Nationality)

(Designated for:)

**NOVARTIS PHARMA GMBH;** Brunner Strasse 59, A-1230 Vienna

AT; AT (Residence); AT (Nationality)

(Designated for: AT)

**Patent Applicant/Inventor:**

**CARBALLIDO HERRERA Jose M**

Bernhard Weissgasse 6/3, A-2380 Perchtoldsdorf; AT; AT (Residence); ES (Nationality); (Designated only for: US)

**GUENTHER Claudia**

An Der Berglehne 14, 01324 Dresden; DE; DE (Residence); DE (Nationality); (Designated only for: US)

**Legal Representative:**

**HILLEBRAND Dirk(agent)**

Novartis AG, Corporate Intellectual Property, CH-4002 Basel; CH;

	Country	Number	Kind	Date
Patent	WO	200593428	A2-A3	20051006
Application	WO	2005EP2986		20050321
Priorities	US	2004555110		20040322

#### Detailed Description:

...average, median, 25%-75% percentiles and SD). Statistical significance is determined using unpaired Student's t test. 10 Clinical data are tested for simple **correlations** by **determining** Pearson's **correlation coefficient** and uncorrected **probability values**.  $P < 0.05$  is considered as significant.

#### EXAMPLE1.

AD is an inflammatory skin disease associated with cutaneous hyperreactivity to **allergens** 1 5 and high IL-4 production. Consequently, AD can provide a suitable environment for CCU 8 upregulation. To demonstrate this, an immunohistochemistry evaluation of...

43/3K/12 (Item 9 from file: 349)

DIALOG(R)File 349: PCT FULLTEXT

(c) 2009 WIPO/Thomson. All rights reserved.

01210761

#### DIAGNOSIS OF ATOPIC DISORDER

DIAGNOSTIC D'UN TROUBLE ATOPIQUE

#### Patent Applicant/Patent Assignee:

**ISIS INNOVATION LIMITED**; 2 South Parks Road, Oxford OX1 3UB

GB; GB(Residence); GB(Nationality)

(For all designated states except: US)

#### Patent Applicant/Inventor:

**COOKSON William Osmond Charles**

University of Oxford Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN;

GB; GB(Residence); GB(Nationality); (Designated only for: US)

**MOFFAT Miriam Fleur**

University of Oxford Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN;

GB; GB(Residence); GB(Nationality); (Designated only for: US)

**HILL Michael Richard**

University of Oxford Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN;

GB; GB(Residence); GB(Nationality); (Designated only for: US)

**TRAHERNE James Arnold**

University of Oxford Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN;

GB; GB(Residence); GB(Nationality); (Designated only for: US)

#### Legal Representative:

**GILL JENNINGS & EVERY(agent)**

Broadgate House, 7 Eldon Street, London EC2M 7LH; GB;

	Country	Number	Kind	Date
Patent	WO	200517505	A2-A3	20050224

Application	WO	2004GB3518		20040816
Priorities	GB	200319135		20030814

#### Detailed Description:

...hyper-responsiveness (21). These coding polymorphisms do not alter receptor function (22, 23).

A limited number of non-coding polymorphisms in FcεRI-β have been

**identified**, and some of these show **associations** with asthma (20, 24), histamine 5 release from mast-cells (25), bronchial hyper-responsiveness (26), **atopic** dermatitis (27) and elevations of the total serum IgE concentration in Caucasian (28) and Aboriginal Australians (28).

The phenotypes with which FcεRI-β polymorphisms have shown... ...more polynucleotides may be used to characterise/determine more than one different SNP.

The association between the presence of polymorphisms in the MS4A2

gene and **atopic** disease was **identified** by studying the **correlation** between the transmission of genetic markers and the prevalence of **atopic** disease throughout generations within a family (so-called linkage analysis).

43/3K/16 (Item 13 from file: 349)

DIALOG(R)File 349: PCT FULLTEXT

(c) 2009 WIPO/Thomson. All rights reserved.

00891847

#### PHYSIOLOGICAL PROFILING

#### ETABLISSEMENT DE PROFILS PHYSIOLOGIQUES

#### Patent Applicant/Patent Assignee:

**CASE WESTERN RESERVE UNIVERSITY**; 10900 Euclide Avenue, Cleveland, OH44106

US; US(Residence); US(Nationality)

(For all designated states except: US)

#### Patent Applicant/Inventor:

**JACOB Howard J**

16565 Burleigh Place, Brookfield, WI 53005; US; US(Residence); US(Nationality); (Designated only for: US)

**TONELLATO Peter J**

4481 North Prospect Avenue, Shorewood, WI 53211; US; US(Residence); US(Nationality); (Designated only for: US)

**SCHORK Nicholas J**

714 Kennebeck Court, San Diego, CA 92109; US; US(Residence); US(Nationality); (Designated only for: US)

**COWLEY Allen W**

16315 Park Circle North, Elm Grove, WI 53122; US; US(Residence); US(Nationality); (Designated only for: US)

#### Legal Representative:

**QUARLES & BRADY LLP(agent)**

411 East Wisconsin Avenue, Milwaukee, WI 53202-4497; US;

	Country	Number	Kind	Date
Patent	WO	200224061	A2-A3	20020328

Application	WO	2001US42236		20010920
Priorities	US	2000234023		20000920

#### Claims:

...determinants comprises  
20 determinants.

6 The method of claim 1, wherein said set of physiological determinants comprises  
50 determinants.

7 A method of assessing the **physiological response** of an organism or organisms to a challenge, comprising:(a) constructing a clustered correlation matrix using a set of physiological **determinants**, wherein **correlation values** for all pairs of **determinants** insaid set were obtained prior to said challenge,(b) constructing a clustered correlation matrix using said set of physiological determinants, wherein correlation values for...

43/3K/18 (Item 15 from file: 349)

DIALOG(R)File 349: PCT FULLTEXT

(c) 2009 WIPO/Thomson. All rights reserved.

00520636

#### METHOD TO DETECT BIOLOGICALLY ACTIVE, ALLERGEN-SPECIFIC IMMUNOGLOBULINS PROCEDE DE DETECTION D'IMMUNOGLOBULINES SPECIFIQUES AUX ALLERGENES, BIOLOGIQUEMENT ACTIVES

**Patent Applicant/Patent Assignee:**

**HESKA CORPORATION;**

	Country	Number	Kind	Date
Patent	WO	9951988	A1	19991014
Application	WO	99US7530		19990406
Priorities	US	9881089		19980408
	US	9899776		19980910

...dat flea, Alternaria, ovalbumin, peanut, and milk proteins. When the sera of 15 experimentally-sensitized high IgE responder dogs were analyzed for immunoglobulins for specific **allergens** using the FcCR a chain-based assay and the immunodot anti-IgE monoclonal antibody-based assay, the **calculated correlation value** was r- 96. However, when the sera of 1 1 1 clinically **atopic** dogs were analyzed for immunoglobulins for specific **allergens** using the Fc,R c& chain-based assay and the immunodot anti-IgE monoclonal antibody-based assay, the **calculated correlation value** was only r- 37. The poor correlation was often due to the ability of the Fc,R a chain-based assay to detect biologically active...



## IV. Text Search Results from Dialog

### A. NPL Files, Abstract

**File 35:Dissertation Abs Online 1861-2009/Apr**  
(c) 2009 ProQuest Info&Learning  
**File 583:Gale Group Globalbase(TM) 1986-2002/Dec 13**  
(c) 2002 Gale/Cengage  
**File 65:Inside Conferences 1993-2009/May 18**  
(c) 2009 BLDSC all rts. reserv.  
**File 2:INSPEC 1898-2009/May W2**  
(c) 2009 The IET  
**File 474:New York Times Abs 1969-2009/May 18**  
(c) 2009 The New York Times  
**File 475:Wall Street Journal Abs 1973-2009/May 18**  
(c) 2009 The New York Times  
**File 99:Wilson Appl. Sci & Tech Abs 1983-2009/Apr**  
(c) 2009 The HW Wilson Co.  
**File 256:TecInfoSource 82-2009/Mar**  
(c) 2009 Info.Sources Inc  
**File 5:Biosis Previews(R) 1926-2009/May W2**  
(c) 2009 The Thomson Corporation  
**File 73:EMBASE 1974-2009/May 14**  
(c) 2009 Elsevier B.V.  
**File 155:MEDLINE(R) 1950-2009/May 15**  
(c) format only 2009 Dialog  
**File 34:SciSearch(R) Cited Ref Sci 1990-2009/May W2**  
(c) 2009 The Thomson Corp  
**File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec**  
(c) 2006 The Thomson Corp  
**File 74:Int.Pharm.Abs 1970-2009/Mar B1**  
(c) 2009 The Thomson Corporation  
**File 42:Pharm. News Index 1974-2009/Apr W3**  
(c) 2009 ProQuest Info&Learning  
**File 156:ToxFile 1965-2009/May W2**  
(c) format only 2009 Dialog  
**File 51:Food Sci.&Tech.Abs 1969-2009/May W3**  
(c) 2009 FSTA IFIS Publishing  
**File 53:FOODLINE(R): Science 1972-2009/May 14**  
(c) 2009 LFRA

Set	Items	Description
S1	4482	(ALLERGEN? ? OR ALLERGIN? ? OR (INFLUENCING OR ATOPIC)() (AGENT? ? OR SUBSTANCE? ?) OR ALLERG?(N) (TRIGGER???) (5N) (POTENTIAL? OR CANDIDATE OR SUSPECT??? OR LIKELY OR PROBABLE)
S2	221	S1(5N) (PLURALITY OR GROUP? ? OR NUMBER OR COMBINATION? ? OR SEVERAL OR MANY OR LIST? ? OR MULTIPLE OR NUMEROUS OR MULTITUDE OR SET OR SETS)
S3	501293	(PATIENT OR PATIENTS OR SUBJECT OR SUBJECTS OR INPATIENT? ? OR OUTPATIENT? ? OR PERSON? ? OR INDIVIDUAL? ? OR USER? ?) (3-N) (EXPOSURE? ? OR EXPOSED OR EXPOSING OR EXPERIENC??? OR CONSUMPTION OR CONSUMED OR CONSUMING OR INHALE OR INHALES OR INHALING OR INHALATION OR INJEST??? OR EAT OR EATS OR EATING OR ATE)
S4	45834	(TRIGGER??? CAUSE? ? OR CAUSING OR CAUSAL OR (LEAD? ? OR LEADING OR LED)() TO OR RESULT???) (5N) (ALLERG? OR (PHYSICAL OR - PHYSIOLOGICAL OR BODILY)() (REACTION? ? OR RESPONSE? ? OR EFFECT? ?) OR ATOPY OR ATOPIC OR HYPERSENSITIVITY OR ANAPHYLAXIS - OR ANAPHYLACT?)
S5	381585	((CORRELATION? ? OR STATISTICAL??) SIGNIFICAN??? OR PROBAB-

ILITY OR PROBABILITIES OR LIKELIHOOD OR CONFIDENCE OR (STRENGTH OR LINEAR OR MAGNITUDE OR DEGREE OR EXTENT) (2N) (ASSOCIATION? ? OR RELATIONSHIP? ?) (3N) (COEFFICIENT? ? OR VALUE OR VALUES OR NUMBER? ? OR PERCENTAGE? ? OR SCORE? ?))  
 S6 26871 S5 (3N) (DETERMIN??? OR CALCULAT???? OR COMPUTE OR COMPUTES OR COMPUTING OR (FIGUR??? OR WORK) () OUT OR ASCERTAIN??? OR IDENTIF? OR ESTIMATE? ? OR ESTIMATING)  
 S7 681633 (CORRELATION? ? OR CONFIDENCE OR STATISTICAL??) SIGNIFICANT??? OR PROBABILITY OR PROBABILITIES OR LIKELIHOOD OR ASSOCIATION? ? OR RELATIONSHIP? ?) (5N) (DETERMIN? OR CALCULAT???? OR COMPUTE OR COMPUTES OR COMPUTED OR COMPUTING OR COMPUTATION? ? OR (FIGUR??? OR WORK) () OUT OR ASCERTAIN??? OR IDENTIF? OR ESTIMATE? ? OR ESTIMATING)  
 S8 51936 S7 (3N) (COEFFICIENT? ? OR VALUE OR VALUES OR NUMBER? ? OR PERCENTAGE? ? OR SCORE? ? OR SCORING)  
 S9 1893 S4 (5N) (IDENTIF? OR DIAGNOS? OR PINPOINT? OR PIN() POINT OR ISOLATE OR ISOLATES OR ISOLATING OR DISTINGUISH??? OR PRONOUNCE? ? OR PRONOUNCING OR INTERPRET???)  
 S10 9 (S5 OR S7) (20N) (FOOD? ? OR ALLERG?) (2N) (CHALLENGE() TEST??? OR ELIMINATION() DIET? ? OR CAUSE(1W) EFFECT)  
 S11 4 (CORRELAT? OR PROBABILITY OR LIKELIHOOD OR CONFIDENCE) (5N) (ALLERG? OR TRIGGER?) (5N) (REACTION? ? OR RESPONSE? ? OR HYPERSENSITIVIT? OR ATOPY OR ATOPIC) (5N) (PATIENT? ? (2N) (EXPOS? OR CONSUM? OR INHAL? OR INJEST? OR EAT???) (5N) (DIAGNOS? OR IDENTIF? OR PINPOINT? OR ISOLAT?)  
 S12 13 S10 OR S11  
 S13 7 S12 NOT PY>2004  
 S14 4 RD (unique items)  
 S15 15 S2 AND S3  
 S16 10 S15 AND S4  
 S17 0 S16 AND S5  
 S18 166 S1 AND S3  
 S19 34 S18 AND S4  
 S20 0 S19 AND (S5 OR S7)  
 S21 4 S19 AND S9  
 S22 24 (S15 OR S19) NOT PY>2004  
 S23 13 RD (unique items)  
 S24 895 S1 AND S4  
 S25 0 S24 AND (S6 OR S8)  
 S26 22 S24 AND (S5 OR S7)  
 S27 5 S26 NOT (S12 OR S23 OR PY>2004)  
 S28 2 RD (unique items)  
 S29 45 S1 AND S9  
 S30 16 S29 NOT (S12 OR S23 OR S28 OR PY>2004)  
 S31 11 RD (unique items)  
 S32 0 S2 AND (S5 OR S7)  
 S33 66 S9 AND (S5 OR S7)  
 S34 26 S33 NOT (S12 OR S23 OR S28 OR S31 OR PY>2004)  
 S35 10 RD (unique items)  
 S36 0 S18 AND (S5 OR S7)  
 S37 9 S1 AND (S6 OR S8)  
 S38 5 S37 NOT (S12 OR S23 OR S28 OR S31 OR S35 OR PY>2004)  
 S39 2 RD (unique items)  
 S40 74 S1 AND (S5 OR S7)  
 S41 28 S40 NOT (S12 OR S23 OR S28 OR S31 OR S35 OR S38 OR PY>2004)  
 S42 13 RD (unique items)

14/3,K/1 (Item 1 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

12162123 **Biosis No.:** 199497183408

**The effect of granulocyte factor and grass pollen allergen on T-lymphocytes from atopic patients in vitro**

**Author:** Kocur E (Reprint); Zeman K; Tchorzewski H

**Author Address:** 2nd Dep. Internal Med., Military Med. Academy, Zeromskiego 113, 90-001 Lodz, Poland\*\*Poland

**Journal:** Journal of Investigational Allergology and Clinical Immunology 3 ( 6 ): p 321-329 1993 1993

**ISSN:** 1018-9068

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Abstract:** ...to evaluate the production of migration inhibitory factor (MIF) under the influence of these substances. The studies were carried out on peripheral blood mononuclear cells **isolated** from patients with type I **hypersensitivity**, before and after the grass pollen season, and from healthy subjects. GF and **allergens** were found to increase the CD8 cell number, particularly in 7-day cultures and in **patients** before **exposure** to **allergens**, which **correlated** with MIF release in these patients under the influence of these factors. The results suggest that the PMNLs may participate in allergic inflammatory reactions.

14/3,K/2 (Item 1 from file: 155)

DIALOG(R)File 155: MEDLINE(R)

(c) format only 2009 Dialog. All rights reserved.

12498691 **PMID:** 9296896

**[The effect of bronchial inhalation provocation tests on levels of interleukin-8 in material from broncho-alveolar fluid of patients with atopic bronchial asthma]**

Jahnz-Rozyk K; Pirozynska E; Pojda Z

Kliniki Chorob Wewnętrznych i Pneumonologii Instytutu Medycyny Wewnętrznej.

Polski merkuriusz lekarski - organ Polskiego Towarzystwa Lekarskiego ( POLAND ) Jan 1997 , 2 (7) p32-5 ,

**ISSN:** 1426-9686--Print **Journal Code:** 9705469

Publishing Model Print

**Document type:** Clinical Trial; Controlled Clinical Trial; English Abstract; Journal Article

**Languages:** POLISH

**Main Citation Owner:** NLM

**Record type:** MEDLINE; Completed

...measure IL-8 concentration (pg/ml) (kits from R&D, USA). There was observed increased level of IL-8 ( $p < 0.05$ ) after histamine and **allergen challenge test**. This increased level of IL-8 was correlated with neutrophils in BAL (Kendall's **correlation coefficient** = +0.5). We conclude that IL-8 may participate in creation of bronchial hyperreactivity in atopic bronchial asthma.

14/3,K/3 (Item 2 from file: 155)

DIALOG(R)File 155: MEDLINE(R)

(c) format only 2009 Dialog. All rights reserved.

10478863 **PMID:** 1414856

**Cross-sectional area of nasal airways during the nasal provocation tests.**

Olive-Perez A

Unitat d'Al·lergia, Hospital Santa Creu i Sant Pau, Barcelona, Spain.

Allergologia et immunopathologia ( SPAIN ) May-Jun 1992 , 20 (3) p101-4 , **ISSN:** 0301-0546--Print **Journal Code:** 0370073

Publishing Model Print

**Document type:** Journal Article

**Languages:** ENGLISH

**Main Citation Owner:** NLM

**Record type:** MEDLINE; Completed

Eighteen patients with **allergic** rhinitis were studied using nasal **challenge tests** to **allergens**. The Rivron algorithm was used to evaluate results. We **calculated** the dose-area **correlation** and changes in the cross-sectional area of the nasal airway during the test.

14/3,K/4 (Item 1 from file: 156)

DIALOG(R)File 156: ToxFile

(c) format only 2009 Dialog. All rights reserved.

746784 **NLM Doc No:** NIOSH/00165263 **Sec. Source ID:** NIOSH/00165263

**Occupational Asthma**

Butcher BT; Salvaggio JE

**Source:** Journal of Allergy and Clinical Immunology, Vol. 78, No. 4, Part 1, pages 547-556, 52 references, 19861986

Pub. Year: 1986

**Coden:** JACIBY

**Languages:** UNSPECIFIED

**Record type:** Completed

...hyperreactivity also suggests that chronic inflammation or injury to airway cell receptors or membranes may be involved. **Identification** of the **causative agent** and diagnosis of **allergic** occupational asthma were discussed. Bronchial provocation testing was recommended as the ultimate tool for **determining a cause/effect relationship** between a putative offending agent and symptom development. The best treatment was prevention of development of the condition. Stringent measures must be taken to prevent...

23/3,K/1 (Item 1 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

16818077 **Biosis No.:** 200200411588

**The preservative iodopropynyl butylcarbamate: Frequency of allergic reactions and diagnostic considerations. Results from the IVDK**

**Author:** Schnuch A (Reprint); Geier J; Brasch J; Uter W

**Author Address:** IVDK-Zentrale/Institut an der Universitaet Goettingen, von Siebold Str. 3, D 37075, Goettingen, Germany\*\*Germany

**Journal:** Contact Dermatitis 46 ( 3 ): p 153-156 March, 2002 2002

**Medium:** print

**ISSN:** 0105-1873

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**The preservative iodopropynyl butylcarbamate: Frequency of allergic reactions and diagnostic considerations. Results from the IVDK**

**Abstract:** ...above. According to readings at D3, 0.3% were allergic to IPBC, with 14+ and 2++ reactions. Doubtful or irritant reactions occurred twice as frequently. **Patients exposed** for 24h (n=1814) reacted less frequently (0.1%) than the remaining **patients exposed** for 48 h (0.5%). Considering the possibility that a certain proportion of + reactions could be false positive, the reaction pattern was evaluated. More than...

**DESCRIPTORS:**

**Chemicals & Biochemicals:** ...**allergen**, concentrations, irritant **potential**, preservative, toxin

23/3,K/2 (Item 2 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

16606068 **Biosis No.:** 200200199579

**IL-10 production in circulating T cells differs between allergen-induced isolated early and dual asthmatic responders**

**Author:** Matsumoto Koichiro; Gauvreau Gail M; Rerecich Tracy; Watson Richard M; Wood Lorna J; O'Byrne Paul M (Reprint)

**Author Address:** Firestone Institute for Respiratory Health, St Joseph's Healthcare, 50 Charlton Ave East, Hamilton, Ontario, L8N 4A6, Canada\*\*Canada

**Journal:** Journal of Allergy and Clinical Immunology 109 ( 2 ): p 281-286 February, 2002 2002

**Medium:** print

**ISSN:** 0091-6749

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Abstract:** Background: IL-10 is an anti-inflammatory cytokine released from various cells, including T cells. The role of IL-10 in asthma pathogenesis remains uncertain. **Allergen inhalation by atopic asthmatic subjects results** in 2 bronchoconstrictor phenotypes: isolated early response and dual response. Persistence of allergen-induced airway inflammation is a feature of dual responders. Objectives: The kinetics of IL-10 production in circulating T cells were investigated to examine a **potential** role of IL-10 in **allergen**-induced responses and airway inflammation. Methods: Fourteen subjects with mild asthma (7 isolated early and 7 dual responders) were challenged with allergen. PBMCs taken before... ..conjugated anti-IL-10 antibody. The frequency of IL-10-producing cells was assessed for CD4+ and CD8+ T-cell subsets by using flow cytometry. **Results:** Before **allergen** administration, the frequency of IL-10-producing CD4+ cells was significantly higher in dual than in isolated early responders. IL-10-producing CD4+ cells significantly... ..cells significantly decreased in dual responders. Simultaneous assessments of IL-5-producing T cells did not show any differences between each group before or after **allergen** administration. Conclusions: These **results** suggest that the contrasting profiles of IL-10 production may be associated with the different time course of allergen-induced airway inflammation between allergen-induced...

23/3,K/3 (Item 3 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

16344188 **Biosis No.:** 200100516027

**Extended allergen exposure in asthmatic monkeys induces neuroplasticity in nucleus tractus solitarius**

**Author:** Chen Chao-Yin; Bonham Ann C; Schelegle Edward S; Gershwin Laurel J; Plopper Charles G; Joad Jesse P (Reprint)

**Author Address:** Department of Pediatrics, University of California, Davis, 256 Stockton Blvd, Sacramento, CA, 95817, USA\*\*USA

**Journal:** Journal of Allergy and Clinical Immunology 108 ( 4 ): p 557-562 October, 2001 2001

**Medium:** print

**ISSN:** 0091-6749

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Abstract:** ...current-clamp recordings were made to measure 3 indices of excitability: resting membrane potential, input resistance, and number of action potentials evoked by current injections. **Results:** Extended **allergen** exposure depolarized the resting membrane **potential** by 14% and increased the **number** of action potentials evoked by current injections (5-fold). **Conclusion:** The finding that NTS neurons in a primate model of allergic asthma undergo intrinsic increases in excitability suggests that CNS mechanisms might contribute to the exaggerated symptoms in asthmatic **individuals exposed** to allergen.

23/3,K/4 (Item 4 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

15763777 **Biosis No.:** 200000482090

**Hypersensitivity to members of the botanical order Fabales (legumes)**

**Author:** Martinez San Ireneo M; Ibanez Sandin M D (Reprint); Fernandez-Caldas E

**Author Address:** Seccion de Alergia, Hospital Nino Jesus, Avenida Menendez Pelayo 65, 28009, Madrid, Spain\*\*Spain

**Journal:** Journal of Investigational Allergology and Clinical Immunology 10 ( 4 ): p 187-199 July-August, 2000 2000

**Medium:** print

**ISSN:** 1018-9068

**Document Type:** Article; Literature Review

**Record Type:** Abstract

**Language:** English

**Abstract:** ...chickpeas are one of the main food allergens. Legumes are also used as food additives due to their emulsifying properties and can be present in **many** manufactured foods. These hidden food **allergens** have the **potential** of **causing** adverse reactions in legume-sensitive subjects. The allergenic composition of various legumes has been investigated. They have been found to contain multiple allergens, a few... ..to more than one species in children is common. Clinical manifestations include cutaneous, digestive and respiratory symptoms. Legumes can cause life-threatening reactions in sensitized **individuals**. **Inhalation** of steam, powder or flour from some legumes may cause respiratory diseases such as rhinitis, asthma and hypersensitivity pneumonitis.

23/3,K/5 (Item 5 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

11779152 **Biosis No.:** 199395081418

**Codfish allergy in adults: Identification and diagnosis**

**Author:** Hansen Tine K (Reprint); Bindslev-Jensen C

**Author Address:** Food Allergy Unit TTA 7523, National Univ. Hosp., 20 Tagensvej, Dk-2200 Copenhagen N, Denmark\*\*Denmark

**Journal:** Allergy (Copenhagen) 47 ( 6 ): p 610-617 1992

**ISSN:** 0105-4538

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Abstract:** ...of codfish were examined together with 27 control subjects (8 nonatopics, 7 pollen allergies, and 12 suffering from atopic dermatitis) all regularly ingesting codfish without **experiencing** reactions. All 37 **subjects** were evaluated by skin prick test, RAST, and histamine release test in order to determine the value of these commonly used diagnostic tests. The results... ..between 6 mg and 6.7 g of freshly prepared codfish, and by DBPCFC, reproducibility was found in 70% of the codfish-hypersensitive patients. The **potential** of commercial codfish **allergen** extract was tested in commonly used diagnostic tests. Results show that a negative skin prick test is an excellent indicator of no clinical codfish **hypersensitivity**, while a positive **result** requires further evaluation. Specificities of 90-97% in skin prick test, RAST, and histamine release test reveal that DBPCFC are still needed to identify clinically...

23/3,K/6 (Item 1 from file: 73)

DIALOG(R)File 73: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0079848601 **EMBASE No:** 2004033421

**Latex and fruit allergy in health care workers**

Alergia ao latex e a frutas em profissionais da area da saude

Marin F.A.; Peres S.P.D.B.A.; Venturini M.D.C.; Francisco R.C.M.; Zuliani A.

Faculdade de Medicina, Universidade Estadual Paulista, Distrito de Rubiao Junior, s/n, 18600-970 Botucatu, SP, Brazil

**Corresp. Author/Affil:** Marin F.A.: Faculdade de Medicina, Universidade Estadual Paulista, Distrito de Rubiao Junior, s/n, 18600-970 Botucatu, SP, Brazil

Revista de Nutricao ( Rev. Nutr. ) ( Brazil ) October 1, 2003 , 16/4 (415-421)

**CODEN:** RVNUA **ISSN:** 1415-5273

**Document Type:** Journal ; Article **Record Type:** Abstract

**Language:** Portuguese **Summary language:** English; Portuguese

**Number of References:** 34

**Introduction:** Latex allergy is becoming an increasing risk to **exposed individuals**, such as the health care workers, and the simultaneous allergy to different types of food, particularly fruits is an aggravating circumstance. **Objective:** To estimate the... ..a specific questionnaire and through puncture cutaneous tests using allergens of latex and fruits (papaya, kiwi, avocado, banana, fig, tomato, nuts) as well as some **potential** inhalatory **allergens**. **Results:** Of the 53 subjects studied, 15 (28.5%) were allergic to the latex. Hypersensitivity to fruits was diagnosed in 14 (26.4%) individuals, 10 of...

23/3,K/7 (Item 2 from file: 73)

DIALOG(R)File 73: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0079700478 EMBASE No: 2003409763

**Allergic contact dermatitis to common ivy (Hedera helix L.)**

Allergische kontaktdermatitis auf efeu (Hedera helix L.)

Ozdemir C.; Schneider L.A.; Hinrichs R.; Staib G.; Weber L.; Weiss J.M.; Scharffetter-Kochanek K.

Univ. Klin. fur Dermatol./Allergol., Ulm, Germany

**Corresp. Author/Affil:** Ozdemir C.: Univ. Klin. fur Dermatol./Allergol., Ulm, Germany

Hautarzt ( Hautarzt ) ( Germany ) October 1, 2003 , 54/10 (966-969)

**CODEN:** HAUTA **ISSN:** 0017-8470

**Item Identifier (DOI):** [10.1007/s00105-003-0584-4](https://doi.org/10.1007/s00105-003-0584-4)

**Document Type:** Journal ; Article **Record Type:** Abstract

**Language:** German **Summary language:** English; German

**Number of References:** 14

Common ivy (Hedera helix L.) is a ubiquitous plant in Europe whose major **allergen** falcarinol has moderate allergic **potential**. It is not related to poison ivy (Toxicodendron spp.). There are no cross reactions between the allergens of common ivy (falcarinol) and poison ivy (urushiol). Contact with common ivy or falcarinol may **lead to** sensitization and then a delayed **hypersensitivity** reaction. There are only few cases described in the literature. We report on a male hobby gardener with appropriate clinical history and positive patch test...

**Medical Descriptors:**

\*

adult; agricultural worker; allergenicity; anamnesis; article; case report; cross reaction; delayed hypersensitivity; Europe; high risk **patient**; human; male; occupational **exposure**; patch test; pathogenesis; protective clothing; sensitization

**Orig. Descriptors:**

23/3,K/8 (Item 3 from file: 73)

DIALOG(R)File 73: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0079532381 EMBASE No: 2003238779

**Overview of allergic rhinitis**

Berger W.E.

Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, CA, United States; Allergy and Asthma Associates, 27800 Medical Center Road, Mission Viejo, CA 92691, United States

**Author email:** weberger@uci.edu

**Corresp. Author/Affil:** Berger W.E.: Allergy and Asthma Associates, 27800 Medical Center Road, Mission Viejo, CA 92691, United States

**Corresp. Author Email:** weberger@uci.edu

Annals of Allergy, Asthma and Immunology ( Ann. Allergy Asthma Immunol. ) ( United States ) June 1, 2003 , 90/SUPPL. (7-12)

**CODEN:** ALAIF **ISSN:** 1081-1206

**Document Type:** Journal ; Conference Paper **Record Type:** Abstract

**Language:** English **Summary language:** English

**Number of References:** 49

...Its incidence is rising in parallel with other IgE-mediated diseases, affecting 10 to 30% of adults and up to 40%



of children. Half the **patients** with allergic rhinitis **experience** symptoms up to 4 months per year, whereas 20% are symptomatic more than 9 months of the year. This disease is often associated with asthma... ..literature concerning the evaluation and treatment of allergic rhinitis. Data Sources: Epidemiologic, pathophysiologic, and clinical studies published in peer-reviewed journals concerning the topic of **allergic** rhinitis. **Results:** Diagnosis of **allergic** rhinitis is based on patient history, signs and symptoms, physical examination, and appropriate testing procedures. Management includes aggressive environmental control measures to reduce exposure to implicated **allergens**, immunotherapy that can change the **potential** clinical course of allergic rhinitis by preventing the initiation and progression of airway inflammation, and pharmacotherapeutic management, including antihistamines and topical nasal corticosteroids. Conclusions: Early...

23/3,K/11 (Item 2 from file: 34)

DIALOG(R)File 34: SciSearch(R) Cited Ref Sci

(c) 2009 The Thomson Corp. All rights reserved.

04301406 **Genuine Article#:** RV053 **No. References:** 40

**IDENTIFICATION OF CHEMICAL RESPIRATORY ALLERGENS - DOSE-RESPONSE RELATIONSHIPS IN THE MOUSE IGE TEST**

**Author:** HILTON J; DEARMAN RJ; BASKETTER DA; KIMBER I

**Corporate Source:** ZENECA CENT TOXICOL LAB,IMMUNOL GRP,ALDERLEY PK/MACCLESFIELD SK10 4TJ/CHESHIRE/ENGLAND/; UNILEVER RES LABS VLAARDINGEN,ENVIRONM SAFETY LAB/SHARNBROOK MK44 1LQ/BEDS/ENGLAND/

**Journal:** TOXICOLOGY METHODS , 1995 , V 5 , N1 ( JAN-MAR ) , P 51-60

**ISSN:** 1051-7235

**Language:** ENGLISH **Document Type:** ARTICLE ( Abstract Available )

**Abstract:** ...4,4'-diisocyanate (MDI), hexamethylene diisocyanate (HDI), and trimellitic anhydride (TMA), all of which are known to cause occupational respiratory allergy in a proportion of **exposed individuals**. Results were compared with those obtained with 2,4-dinitrochlorobenzene (DNCB) and oxazolone, two contact **allergens** known or **suspected** not to cause sensitization of the respiratory tract. In each case, induced changes in serum IgE were measured under conditions of exposure, with respect to... ..dose-related increase in the serum concentration of IgE measured 14 days following the initiation of treatment. In contrast, exposure of mice to the contact **allergens** DNCB and oxazolone **resulted** in either no change in serum IgE levels (DNCB) or only a comparatively modest increase (oxazolone). These data confirm that chemical contact and respiratory allergens...

**Identifiers--**

23/3,K/12 (Item 1 from file: 156)

DIALOG(R)File 156: ToxFile

(c) format only 2009 Dialog. All rights reserved.

1119283 **NLM Doc No:** CIS/00/00482 **Sec. Source ID:** CIS/00/00482

**Occupational respiratory allergy in bakery workers: A review of the literature**

Houba R; Doekes G; Heederik D

**Source:** American Journal of Industrial Medicine Dec. 1998, Vol.34, No.6, p.529-546. 177 ref.

Pub. Year: 1998 **ISSN:** 0271-3586

**Document type:** Journal Article

**Languages:** ENGLISH

**Record type:** Completed

...baker's allergy is reviewed focusing on the allergens involved, epidemiologic research, exposure assessment, evidence of exposure-response relationships and possible prevention strategies. A large **number** of **potential**

**allergens** have been identified and are described here. While little is known about the incidence of baker's allergy, a large number of cross-sectional studies...

23/3,K/13 (Item 2 from file: 156)  
DIALOG(R)File 156: ToxFile  
(c) format only 2009 Dialog. All rights reserved.

771113 NLM Doc No: NIOSH/00195038 Sec. Source ID: NIOSH/00195038  
**Rose Hips: A New Occupational Allergen**

Kwaselow A; Rowe M; Sears-Ewald D; Ownby D  
**Source:** Journal of Allergy and Clinical Immunology, Vol. 85, No. 4, pages 704-708, 7 references, 1990  
Pub. Year: 1990  
**Coden:** JACIBY  
**Languages:** UNSPECIFIED  
**Record type:** Completed

...performed for 13 employees of a Vitamin manufacturer. The subjects were all characterized by respiratory symptoms which were thought to be related to rose hip **exposure**. **Subjects** were subjected to a battery of tests which included spirometry or peak flow determinations for asthmatics, skin prick exposures to various allergens, bronchial provocation tests... The authors state that this is the first investigation to demonstrate an immunoglobulin-E mediated reaction to rose hips. They conclude that rose hips are **potential** occupational **allergens** which can **result** in a variety of symptoms, including bronchial asthma.

28/3,K/1 (Item 1 from file: 5)  
DIALOG(R)File 5: Biosis Previews(R)  
(c) 2009 The Thomson Corporation. All rights reserved.

15578829 **Biosis No.:** 200000297142  
**Use of the local lymph node assay for the estimation of relative contact allergenic potency**

**Author:** Basketter D A (Reprint); Blaikie L; Dearman R J; Kimber I; Ryan C A; Gerberick G F; Harvey P; Evans P; White I R; Rycroft R J G  
**Author Address:** SEAC Toxicology Unit, Unilever Research Colworth, Sharnbrook, Bedford, MK44 1LQ, UK\*\*UK  
**Journal:** Contact Dermatitis 42 ( 6 ): p 344-348 June, 2000 2000  
**Medium:** print  
**ISSN:** 0105-1873  
**Document Type:** Article  
**Record Type:** Abstract  
**Language:** English

**Abstract:** ...allergic contact dermatitis (ACD) in humans. However, this hazard is not an all-or-none phenomenon; clear dose-response relationships can be discerned and thresholds **identified** for both the induction of sensitization and the elicitation of contact dermatitis. Commonly, these parameters are grouped under the heading of potency, determination of which ...

28/3,K/2 (Item 2 from file: 5)  
DIALOG(R)File 5: Biosis Previews(R)  
(c) 2009 The Thomson Corporation. All rights reserved.

09596177 **Biosis No.:** 198987044068

**APPLICATIONS OF TESTS AND MEASURES OF ASSOCIATIONS IN THE CASE OF 2 X 2 CONTINGENCY TABLE WITH THE EXAMINATION OF ALLERGEN-SENSITIVE ASTHMATIC CHILDREN**

**Author:** BORZSONYI L (Reprint); CSERHARTI E; OSZTIE E

**Author Address:** SEMMELWEIS ORVOSTUDOMANYI EGYETEM, SZAMINTOKOZPONT, KULICH GYULA TER 5, BUDAPEST, H-1089 HUNG\*\*HUNGARY

**Journal:** Biometrical Journal 30 ( 5 ): p 561-569 1988

**ISSN:** 0323-3847

**Document Type:** Article

**Record Type:** Abstract

**Language:** ENGLISH

**Abstract:** ...in order to be consequent. In addition to general description of the relationships, a special application and operative interpretation of the Somer's measure of **association** are presented. **Determination** of similarity among the allergens with cluster analysis yields an interesting parallelism in the results. According to our **results** the development of specific **allergen** sensitivity can **potentially** be reduced in children to be born.

31/3,K/2 (Item 1 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

14110992 **Biosis No.:** 199799745052

**Is patch testing necessary in vulval vestibulitis?**

**Author:** Nunns D (Reprint); Ferguson J; Beck M; Mandal D

**Author Address:** Dep. OB/GYN, Leicester Royal Infirmary, Leicester LE2 7GT, UK\*\*UK

**Journal:** Contact Dermatitis 37 ( 2 ): p 87-89 1997 1997

**ISSN:** 0105-1873

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Abstract:** ...women with vulval vestibulitis were patch tested using a standard series of contact allergens and a special series relevant to perianal and vulval disorders. Other **potential allergens identified** by the patients as **causing** aggravation were also included. There were 5 positive reactions, 4 to nickel and 1 to fragrance mix, though none of these reactions were considered relevant...

31/3,K/3 (Item 1 from file: 73)

DIALOG(R)File 73: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0079127069 **EMBASE No:** 2002290829

**Asthma and food allergy: About 163 pediatrics cases**

Asthme et allergies alimentaires: A propos de 163 observations pediatriques

Rance F.; Dutau G.

Serv. d'Allergol. et de Pneumologie, Hopital des Enfants, CHU Toulouse, 330. Avenue de Grande-Bretagne, 31026 Toulouse Cedex, France

**Corresp. Author/Affil:** Rance F.: Serv. d'Allergol. et de Pneumologie, Hopital des Enfants, CHU Toulouse, 330. Avenue de Grande-Bretagne, 31026 Toulouse Cedex, France  
**Corresp. Author Email:** rance.f@chu-toulouse.fr

Archives de Pediatrie ( Arch. Pediatr. ) ( France ) August 27, 2002 , 9/SUPPL. 3 (402-407)

**CODEN:** APEDE **ISSN:** 0929-693X

**Item Identifier (DOI):** [10.1016/S0929-693X\(02\)00151-3](https://doi.org/10.1016/S0929-693X(02)00151-3)

**Document Type:** Journal ; Article **Record Type:** Abstract

**Language:** French **Summary language:** English; French

**Number of References:** 33

...cashew) and spices. Diagnosis relied upon data obtained from history, skin prick-tests and specific IgE. Oral food challenge is the corner stone of the **diagnosis**. Asthma induced by food **allergens** is **potentially** severe **leading to** prescribe to these patients a first aid kit with bronchodilators and epinephrine auto-injectors. (c) 2002.

31/3,K/4 (Item 2 from file: 73)

DIALOG(R)File 73: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0078567772 **EMBASE No:** 2001173914

**Original article-allergic reaction to soy due to IgE-mediated cross-reactivity and hypersensitivity to bet v1**

Schwere allergische reaktionen auf sojaeiweiss-haltiges diaspulver durch ige-vermittelte kreuzreaktivitasst bei ausgeprassgter bet v1-sensibilisierung

Kleine-Tebbe J.; Vieths S.; Franke S.; Jahreis A.; Rytter M.; Haustein U.-F.

Klinische Allergologie, Berufs- und Umweltdermatologie, Universitatshautklinik Leipzig, Stephanstr. 11, D-04103 Leipzig, Germany

**Corresp. Author/Affil:** Kleine-Tebbe J.: Klinische Allergologie, Berufs- und Umweltdermatologie, Universitatshautklinik Leipzig, Stephanstr. 11, D-04103 Leipzig, Germany

Allergo Journal ( Allergo J. ) ( Germany ) May 24, 2001 , 10/3 (154-159)

**CODEN:** ALJOE **ISSN:** 0941-8849

**Document Type:** Journal ; Article **Record Type:** Abstract

**Language:** German **Summary language:** English; German

**Number of References:** 18

...is possible that local and systemic symptoms in birch pollen allergic subjects after ingestion of soyproteins do not represent a "classical" food hypersensitivity to soybean **allergens** previously **identified**. More **likely**, they **result** from crossreactive IgE epitopes of birch pollen major allergen Bet v1 and a pathogenesis-related soyprotein (SAM22) with partial aminoacid sequence identity.

31/3,K/5 (Item 3 from file: 73)

DIALOG(R)File 73: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0077155238 **EMBASE No:** 1998063701

**Diagnosis and etiologies of occupational asthma**

ASTHME PROFESSIONNEL. DIAGNOSTIC ET ETIOLOGIES

Magnan A.; Vervloet D.

UPRES 2050, Service de Pneumo-Allergologie, Hopital Sainte-Marguerite, Marseille, France; UPRES 2050, Service de Pneumo-Allergologie, Hopital Sainte-Marguerite, BP 29, F 13274 Marseille Cedex 09, France

**Author email:** dvervloe@ap-hm.fr

**Corresp. Author/Affil:** Magnan A.: UPRES 2050, Service de Pneumo-Allergologie, Hopital Sainte-Marguerite, BP 29, F 13274 Marseille Cedex 09, France

**Corresp. Author Email:** dvervloe@ap-hm.fr

Presse Medicale ( Presse Med. ) ( France ) February 21, 1998 , 27/7 (325-329)

**CODEN:** PRMEE **ISSN:** 0755-4982

**Document Type:** Journal ; Review **Record Type:** Abstract

**Language:** French **Summary language:** French; English

**Number of References:** 43

...workplace and during off periods. In certain cases specific provocation tests are needed. Finally skin prick test or radioallergosorbent test (RAST) may be useful for **diagnosis**, particularly when high molecular-weight **allergens** are **suspected**. Numerous **causal** agents: More than 250 substances have been demonstrated to cause occupational asthma. Cereal flour and isocyanates are among the most frequent. Recently, the number of...

31/3,K/6 (Item 4 from file: 73)

DIALOG(R)File 73: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0076589855 **EMBASE No:** 1996266058

**Application of molecular biology for diagnosis and treatment of allergic diseases**

Mohapatra S.S.; Mohapatra S.

Department of Internal Medicine, Division of Allergy and Immunology, Univ. South Florida College Medicine, 13000 Bruce B. Downs Boulevard, Tampa, FL 33612, United States

**Corresp. Author/Affil:** Mohapatra S.S.: Department of Internal Medicine, Division of Allergy and Immunology, Univ. South Florida College Medicine, 13000 Bruce B. Downs Boulevard, Tampa, FL 33612, United States

Immunology and Allergy Clinics of North America ( IMMUNOL. ALLERGY CLIN. NORTH AM. ) ( United States ) September 14, 1996 , 16/3 (591-611)

**CODEN:** INCAE **ISSN:** 0889-8561

**Document Type:** Journal ; Review **Record Type:** Abstract

**Language:** English **Summary language:** English

Recently, application of recombinant DNA techniques for characterization of **allergens** has **led to** the development of potentially useful **diagnostic** and therapeutic approaches for allergic diseases. An array of molecular biology techniques has aided in the synthesis of a number of recombinant allergens, identification of...  
...develop new approach(es) of specific immunotherapy using recombinant allergens and T-cell epitopes. Clinical trials using T-cell peptides are currently under way. The **potential** application of recombinant **allergens** and epitopes in clinical realms also is discussed.

31/3,K/7 (Item 1 from file: 155)

DIALOG(R)File 155: MEDLINE(R)

(c) format only 2009 Dialog. All rights reserved.

15425701 **PMID:** 12839106

**Overview of allergic rhinitis.**

Berger William E

Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, California, USA.  
weberger@uci.edu

Annals of allergy, asthma & immunology - official publication of the American College of Allergy, Asthma, & Immunology ( United States ) Jun 2003 , 90 (6 Suppl 3) p7-12 , ISSN: 1081-1206--Print **Journal Code:** 9503580  
Publishing Model Print

**Document type:** Journal Article; Review

**Languages:** ENGLISH

**Main Citation Owner:** NLM

**Record type:** MEDLINE; Completed

...literature concerning the evaluation and treatment of allergic rhinitis. DATA SOURCES: Epidemiologic, pathophysiologic, and clinical studies published in peer-reviewed journals concerning the topic of **allergic** rhinitis. **RESULTS: Diagnosis** of **allergic** rhinitis is based on patient history, signs and symptoms, physical examination, and appropriate testing procedures. Management includes aggressive environmental control measures to reduce exposure to implicated **allergens**, immunotherapy that can change the **potential** clinical course of allergic rhinitis by preventing the initiation and progression of airway inflammation, and pharmacotherapeutic management, including antihistamines and topical nasal corticosteroids. **CONCLUSIONS:** Early...

31/3,K/9 (Item 1 from file: 34)

DIALOG(R)File 34: SciSearch(R) Cited Ref Sci

(c) 2009 The Thomson Corp. All rights reserved.

09088733 **Genuine Article#:** 365ZP **No. References:** 50

**Digestibility of allergens extracted from natural rubber latex and vegetable foods**

**Author:** Yagami T (REPRINT) ; Haishima Y; Nakamura A; Osuna H; Ikezawa Z

**Corporate Source:** NATL INST HLTH SCI,DIV MED DEVICES, SETAGAYA KU, KAMIYOGA 1-18-1/TOKYO 1588501//JAPAN/ (REPRINT); YOKOHAMA CITY UNIV,SCH  
MED/YOKOHAMA/KANAGAWA 232/JAPAN/

**Journal:** JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY , 2000 , V 106 , N4 ( OCT ) , P 752-762

**ISSN:** 0091-6749 **Publication date:** 20001000

**Publisher:** MOSBY, INC , 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318

**Language:** English **Document Type:** ARTICLE ( ABSTRACT AVAILABLE )

**Abstract:** ...An aliquot of each digest was periodically withdrawn and analyzed. Allergens were detected with pooled sera from individuals with latex allergy or patients given a **diagnosis** of oral **allergy** syndrome,

**Results:** Most latex and vegetable food proteins were digested by the SGF within 4 minutes. Numerous allergens were also decomposed by the SGF within 8 minutes...

**Identifiers--** ...TRANSGENIC TOMATO PLANTS; CROSS-REACTIVITY; IN-VITRO; **POTENTIAL** PANALLERGENS; POLLEN **ALLERGENS**; MAJOR **ALLERGEN**; FRUIT SYNDROME; TREE POLLEN; PROTEINS; DEFENSE

31/3,K/10 (Item 1 from file: 156)

DIALOG(R)File 156: ToxFile

(c) format only 2009 Dialog. All rights reserved.

804271 **NLM Doc No:** NIOSH/00231695 **Sec. Source ID:** NIOSH/00231695

## Allergic Contact Dermatitis from Iroko and Pine Wood Dust

Hinnen U; Willa-Craps C; Elsner P

**Source:** Contact Dermatitis, Vol. 33, No. 6, page 428, 3 references, 1995

Pub. Year: 1995

**Coden:** CODEDG

**Languages:** UNSPECIFIED

**Record type:** Completed

...positive reactions to colophony and a variety of woods. Allergic reactions to pine and iroko dusts were confirmed after a third series of patch tests, **leading to a diagnosis** of occupational **allergic** contact dermatitis from iroko, pine, and colophony. The patient was advised to avoid further contact with the allergens, but intermittent contact with pine dust was... ..the face over the next few months. The authors conclude that, given its major uses in furniture and building purposes, iroko should be considered a **potential** occupational contact **allergen** in those working with tropical timber. (

35/3,K/1 (Item 1 from file: 35)

DIALOG(R)File 35: Dissertation Abs Online

(c) 2009 ProQuest Info&Learning. All rights reserved.

01307333 ORDER NO: AAD93-22354

**HUMAN PHYSIOLOGICAL AND SUBJECTIVE RESPONSES DURING MOTION SICKNESS INDUCED BY UNUSUAL VISUAL AND VESTIBULAR STIMULATION (VISUAL STIMULATION, ANXIETY, ELECTROGASTROGRAPHY)**

**Author:** LAWSON, BENTON D.

**Degree:** PH.D.

**Year:** 1993

**Corporate Source/Institution:** BRANDEIS UNIVERSITY ( 0021 )

**Source:** Volume 5404B of Dissertations Abstracts International.

PAGE 2249 . 128 PAGES

...stimulus did not require voluntary activity (Graybiel and Lackner, 1977, 1979, 1980b). The experiments in this dissertation may help to explain why previous efforts to **identify a correlation** between MS and **physiological response** have yielded conflicting **results**. It is possible that some past researchers have been measuring the MS syndrome confounded with other factors, such as changes in arousal state, movement artifacts...

35/3,K/2 (Item 1 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

17145514 **Biosis No.:** 200300104233

**Association between mite allergen (Der p 1, Der f 1, Blo t 5) levels and microscopic identification of mites or skin prick test results in asthmatic subjects.**

**Author:** Medeiros Manoel (Reprint); Figueiredo Joanemile P; Almeida Maria C; Atta Ajax M; Taketomi Ernesto A; Silva Deise A O; Terra Silvia A; Amorim Welma W ; Pinho Ricardo S; Araujo Maria I; Carvalho Edgar M

**Author Address:** Servico de Imunologia, Hospital Universitario Professor Edgar Santos, Federal University of Bahia, Rua Joao das Botas, s/n, 5th Andar-Canela, 41110.160, Salvador, BA, Brazil\*\*Brazil

**Author E-mail Address:** imuno@ufba.br

**Journal:** International Archives of Allergy and Immunology 129 ( 3 ): p 237-241 November 2002 2002

**Medium:** print  
**ISSN:** 1018-2438  
**Document Type:** Article  
**Record Type:** Abstract  
**Language:** English

**Abstract:** ...the knowledge of regional mite fauna and the remediation of mite allergens in allergic diseases. The present study analyzed the association between levels of HDM **allergen** and **results** of mite **identification** or skin prick test (SPT) in two different areas of Bahia, Brazil. Methods: Forty-two asthmatic subjects from a rural area (group I; n=21) and a slum (group II; n=21) were evaluated through SPT with HDM allergens and had dust samples collected at their homes for mite **identification** and **allergen** measurements. **Results:** Positive SPT to Dermatophagoides pteronyssinus, Dermatophagoides farinae and Blomia tropicalis allergens were observed in 42.9, 38.0 and 42.9% subjects from group I... ..samples from groups I and II, respectively (p<0.005). Der p 1, Der f 1 and Blo t 5 detection were associated with mite **identification** (p<0.05). **Association** between HDM allergen levels over 2 mug/g of dust and positive SPT occurred only with D. pteronyssinus (p<0.0001). Conclusions: D. pteronyssinus was...

35/3,K/3 (Item 2 from file: 5)  
DIALOG(R)File 5: Biosis Previews(R)  
(c) 2009 The Thomson Corporation. All rights reserved.

16004096 **Biosis No.:** 200100175935

**Influence of weather and climate on subjective symptom intensity in atopic eczema**

**Author:** Vocks E (Reprint); Busch R; Frohlich C; Borelli S; Mayer H; Ring J  
**Author Address:** Department of Dermatology and Allergology Biederstein, Technical University of Munich, Biedersteinerstr. 29, D-80802, Muenchen, Germany\*\*Germany  
**Journal:** International Journal of Biometeorology 45 ( 1 ): p 27-33 February, 2001 2001  
**Medium:** print  
**ISSN:** 0020-7128  
**Document Type:** Article  
**Record Type:** Abstract  
**Language:** English

**Abstract:** ...univariate analyses and multiple regressions, itch intensity was found to be correlated with some meteorological variables. A clear-cut inverse correlation exists with air temperature (**coefficient of correlation:** - 0.235, P<0.001), but the effects of water vapour pressure, air pressure and hours of sunshine are less **pronounced**. The **results** show that **itching** in **atopic** eczema is **significantly dependent on meteorological conditions**. The data suggest that, in patients with atopic eczema, a certain range of thermo-hygric atmospheric conditions with...

35/3,K/4 (Item 3 from file: 5)  
DIALOG(R)File 5: Biosis Previews(R)  
(c) 2009 The Thomson Corporation. All rights reserved.

15055124 **Biosis No.:** 199900314784

**Perceived prevalence of peanut allergy in Great Britain and its association with other atopic conditions and with peanut allergy in other household members**

**Author:** Emmett S E; Angus F J (Reprint); Fry J S; Lee P N  
**Author Address:** Leatherhead Food Research Association, Randalls Road, Leatherhead, Surrey, KT22 7RY,



UK\*\*UK

**Journal:** Allergy (Copenhagen) 54 ( 4 ): p 380-385 April, 1999 1999

**Medium:** print

**ISSN:** 0105-4538

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Abstract:** ...16434 adults (aged 15+ years) reported their own allergies and atopies and named cohabitants with peanut allergy (stage 1). Follow-up interviews were conducted with **identified** sufferers from peanut **allergy** (stage 2). **Results:** At stage 1, peanut **allergy** was reported in 58 respondents and 205 other household members. When we accounted for cases where peanut allergy was unconfirmed or newly reported at stage 2, the prevalence, based on 124 confirmed sufferers, was **estimated** as 0.48% (95% **confidence** interval 0.40%-0.55%). The prevalence in children (0.61%, 0.41%-0.82%) was slightly higher than in adults; age-of-onset was...

35/3,K/7 (Item 2 from file: 73)

DIALOG(R)File 73: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0077080570 **EMBASE No:** 1997373840

**Skin prick reaction and nasal provocation response in diagnosis of nasal allergy to the house dust mite**

Kanthawatana S.; Maturim W.; Fooanan S.; Trakultivakorn M.

Department of Pharmacology, Chiang Mai University, Faculty of Medicine, Chiang Mai, Thailand

**Corresp. Author/Affil:** Kanthawatana S.: Rheumatology Allergy/Immunology Div., Medical College of Virginia, P.O. Box 980263, Richmond, VA 23298-0263, United States

Annals of Allergy, Asthma and Immunology ( ANN. ALLERGY ASTHMA IMMUNOL. ) ( United States )

December 20, 1997 , 79/5 (427-430)

**CODEN:** ALAIF **ISSN:** 1081-1206

**Document Type:** Journal ; Article **Record Type:** Abstract

**Language:** English **Summary language:** English

**Number of References:** 12

Background: The allergen skin test is commonly used to ensure the **diagnosis** of **allergic** rhinitis even though positive **results** do not necessarily indicate that rhinitis is of allergic origin. Objective: To **determine** the **association** between skin prick reactions and nasal provocation responses to Dermatophagoides pteronyssinus (Der p) allergen extract. Methods: Twenty-six patients with perennial rhinitis and 25 controls...

35/3,K/8 (Item 3 from file: 73)

DIALOG(R)File 73: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0076100743 **EMBASE No:** 1995142906

**Antibodies to complementary peptides as probes for receptors**

McGuigan J.E.

Department of Medicine, Univ. of Florida College of Medicine, Gainesville, FL 32610, United States

**Corresp. Author/Affil:** McGuigan J.E.: Department of Medicine, Univ. of Florida College of Medicine, Gainesville, FL 32610, United States

ImmunoMethods ( IMMUNOMETHODS ) ( United States ) December 1, 1994 , 5/2 (158-166)

**CODEN:** IMUME **ISSN:** 1058-6687

**Item Identifier (DOI):** [10.1006/immu.1994.1050](https://doi.org/10.1006/immu.1994.1050)

**Document Type:** Journal ; Review **Record Type:** Abstract

**Language:** English **Summary language:** English

...antibody binding sites may mimic the actions of the peptide hormone by binding to receptors and evoke cell responses associated with the hormone. A provocative **relationship** was **identified** in the genetic code, which recognized that complementary codons for strongly hydrophobic amino acids code for strongly hydrophilic amino acids. This led to the proposal... ...spanning segments, identified by defined consecutive groupings of hydrophobic and hydrophilic amino acids and the signal transduction mechanisms by which they evoke the intracellular events **leading to physiological responses** characteristically **identified** with the hormone. As for other proteins, the functions of receptor proteins, including the specificity and affinity of their ligand binding, are dictated by their...

35/3,K/9 (Item 4 from file: 73)

DIALOG(R)File 73: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0075665304 **EMBASE No:** 1994091117

**The role of IgE-mediated hypersensitivity in otitis media with effusion**

Corey J.P.; Adham R.E.; Abbass A.H.; Seligman I.

University of Chicago Medical Center, MC 1035, 5841 S Maryland Ave, Chicago, IL 60637, United States

**Corresp. Author/Affil:** Corey J.P.: University of Chicago Medical Center, MC 1035, 5841 S Maryland Ave, Chicago, IL 60637, United States

American Journal of Otolaryngology - Head and Neck Medicine and Surgery ( AM. J. OTOLARYNGOL. HEAD NECK MED. SURG. ) ( United States ) March 29, 1994 , 15/2 (138-144)

**CODEN:** AJOTD **ISSN:** 0196-0709

**Item Identifier (DOI):** [10.1016/0196-0709\(94\)90063-9](https://doi.org/10.1016/0196-0709(94)90063-9)

**Document Type:** Journal ; Article **Record Type:** Abstract

**Language:** English **Summary language:** English

...analysis of specific serum IgE levels was undertaken for 26 allergens on 89 children in the study group and 59 children in the control group. **Results:** The incidence of **allergen** as **diagnosed** by RAST score was higher in children with OME than children in the control group ( $P > .05$ ). There was no **correlation** between positive RAST **scores** and the number of polyethylene-ventilating (PE) tubes previously placed, history of tonsillectomy, history of adenoidectomy, or the character of the effusion (mucous v serous...

35/3,K/10 (Item 1 from file: 155)

DIALOG(R)File 155: MEDLINE(R)

(c) format only 2009 Dialog. All rights reserved.

15536725 **PMID:** 12974191

**In vitro diagnostic evaluation of patients with inhalant allergies: summary of probability outcomes comparing results of CLA- and CAP-specific immunoglobulin E test systems.**

Nepper-Christensen Steen; Backer Vibeke; DuBuske Lawrence M; Nolte Hendrik

Asthma and Allergy Unit, Department of Internal Medicine, Bispebjerg University Hospital, Copenhagen,

Denmark.

Allergy and asthma proceedings - the official journal of regional and state allergy societies ( United States ) Jul-Aug 2003 , 24 (4) p253-8 , ISSN: 1088-5412--Print **Journal Code:** 9603640

Publishing Model Print

**Document type:** Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't

**Languages:** ENGLISH

**Main Citation Owner:** NLM

**Record type:** MEDLINE; Completed

**In vitro diagnostic evaluation of patients with inhalant allergies: summary of probability outcomes comparing results of CLA- and CAP-specific immunoglobulin E test systems.**

...combination of allergen-specific symptoms and a positive SPT. A test concordance of 79% was found between the CLA and CAP test results with a **correlation coefficient** of 0.8. Allergen-specific IgE assay sensitivity of the CLA and CAP systems was similar and allergen dependent, ranging from 67 to 100%. Assay... ..had a negative SPT. The overall concordance between skin tests and in vitro tests was 76% for CLA and 67% for CAP. CLA and CAP **score values** showed good **correlation** and both tests may be useful when skin tests cannot be performed to identify subjects with IgE-mediated allergy. The CLA and CAP assays for... (

39/3,K/1 (Item 1 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

11914419 **Biosis No.:** 199396078835

**Influence of meteorological factors on the air spora**

**Author:** Hasnain Syed M

**Author Address:** Dep. Biological Med. Res., King Faisal Specialist Hosp. Res. Cent., P.O. Box 3354, Riyadh 11211, Saudi Arabia\*\*Saudi Arabia

**Journal:** Grana 32 ( 3 ): p 184-188 1993

**ISSN:** 0017-3134

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Abstract:** An aerobiological study to determine the spectrum of air spora and to identify the **potential aero-allergens** in Auckland, New Zealand was undertaken at three different locations spanning an area of 30 km, encompassing agricultural, horticultural and forested environments within the region... ..location. The fourteen most frequent categories of fungal air spora were selected to study the influences of meteorological factors. Hourly meteorological and spore data were **computed** and the "Spearman Rank" **correlation coefficient** method was used to analyse for relationships. The results showed significant negative correlations between wind speed and basidiospores of Ganoderma, and with the coloured "basidiospores...

39/3,K/2 (Item 1 from file: 73)

DIALOG(R)File 73: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0079623752 **EMBASE No:** 2003331806

**Structure-activity relationships in allergic contact dermatitis. Part III. The sensitizing capacity of substituted phenanthrenequinones: A quantum-mechanical approach**

Hausen B.M.; Elsasser B.; Krohn K.; Loock U.

American Journal of Contact Dermatitis ( Am. J. Contact Dermatitis ) ( United States ) June 1, 2003 , 14/2 (82-89)

**CODEN:** AJCDF **ISSN:** 1046-199X

**Document Type:** Journal ; Article **Record Type:** Abstract

**Language:** English **Summary language:** English

**Number of References:** 35

...at the carbons of the three rings of the PAC will influence the sensitizing power of the molecule. Subsequently, the lowest unoccupied molecular orbital (LUMO) **coefficients** were **calculated** to show whether a **correlation** exists between chemical reactivity and sensitizing capacity. Results: Sensitizing capacity was found to be strong in two PACs, moderate in eight PACs, and weak in... ..ring A) led to a weak sensitizing capacity. The ortho-quinones 1,2-PAC and 9,10-PAC were also weakly sensitizing. In fact, LUMO **coefficient calculations** corroborated a good **correlation** between chemical reactivity and sensitizing capacity. Conclusion: Substitution with methoxy groups at C-7 and/or at C-8 of ring C of 1,4... ..yet-unstudied phenanthrenequinones occurring in plants or trees and having no substituents at C-2 or C-3 of the quinonoid ring must be considered **potentially** strong **allergens**.

42/3,K/3 (Item 2 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

14244934 **Biosis No.:** 199800039181

**Prioritizing testing of organic compounds detected as gas phase air pollutants: Structure-activity study for human contact allergens**

**Author:** Johnson Robert; Macina Orest T; Graham Cynthia; Rosenkranz Herbert S; Cass Glen R; Karol Meryl H (Reprint)

**Author Address:** Univ. Pittsburgh, Grad Sch. Public Health, Cent. Environ. Occup. Health Toxicol., 260 Kappa Drive, Pittsburgh, PA 15238, USA\*\*USA

**Journal:** Environmental Health Perspectives 105 ( 9 ); p 986-992 Sept., 1997 1997

**Medium:** print

**ISSN:** 0091-6765

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Abstract:** ...be identified through their presence in the urban atmosphere and in air pollutant source emissions. Compounds **identified** by this method were screened to **evaluate** their **potential** to act as contact **allergens**. The CASE and MULTICASE computer programs, which are based on the **detection of** structure-activity **relationships** (SAR), were used to evaluate this potential. These **relationships** first are **determined** by comparing chemical structures to biological activity within a learning set comprised of 458 compounds, each of which had been tested experimentally in human trials...

42/3,K/4 (Item 3 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

12915915 **Biosis No.:** 199598383748

## **Latex allergens in glove-powdering slurries**

**Author:** Lundberg M (Reprint); Wrangsjo K; Johansson S G O

**Author Address:** MIAB, Box 97, S-741 00 Knivsta, Sweden\*\*Sweden

**Journal:** Allergy (Copenhagen) 50 ( 4 ): p 378-380 1995 1995

**ISSN:** 0105-4538

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Abstract:** ...the commonly used wet-powdering process in glove manufacturing, powder is applied by dipping gloves in a cornstarch suspension, a slurry. The slurry is a **potential** source of **allergen** contamination of the powder. The protein and latex allergen contents in five different slurries and in extracts from the corresponding latex gloves were measured using the BCA assay and the IgE antibody inhibition assay (EAI assay). Latex allergens were found in all slurries and gloves. No **correlation** between the **values** of protein contents and allergen contents was found. Wet powdering of gloves induces a risk of latex protein contamination of the cornstarch.

42/3,K/5 (Item 4 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

11914420 **Biosis No.:** 199396078836

## **Analysis of exine mineral contents relationships with soil composition and inter-population variability**

**Author:** Dajoz Isabelle (Reprint); Haut Christian

**Author Address:** Ecole Normale Supérieure, Lab. d'Ecologie, CNRS-URA 258, 46 rue d'Ulm, 752 Paris Cedex 05, France\*\*France

**Journal:** Grana 32 ( 3 ): p 176-183 1993

**ISSN:** 0017-3134

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

### **DESCRIPTORS:**

**Miscellaneous Terms: Concept Codes:** ...POTENTIAL ALLERGENS; ... ..SPEARMAN RANK  
**CORRELATION COEFFICIENT METHOD**

42/3,K/6 (Item 1 from file: 73)

DIALOG(R)File 73: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0079865201 **EMBASE No:** 2004050055

## **Increased Thrombin Activity after Allergen Challenge: A Potential Link to Airway Remodeling?**

Terada M.; Kelly E.A.B.; Jarjour N.N.

Pulmon. and Critical Care Med. Sect., Department of Medicine, University of Wisconsin, Madison, WI, United States

**Author email:** nnj@medicine.wisc.edu

**Corresp. Author/Affil:** Jarjour N.N.: Pulmon. and Critical Care Med. Sect., University of Wisconsin, School of Medicine, 600 Highland Avenue, Madison, WI 53792, United States

**Corresp. Author Email:** nnj@medicine.wisc.edu

American Journal of Respiratory and Critical Care Medicine ( Am. J. Respir. Crit. Care Med. ) ( United States )  
February 1, 2004 , 169/3 (373-377)

**CODEN:** AJCME **ISSN:** 0003-0805

**Document Type:** Journal ; Article **Record Type:** Abstract

**Language:** English **Summary language:** English

**Number of References:** 52

**Increased Thrombin Activity after Allergen Challenge: A Potential Link to Airway Remodeling?**

**Medical Descriptors:**

\*

...analysis; enzyme assay; enzyme linked immunosorbent assay; female; fibroblast; human; human cell; inhalation test; lung lavage; male; metabolism; mitogenicity; nonparametric test; pathophysiology; physiology; priority journal; **probability**; prospective study; protein analysis; protein **determination**; protein function; provocation test; sensitivity and specificity

**Orig. Descriptors:**

42/3,K/7 (Item 2 from file: 73)

DIALOG(R)File 73: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0078720881 **EMBASE No:** 2001327212

**Contact allergenic potency: Correlation of human and local lymph node assay data**

Gerberick G.F.; Robinson M.K.; Ryan C.A.; Dearman R.J.; Kimber I.; Basketter D.A.; Wright Z.; Marks J.G.  
Human and Environmental Safety Division, Procter and Gamble, Cincinnati, OH , United States; Zeneca Central Toxicology Laboratory, Alderley Park, Macclesfield, United Kingdom; SEAC Toxicology Unit, Unilever Research, Colworth House, Sharnbrook, Bedford, United Kingdom; Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA, United States

**Corresp. Author/Affil:** Gerberick G.F.: Procter and Gamble Company, Miami Valley Laboratory, 11810 East Miami River Rd, Cincinnati, OH 45252, United States

**Corresp. Author Email:** gerberick.gf@pg.com

American Journal of Contact Dermatitis ( Am. J. Contact Dermatitis ) ( United States ) September 29, 2001 , 12/3 (156-161)

**CODEN:** AJCDF **ISSN:** 1046-199X

**Item Identifier (DOI):** [10.1053/ajcd.2001.23926](https://doi.org/10.1053/ajcd.2001.23926)

**Document Type:** Journal ; Article **Record Type:** Abstract

**Language:** English **Summary language:** English

**Number of References:** 46

Background: Effective toxicologic evaluation of skin sensitization requires that **potential** contact **allergens** are **identified** and that the **likely** risks of sensitization among exposed populations are assessed. By definition, chemicals that are classified as contact sensitizers have the capacity to cause allergic contact dermatitis (ACD) in humans. However, this hazard is not an all-or-nothing phenomenon; clear dose-response **relationships** can be discerned and thresholds **identified** for both the induction of sensitization and the elicitation of ACD. Commonly, these parameters are grouped under the heading of potency, the determination of which...

42/3,K/10 (Item 1 from file: 34)  
DIALOG(R)File 34: SciSearch(R) Cited Ref Sci  
(c) 2009 The Thomson Corp. All rights reserved.

03275072 **Genuine Article#:** NT320 **No. References:** 22  
**WORKSHOP ON STATUS OF TEST METHODS FOR ASSESSING POTENTIAL OF CHEMICALS TO INDUCE RESPIRATORY ALLERGIC REACTIONS**

**Author:** SELGRADE MK; ZEISS CR; KAROL MH; SARLO K; KIMBER I; TEPPER JS; HENRY MC  
**Corporate Source:** US EPA,OFF RES & DEV,HLTH EFFECTS RES LAB,MD 92/RES TRIANGLE PK//NC/27711; NORTHWESTERN UNIV,VET AFFAIRS MED CTR/CHICAGO//IL/60611; UNIV PITTSBURGH/PITTSBURGH//PA/15260; PROCTER & GAMBLE CO,MIAMI VALLEY LABS/CINCINNATI//OH/45247; ZENECA CENT TOXICOL LAB/CHESHIRE//ENGLAND/; MANTECH ENVIRONM TECHNOL INC/RES TRIANGLE PK//NC/00000; US EPA,OFF POLLUT PREVENT & TOX/WASHINGTON//DC/20460

**Journal:** INHALATION TOXICOLOGY , 1994 , V 6 , N3 ( MAY-JUN ) , P 303-319

**ISSN:** 0895-8378

**Language:** ENGLISH **Document Type:** EDITORIAL ( Abstract Available )

**Abstract:** ...a workshop convened by OPPT in collaboration with EPA's Health Effects Research Laboratory to discuss presently available test methods that might be applied to **potential** chemical **allergens** during the PMN process, the types of chemicals that should be considered suspect, and the kinds of research and validation needed to improve our capability... ...IgE test. Chemicals testing positive in this preliminary screen would have to be further evaluated using an animal model of allergic bronchoconstriction in order to **determine** dose-response **relationships** and establish "safe" exposure levels. There was a general consensus that the options currently available for testing chemicals for their potential to induce respiratory allergy...

**Identifiers--**

42/3,K/12 (Item 2 from file: 156)  
DIALOG(R)File 156: ToxFile  
(c) format only 2009 Dialog. All rights reserved.

765431 **NLM Doc No:** NIOSH/00188321 **Sec. Source ID:** NIOSH/00188321  
**Contact Dermatitis and Workers' Compensation: Criteria for Establishing Occupational Causation and Aggravation**

Mathias CGT

**Source:** Journal of the American Academy of Dermatology, Vol. 20, No. 5, Part 1, pages 842-848, 17 references, 1989

**Pub. Year:** 1989

**Coden:** JAADDB

**Languages:** UNSPECIFIED

**Record type:** Completed

**Diagnostic criteria** for **determining probability** that contact **dermatitis arose from** a job related **agent** or was aggravated by such an **agent**, for coverage under workers compensation laws were presented. The criterion were: is the clinical appearance consistent with contact dermatitis; are there workplace exposures to **potential** cutaneous irritants or **allergens**; is the anatomic distribution of dermatitis consistent with the form of cutaneous exposure in relation to the job task; is the temporal relationship between exposure...

42/3,K/13 (Item 1 from file: 53)  
DIALOG(R)File 53: FOODLINE(R): Science

(c) 2009 LFRA. All rights reserved.

01028419 Foodline Accession Number: 653221

**GRAS notification: a case study.**

Kruger C L

Prepared Foods (September), 173 (9), 55-56+58 (0 ref.)

2004

**ISSN Number:** 0747-2536

**Language:** English

**Document Type:** Journal article

**Abstract:** GRAS evaluation of bovine milk-derived lactoferrin is described. Lactoferrin may be a **potential allergen**, since it is derived from milk, a known source of allergenic proteins. Lactoferrin has been approved for use as an antimicrobial spray in several beef... ..known to exist within beef. Results of estimated neutrophil-derived lactoferrin intakes and bovine milk-derived lactoferrin intake from lactoferrin-treated beef carcasses are tabulated. **Determination** of the **likelihood** of an allergic reaction to lactoferrin, intake estimation and GRAS evaluation are considered.

**Section Heading:**

## B. NPL Files, Full-text

**File 20:Dialog Global Reporter 1997-2009/May 18**

(c) 2009 Dialog

**File 149:TGG Health&Wellness DB(SM) 1976-2009/Apr W3**

(c) 2009 Gale/Cengage

**File 444:New England Journal of Med. 1985-2009/May W2**

(c) 2009 Mass. Med. Soc.

**File 129:PHIND(Archival) 1980-2009/May W2**

(c) 2009 Informa UK Ltd

**File 130:PHIND(Daily & Current) 2009/May 18**

(c) 2009 Informa UK Ltd

**File 455:Drug News & Perspectives 1992-2005/Aug**

(c) 2005 Prous Science

Set	Items	Description
S1	1448	(ALLERGEN? ? OR ALLERGIN? ? OR (INFLUENCING OR ATOPIC OR CAUSATIVE? ? OR CAUSING)() (AGENT? ? OR SUBSTANCE? ?) OR ALLERG?(N) (TRIGGER???) (5N) (POTENTIAL? OR CANDIDATE OR SUSPECT??? OR LIKELY OR PROBABLE)
S2	118	S1(5N) (PLURALITY OR GROUP? ? OR NUMBER OR COMBINATION? ? OR SEVERAL OR MANY OR LIST? ? OR MULTIPLE OR NUMEROUS OR MULTITUDE OR SET OR SETS)
S3	221942	(PATIENT OR PATIENTS OR SUBJECT OR SUBJECTS OR INPATIENT? ? OR OUTPATIENT? ? OR PERSON? ? OR INDIVIDUAL? ? OR USER? ?) (3-N) (EXPOSURE? ? OR EXPOSED OR EXPOSING OR EXPERIENC??? OR CONSUMPTION OR CONSUMED OR CONSUMING OR INHALE OR INHALES OR INHALING OR INHALATION OR INJECT??? OR EAT OR EATS OR EATING OR ATE)
S4	6390	(TRIGGER??? CAUSE? ? OR CAUSING OR CAUSAL OR (LEAD? ? OR LEADING OR LED)() TO OR RESULT???) (5N) (ALLERG? OR (PHYSICAL OR - PHYSIOLOGICAL OR BODILY)() (REACTION? ? OR RESPONSE? ? OR EFFECT? ?) OR ATOPY OR ATOPIC OR HYPERSENSITIVITY OR ANAPHYLAXIS - OR ANAPHYLACT?)
S5	31654	((CORRELATION? ? OR STATISTICAL??) SIGNIFICAN??? OR PROBABILITY OR PROBABILITIES OR LIKELIHOOD OR CONFIDENCE OR (STRENG-



TH OR LINEAR OR MAGNITUDE OR DEGREE OR EXTENT OR MEASUR?)(2N)-  
 (ASSOCIATION? ? OR RELATIONSHIP? ?))(3N)(COEFFICIENT? ? OR VA-  
 LUE OR VALUES OR NUMBER? ? OR PERCENTAGE? ? OR SCORE? ?))

S6 1631 S5 (3N)(DETERMIN??? OR CALCULAT??? OR COMPUTE OR COMPUTES  
 OR COMPUTING OR (FIGUR??? OR WORK)()OUT OR ASCERTAIN??? OR ID-  
 ENTIF? OR ESTIMATE? ? OR ESTIMATING)

S7 99699 (CORRELATION? ? OR CONFIDENCE OR STATISTICAL??())SIGNIFICAN-  
 ??? OR PROBABILITY OR PROBABILITIES OR LIKELIHOOD OR ASSOCIAT-  
 ION? ? OR RELATIONSHIP? ?)(5N)(DETERMIN? OR CALCULAT??? OR C-  
 OMPUTE OR COMPUTES OR COMPUTED OR COMPUTING OR COMPUTATION? ?  
 OR (FIGUR??? OR WORK)()OUT OR ASCERTAIN??? OR IDENTIF? OR EST-  
 IMATE? ? OR ESTIMATING)

S8 3938 S7 (3N)(COEFFICIENT? ? OR VALUE OR VALUES OR NUMBER? ? OR -  
 PERCENTAGE? ? OR SCORE? ? OR SCORING)

S9 216 S4(5N)(IDENTIF? OR DIAGNOS? OR PINPOINT? OR PIN()POINT OR -  
 ISOLATE OR ISOLATES OR ISOLATING OR DISTINGUISH??? OR PRONOUN-  
 CE? ? OR PRONOUNCING OR INTERPRET???)

S10 3 (S5 OR S7)(20N)(FOOD? ? OR ALLERG?)(2N)(CHALLENGE()TEST???  
 OR ELIMINATION()DIET? ? OR CAUSE(1W)EFFECT)

S11 16 (CORRELAT? OR PROBABILITY OR LIKELIHOOD OR CONFIDENCE)(5N)-  
 (ALLERG? OR TRIGGER?)(5N)(REACTION? ? OR RESPONSE? ? OR HYPER-  
 SENSITIVIT? OR ATOPY OR ATOPIC)(5N)(DIAGNOS? OR IDENTIF? OR P-  
 INPOINT? OR ISOLAT?)

S12 0 S2 (10N) S3

S13 8 S2 (20N) S4

S14 0 S13 AND (S5 OR S7)

S15 0 S2 (30N)(S6 OR S8)

S16 0 S2 (30N)(S5 OR S7)

S17 1 S2 (20N) S9

S18 7 S1 (10N) S3

S19 2 S1 (20N) S9

S20 47 S1 (20N) S4

S21 0 S20 (20N) (S5 OR S7)

S22 5 S20 AND S9

S23 37 S10 OR S11 OR S13 OR S17 OR S18 OR S19 OR S22

S24 30 S23 NOT PY>2004

S25 28 RD (unique items)

S26 0 S9 (30N)(S6 OR S8)

S27 0 S9 (30N) (S5 OR S7)

S28 0 S4 (20N) (S6 OR S8)

S29 11 S4 (20N)(S5 OR S7)

S30 9 S29 NOT (S23 OR PY>2004)

S31 9 RD (unique items)

S32 0 S1 (30N)(S6 OR S8)

S33 1 S1(30N)(S5 OR S7)

S34 1 S33 NOT (S23 OR S31 OR PY>2004)

S35 0 S2 AND S3 AND S4 AND S9

S36 3 S2 AND S3 AND S4 AND (S5 OR S7)

S37 2 S36 NOT (S23 OR S31 OR S34 OR PY>2004)

S38 2 RD (unique items)

25/3,K/4 (Item 4 from file: 20)

DIALOG(R)File 20: Dialog Global

Reporter

(c) 2009 Dialog. All rights reserved.

12106496

**(USE FORMAT 7 OR 9 FOR FULLTEXT)**

**ELAST**

**Technologies, Inc. Announces Significant Innovation in the Development of Its**

## Allergy Testing Device

BUSINESS

WIRE

July 26, 2000

### Journal Code:

WBWE Language: English Record Type: FULLTEXT

...has successfully enhanced the diagnostic capabilities of its allergy-testing device (the ELAST Device(TM)) through the development of an additional non-invasive method of **exposing** the testing **subject** to a **potential allergen**.

The ELAST Device(TM) is a patented, non-invasive diagnostic tool designed to accurately diagnose allergies, as well as food and chemical sensitivities immediately and...  
...subject's profile of reactions to various substances. "By employing the breakthrough announced today ELAST's scientists now have an alternative non-invasive method of **exposing** the testing **subject** to a **potential allergen**, thereby increasing the opportunities to measure the alteration in the body's electrical response to a sensitivity," stated ELAST Technologies' founder and Chief Scientist Robert...

25/3,K/6 (Item 1 from file: 149)

DIALOG(R)File 149: TGG Health&Wellness

DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

02949271

**Supplier Number:** 111490242 (USE FORMAT 7  
OR 9 FOR FULL TEXT )

**Atopic dermatitis.(Featured CME Topic:**

**Allergy)**

Ahuja, Angela; Land, Kelly; Barnes,

Cheryl J.

Southern Medical Journal , 96

, 11 , 1068(5)

Nov ,

2003

### Publication

**Format:** Magazine/Journal

ISSN: 0038-4348

**Language:** English

**Record Type:** Fulltext **Target Audience:** Professional

**Word Count:** 3625 **Line**

**Count:** 00312

...allergies. When the causal food allergens were removed, the symptoms resolved but could be elicited again if these foods were reintroduced into the diet. (13)

### Diagnostic Testing

Patients with **atopic** dermatitis produce IgE to a wide variety of inhalant, environmental, and food **allergens**. However, the presence of IgE to specific **allergens** does not necessarily **correlate** with **atopic** symptoms on exposure to them. For

instance, the presence of a household dust mite (*D. pteronyssinus*)-specific serum IgE test in atopic patients does not...

25/3,K/7 (Item 2 from file: 149)

DIALOG(R)File 149: TGG Health&Wellness

DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

02949270

**Supplier Number:** 111490241 (USE FORMAT 7  
OR 9 FOR FULL TEXT )

**Asthma.(Featured CME Topic: Allergy)**

Roy, Sitiesh R.

Southern Medical Journal , 96 , 11 ,

1061(7)

Nov ,

2003

**Publication Format:**

Magazine/Journal

ISSN: 0038-4348

**Language:** English

**Record Type:** Fulltext **Target Audience:** Professional

**Word Count:** 4839 **Line**

**Count:** 00487

...conditions, such as emphysema. Upper airway inflammation with nasal pallor or erythema, nasal secretions, mucosal edema, turbinate hypertrophy, and/or nasal polyps as well as **allergic** shiners may be noted on examination. The presence of **atopic** dermatitis/eczema will increase the **likelihood** of finding concomitant asthma.

Pulmonary Function Testing

**Diagnostic** testing in asthma initially involves both clinic-based spirometry and home-based peak flow (PF) monitoring. Clinic-based spirometry is the "gold standard" for the...

25/3,K/9 (Item 4 from file: 149)

DIALOG(R)File 149: TGG Health&Wellness

DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

02944507

**Supplier Number:** 106422250 (USE FORMAT 7  
OR 9 FOR FULL TEXT )

**Key issues for the assessment of the  
allergenic potential of genetically modified foods: breakout group reports.  
(Genetically Modified Foods Mini-Monograph).**

Germolec, Dori R.; Kimber, Ian; Goldman, Lynn;

Selgrade, Mary Jane  
Environmental Health  
Perspectives , 111 , 8 , 1131(9)  
June 15 ,  
2003

**Publication Format:** Magazine/Journal  
**ISSN:**  
0091-6765  
**Language:** English  
**Record Type:** Fulltext  
**Target Audience:** Academic  
**Word Count:**  
10905 **Line Count:** 01001

...vitro and oral challenge results in fish-allergic patients. J Allergy Clin Immunol 89:730-737.

Bernhisel-Broadbent J, Taylor S, Sampson HA. 1989. Cross-**allergenecity** in the legume botanical family in children with food **hypersensitivity**. II. Laboratory **correlates**. J Allergy Clin Immunol 84:701-709.

Bindslev-Jensen C, Poulsen LK. 1997. In vitro **diagnostic** methods in the evaluation of food hypersensitivities. In: Food Allergy: Adverse Reactions to Foods and Food Additives, Second ed. (Metcalf DD, Sampson HA, Simon RA...

25/3,K/10 (Item 5 from file: 149)  
DIALOG(R)File 149: TGG Health&Wellness  
DB(SM)  
(c) 2009 Gale/Cengage. All rights reserved.

02917585  
**Supplier Number:** 73959364 (USE FORMAT 7  
OR 9 FOR FULL TEXT )  
**European Breakthrough in Allergy  
Therapy.(bio-energetic therapy)**

Stone, Tom

Townsend Letter for Doctors and Patients  
, 90  
May ,  
2001

**Publication Format:** Magazine/Journal  
**ISSN:** 1525-4283  
**Language:**  
English  
**Record Type:** Fulltext **Target Audience:**  
Consumer; Professional  
**Word Count:** 2130  
**Line Count:** 00168

...to the chemical presence of a substance or the presence of specific IgA molecules in the blood.

With electro-acupuncture, the testing is done by **exposing** the **patient** to a therapy impulse of the "inverse oscillation" of the **potential** offending **allergens**. Inverse oscillation means that an electronic circuit in a bio-energetic therapy device is used to create the mirror image or inversion of the wave...

25/3,K/11 (Item 6 from file: 149)

DIALOG(R)File 149: TGG Health&Wellness DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

02911061 **Supplier Number:** 58545080 (USE FORMAT 7 OR 9 FOR FULL TEXT )

**When to consider allergy testing for your patients with asthma.**

LI, JAMES T.C.; SHEELER, ROBERT D.

Journal of Respiratory Diseases , 20 , 12 , 802

Dec ,

1999

**Publication Format:** Magazine/Journal

ISSN: 0194-259X

**Language:** English

**Record Type:** Fulltext **Target Audience:** Professional

**Word Count:** 3462 **Line Count:** 00285

...allergy skin tests (or in vitro tests) can be quite helpful in the management of asthma. Skin testing helps you select which patients are most **likely** to benefit from **allergen** avoidance measures, and positive **results** guide the specific recommendations for **allergen** avoidance.

Measures to reduce dust mite allergen levels include removing carpeting from bedrooms, using allergy-proof coverings on mattresses and pillows, lowering the indoor humidity...

...but the test results also can improve adherence to your instructions. This is particularly important because compliance with allergen avoidance measures is difficult for many **patients**.

In our **experience**, **patients** with clinically significant allergies are more **likely** to comply with **allergen** avoidance instructions if the diagnosis has been made definitively by skin testing. With positive test results, you can confidently advise the patient to reduce harmful...

...patient can then focus your time and energy on other components of asthma care, such as medication use or home peak flow monitoring. When the **diagnosis** of asthma is questionable, negative **allergy** skin test **results** may suggest other conditions, such as vocal cord dysfunction.

25/3,K/12 (Item 7 from file: 149)

DIALOG(R)File 149: TGG Health&Wellness DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

02530393 **Supplier Number:** 126073117 (USE FORMAT 7 OR 9 FOR FULL TEXT )  
**If it seems too good to be true ...(Skin Disorders)**

Jancin, Bruce  
Family Practice News , 34 , 21 , 27(1)  
Nov 1 ,  
2004

**Publication Format:** Magazine/Journal

ISSN: 0300-7073

**Language:** English

**Record Type:** Fulltext **Target Audience:** Professional

**Word Count:** 400 **Line Count:** 00035

...diets. And while it's true that some authorities still maintain every patient with chronic idiopathic urticaria ought to go on a rice-and-water/**food elimination diet** at least once, Dr. Jorizzo has been skeptical about the **likelihood** of **identifying** an **allergic** cause ever since he observed British dermatologists conducting studies in which they put patients in a reverse-flow room and placed them on elimination diets...

25/3,K/13 (Item 8 from file: 149)  
DIALOG(R)File 149: TGG Health&Wellness DB(SM)  
(c) 2009 Gale/Cengage. All rights reserved.

02361401 **Supplier Number:** 116187980 (USE FORMAT 7 OR 9 FOR FULL TEXT )  
**Implications for management: four case discussions.**

Journal of Family Practice , 53 , 4 , S15(16)  
April ,  
2004

**Publication Format:** Magazine/Journal; Refereed

ISSN: 0094-3509

**Language:** English

**Record Type:** Fulltext **Target Audience:** Professional

**Word Count:** 7298 **Line Count:** 00721

...chronic skin condition, poorly controlled asthma, or increased risk of anaphylaxis to the skin-test allergen.

Blood or skin testing for specific IgE can confirm **hypersensitivity** to a wide variety of **allergens**; however, test results alone are not **diagnostic** (Table 4). Results must **correlate** with the patient's symptoms and history--the amount of specific IgE in the serum or the size of a skin test wheal is not...

25/3,K/14 (Item 9 from file: 149)  
DIALOG(R)File 149: TGG Health&Wellness

DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

02303845

**Supplier Number:** 111572851 (USE FORMAT 7  
OR 9 FOR FULL TEXT )

**Diet linked to lower childhood**

**asthma.(goodnews: essential natural health news)(Brief Article)**

Better Nutrition , 66 , 1 ,

28(1)

Jan ,

2004

**Document Type:** Brief

Article **Publication Format:** Magazine/Journal

ISSN: 0405-668X

**Language:** English

**Record Type:** Fulltext **Target**

**Audience:** Consumer

**Word Count:** 181

**Line Count:** 00018

...47 food groups. They found that regular whole milk consumption is associated with a 34 percent lower risk of current asthma; and it reduces the **likelihood** of doctor-**diagnosed** asthma and **atopy**--**allergy**--by almost 30 percent. Apples and pears also protected against asthma.

Prior research linking fruit and vegetable intake to better respiratory health suggests the high...

25/3,K/16 (Item 11 from file: 149)

DIALOG(R)File 149: TGG

Health&Wellness DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

02114374 **Supplier Number:**

93609581 (USE FORMAT 7 OR 9 FOR FULL TEXT )

**Peanut allergy: an increasing health risk for children.  
(Primary Care Approaches).**

Jackson, Patricia

L.

Pediatric Nursing , 28 , 5 , 496(4)

Sept-Oct ,

2002

**Publication Format:**

Magazine/Journal; Refereed  
ISSN: 0097-9805  
Language: English

**Record Type:** Fulltext; Abstract **Target Audience:**  
Professional

**Word Count:** 2822

**Line Count:** 00254

...exposure in allergic children and methods of decreasing possible hidden sources of peanut allergens or contamination of cooking or eating areas. Pediatric nurses should also **identify** those children in the primary care setting with higher **probability** of peanut **allergy** due to their history of **atopy**, asthma, other food **allergies**, or family history. Parents should be educated and provided with written material on signs and symptoms of food allergies, anaphylactic reactions, and emergency treatment so...

25/3,K/17 (Item 12 from file: 149)  
DIALOG(R)File 149: TGG  
Health&Wellness DB(SM)  
(c) 2009 Gale/Cengage. All rights reserved.

02098043 **Supplier Number:**  
90607850 (USE FORMAT 7 OR 9 FOR FULL TEXT )

### **Allergy testing.**

Li, James T.  
American Family Physician , 66 , 4 ,  
621  
August 15 ,  
2002

#### **Publication**

**Format:** Magazine/Journal; Refereed  
ISSN: 0002-838X  
**Language:**  
English

**Record Type:** Fulltext; Abstract **Target Audience:**  
Professional

**Word Count:** 2475

**Line Count:** 00233

...to pets).

TABLE 1

Major Indications for Allergy Testing

Condition

Major indication

Rhinitis

Symptoms not controlled by  
medications and allergen avoidance

Asthma

Persistent asthma in **patients**  
**exposed** to perennial indoor **allergens**



<b>Suspected</b> food allergy	Previous <b>suspected</b> systemic reaction to food
Suspected drug allergy	Previous suspected systemic reaction to drug, and clinical indication for suspected drug
Suspected insect sting	Previous suspected systemic...

25/3,K/19 (Item 14 from file: 149)  
 DIALOG(R)File 149: TGG Health&Wellness DB(SM)  
 (c) 2009 Gale/Cengage. All rights reserved.

01977477 **Supplier Number:** 71873761 (USE FORMAT 7 OR 9 FOR FULL TEXT )  
**Residential Exposures Associated With Asthma in US Children.**

Lanphear, Bruce P.; Aligne, C. Andrew; Auinger, Peggy; Weitzman, Michael; Byrd, Robert S.  
 Pediatrics , 107 , 3 , 505  
 March ,  
 2001

**Publication Format:** Magazine/Journal; Refereed  
 ISSN: 0031-4005

**Language:** English

**Record Type:** Abstract **Target Audience:** Academic; Professional

**Author Abstract:** ...among boys (6.7%) than girls (5.1%) and was higher among black children (8.9%) than white children (5.2%). Risk factors for doctor-**diagnosed** asthma included a family history of **atopy** (odds ratio (OR): 2.2; 95% **confidence** interval (CI): 1.5, 3.1), child's history of **allergy** to a pet (OR: 24.2; 95% CI: 8.4, 69.5), exposure to environmental tobacco smoke (OR: 1.8; 95% CI: 1.2-2...

25/3,K/20 (Item 15 from file: 149)  
 DIALOG(R)File 149: TGG  
 Health&Wellness DB(SM)  
 (c) 2009 Gale/Cengage. All rights reserved.

01957471 **Supplier Number:**  
 67372584 (USE FORMAT 7 OR 9 FOR FULL TEXT )

**Health-Care Workers and Latex Allergy.**

ZAK, HEATHER N.; KASTE, LINDA M.;  
 SCHWARZENBERGER, KATHRYN; BARRY, MARK J.; GALBRAITH, GILLIAN M.P.

Archives of Environmental Health , 55 ,  
 5 , 336  
 Sept ,

2000

**Publication Format:**

Magazine/Journal; Refereed

ISSN: 0003-9896

**Language:** English

**Record Type:** Fulltext; Abstract **Target Audience:**

Professional

**Word Count:** 7431

**Line Count:** 00733

...high risk that exists via occupational exposure to latex, healthcare workers must be aware that additional factors, such as those mentioned above, may increase the **probability** of developing latex **hypersensitivity**.

Testing for Latex **Allergy**

**Diagnosis** of latex **allergy** is made from patient history and **diagnostic** tests. Although tests can confirm hypersensitivity, the most important tool for identifying those at risk is a comprehensive medical history. Investigators should question every health...

25/3,K/21 (Item 16 from file: 149)

DIALOG(R)File 149: TGG

Health&Wellness DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

01849497 **Supplier Number:**

55391905 (USE FORMAT 7 OR 9 FOR FULL TEXT )

**Letters to the Editor.**

American Family Physician , 60 ,

2 , 392

August ,

1999

**Publication**

**Format:** Magazine/Journal; Refereed

ISSN: 0002-838X

**Language:**

English

**Record Type:** Fulltext **Target Audience:**

Professional

**Word Count:** 1750

**Line Count:** 00151

...although the technique is still practiced and may not be a benign modality, especially if misused.<sup>6</sup>

When a question concerning true reactivity to a **food** arises, even in the face of positive tests for **food**-specific IgE antibody, the only way to **determine** a **cause** and **effect relationship** is through physician- supervised, double-blind, placebo-controlled oral **food** challenges. This diagnostic method is considered the "gold standard" since physician and patient bias is removed. I suggest that any diagnostic or therapeutic modality be...

25/3,K/23 (Item 18 from file: 149)  
DIALOG(R)File 149: TGG  
Health&Wellness DB(SM)  
(c) 2009 Gale/Cengage. All rights reserved.

01758087   **Supplier Number:**  
19580084 (USE FORMAT 7 OR 9 FOR FULL TEXT )

**When edibles become the enemy(Food Allergies.)**

Sheffer, Albert L.  
Harvard Health Letter , v22 , n9 ,  
p4(2)  
July ,  
1997

**Publication Format:**

Newsletter  
ISSN: 1052-1577

**Language:** English

**Record**

**Type:** Fulltext; Abstract   **Target Audience:** Academic;  
Professional

**Word Count:** 1422

**Line Count:** 00119

...a medical history alone -- is food-induced, exercise-related anaphylaxis. People with this condition develop serious allergic reactions to food only if they exercise after **eating** it. These **individuals** should avoid exercise until 4-6 hours after eating a **potential allergen** and stop exercising if symptoms begin.

Those who are not sure if they have an allergy -- or what they're allergic to -- may be given...

25/3,K/27 (Item 22 from file: 149)  
DIALOG(R)File 149: TGG  
Health&Wellness DB(SM)  
(c) 2009 Gale/Cengage. All rights reserved.

01476970   **Supplier Number:**  
14975448 (USE FORMAT 7 OR 9 FOR FULL TEXT )

**Defending aspartame. (An Aspartame Controversy)**

Moser, Robert H.  
Nutrition Health Review , n68 , p 19(2)  
Wntr ,  
1994

**Publication Format:**

Newsletter  
ISSN: 0164-7202

**Language:** English

**Record**

**Type:** Fulltext   **Target Audience:** Consumer

**Word Count:**

511 **Line Count:** 00053

...hypersensitivity to other foods and ingredients, which may account for allergic symptoms.

The U.S. Food and Drug Administration has reviewed the anecdotal reports of **allergic** reactions thought by the consumer to be associated with the consumption of aspartame. They have not **identified a cause-effect relationship.**

Dr. Margarita Garriga and coworkers from the National Institute of **Allergy** and Infectious Diseases undertook a 32-month study to investigate people with alleged hypersensitivity reactions to aspartame. The researchers advertised in local newspapers and worked...

31/3,K/4 (Item 4 from file: 20)

DIALOG(R)File 20: Dialog Global

Reporter

(c) 2009 Dialog. All rights reserved.

04274657

**(USE FORMAT 7 OR 9 FOR FULLTEXT)**

**Journal of**

**Allergy and Clinical Immunology: February 1999 Highlights**

PR NEWSWIRE

February 08, 1999

**Journal Code:** WPRW

**Language:** English **Record Type:** FULLTEXT

**Word Count:**

1180

**(USE**

**FORMAT 7 OR 9 FOR FULLTEXT)**

...a gelatin-containing DTaP vaccine.

(From: "The Jell-O(R) story." J Allergy Clin Immunol 1999;103: 200-202; and " A clinical analysis of gelatin **allergy** and **determination** of its **causal relationship** to the previous administration of gelatin-containing acellular pertussis vaccine combined with the diphtheria and tetanus toxoids." J Allergy Clin Immunol 1999;103: 321-325...

31/3,K/5 (Item 1 from file: 149)

DIALOG(R)File 149: TGG Health&Wellness DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

02945451 **Supplier Number:** 107756471 **(USE FORMAT 7 OR 9 FOR FULL TEXT )**

**Distribution and determinants of mouse allergen exposure in low-income New York City apartments.(Children's Health Article)**

Chew, Ginger L.; Perzanowski, Matthew S.; Miller, Rachel L.; Correa, Juan C.; Hoepner, Lori A.; Jusino, Carlos M.; Becker, Mark G.; Kinney, Patrick L.

Environmental Health Perspectives , 111 , 10 , 1348(4)

August ,

2003

**Publication Format:** Magazine/Journal

ISSN: 0091-6765

**Language:** English

**Record Type:** Fulltext **Target Audience:** Academic

**Word Count:** 4467 **Line Count:** 00423

...1 (micro)g/g to 184.6 (micro)g/g were assayed with the commercially available Mus m 1 assay (Indoor Biotechnologies, Charlottesville, VA). The **results** from both mouse **allergen** assays were **highly correlated** (Spearman rank **correlation coefficient** = 0.96;  $p < 0.0001$ ), and for these samples, the median concentration of MUP was 3-fold higher than that of Mus m 1. Antigens...

31/3,K/6 (Item 2 from file: 149)

DIALOG(R)File 149: TGG Health&Wellness

DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

02325781

**Supplier Number:** 111895705 (USE FORMAT 7  
OR 9 FOR FULL TEXT )

**The prevalence of latex allergy among  
health care workers in Bolu (Turkey).(International Perspective/Research)**

Ozkan, Ozlem; Gokdogan, Feray

Dermatology Nursing , 15 , 6 , 543(6)

Dec ,

2003

**Publication Format:**

Magazine/Journal; Refereed

ISSN: 1060-3441

**Language:** English

**Record Type:** Fulltext; Abstract **Target Audience:**

Professional

**Word Count:** 3558

**Line Count:** 00363

...to compare the categorical and binomial variables. All probability values were two tailed, and those  $< 0.05$  were considered significant. The odds ratio and 95% **confidence** intervals were **calculated** using the not sensitized group as reference to detect possible risk factors such as sex, history of **allergy**, **atopic** disease, glove use, etc. **Results** are presented using the following nomenclature: 95% CI = 95% **confidence** interval, and OR = **estimated** odds ratio.

**Results**

Prevalence of latex **allergy** or **hypersensitivity** among HCWs was 19.1%. Sixty-three HCWs in the sample responded positively to at least one item of the latex-screening questionnaire.

Among HCWs...

31/3,K/9 (Item 1 from file: 455)

DIALOG(R)File 455: Drug News & Perspectives

(c) 2005 Prous Science. All rights reserved.

00353627 (USE FORMAT 7 FOR FULLTEXT)

**IMMULOGIC UPDATES STATUS OF ALLERVAX RAGWEED TRIALS**

Drug News & Perspectives , R&D Briefs Section [ Unpublished ]

April 24 1996

**Document Type:** Journal **Language:** English **Record Type:** FullText

**Word Count:** 148

ImmuLogic Pharmaceutical Corp. reported April 18, 1996, positive

**results** from its Allervax Ragweed 1995 **allergy** season trials.

These **results** showed a **statistically significant** reduction in symptom **scores** in the treatment group receiving four 750-mcg doses of Allervax Ragweed compared to placebo. The company has recently designed a pivotal phase III trial...

34/3,K/1 (Item 1 from file: 149)

DIALOG(R)File 149: TGG Health&Wellness

DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

02939921

**Supplier Number:** 99185855 (USE FORMAT 7  
OR 9 FOR FULL TEXT )

**A human dendritic cell-based method to  
identify CD(4.sup.+) T-cell epitopes in potential protein allergens.**

**(Mini-Monograph).**

Stickler, Marcia; Mucha,

Jeanette; Power, Scott; Harding, Fiona

Environmental

Health Perspectives , 111 , 2 , 251(4)

Feb ,

2003

**Publication Format:** Magazine/Journal

ISSN:

0091-6765

**Language:** English

**Record Type:** Fulltext

**Target Audience:** Academic

**Word Count:** 4708

**Line Count:** 00380

...and 139-153 (8.5%).

(FIGURE 3 OMITTED)

Figure 3B shows the distribution of responses to the Cry3Aa peptide set. No responses were significant.

HLA **associations** were not **determined** because of the low number of responding donors.

Discussion

We tested a known food allergen, Brazil nut 2S storage protein Ber e 1, and two **potential** food **allergens**, Cry1Ab and Cry3Aa, in our epitope mapping assay. We found that the Brazil nut protein contained one major epitope in the light-chain and at...

38/3,K/1 (Item 1 from file: 149)

DIALOG(R)File 149: TGG Health&Wellness

DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

02944504

**Supplier Number:** 106422247 (USE FORMAT 7  
OR 9 FOR FULL TEXT )

**Clinical and laboratory investigation of  
allergy to genetically modified foods. (Genetically Modified Foods  
Mini-Monograph).**

Bernstein, Jonathan A.;

Bernstein, I. Leonard; Bucchini, Luca; Goldman, Lynn R.; Hamilton, Robert G.;

Lehrer, Samuel; Rubin, Carol; Sampson, Hugh A.

Environmental Health Perspectives , 111

, 8 , 1114(8)

June 15 ,

2003

**Publication Format:** Magazine/Journal

ISSN: 0091-6765

**Language:**

English

**Record Type:** Fulltext **Target Audience:**

Academic

**Word Count:** 9926

**Line Count:** 00869

...challenges, an itchy, red, morbilliform (measles-like) rash develops within 10 to 90 min of allergen ingestion (Sampson and McCaskill 1985). Repeated ingestion of the **allergen** may **result** in the development of an itchy, eczematous rash (Sampson 1992).

Food allergy can cause both upper and lower respiratory symptoms (Bock 1992; James et al...breathing) consistent with acute allergic reaction to a food product seeks medical care, the treatment is usually symptomatic, the episode is often isolated, and the **potential allergen** is seldom identified. The **number** of such medical visits is not tabulated. Even repeat visits for allergic reactions to well-known allergens such as peanuts or milk are not counted...

...animal consumption was identified in products on grocery-store shelves, there was no way to easily determine if consumption of this genetically engineered protein was **resulting** in **allergic** reactions in humans (Bucchini and Goldman 2002).

In a coordinated effort to determine if StarLink corn was indeed responsible for adverse human health effects, the...

...and 30 November 2000 that mentioned consumption of a corn product. With all personal identifiers removed, these reports were sent to CDC for review to **determine** the **likelihood** that any of the reports were potentially related to StarLink.

CDC developed a case definition that included a) a suspected anaphylactic reaction (e.g., dizziness...

...RS. 1967. Allergic gastroenteropathy: a cause of excessive gastrointestinal protein loss. N Engl J Med 276:761-769.

Yocum MW, Khan DA. 1994. Assessment of **patients** who have **experienced** anaphylaxis: a 3-year survey. Mayo Clin Proc 69:16-23.

Young E, Stoneham MD, Petruckevitch A, Barton J, Rona R. 1994. A

population study...

**File 15:ABI/Inform(R) 1971-2009/May 18**  
(c) 2009 ProQuest Info&Learning  
**File 9:Business & Industry(R) Jul/1994-2009/May 18**  
(c) 2009 Gale/Cengage  
**File 610:Business Wire 1999-2009/May 19**  
(c) 2009 Business Wire.  
**File 810:Business Wire 1986-1999/Feb 28**  
(c) 1999 Business Wire  
**File 275:Gale Group Computer DB(TM) 1983-2009/Apr 23**  
(c) 2009 Gale/Cengage  
**File 624:McGraw-Hill Publications 1985-2009/May 18**  
(c) 2009 McGraw-Hill Co. Inc  
**File 621:Gale Group New Prod.Annou.(R) 1985-2009/Apr 14**  
(c) 2009 Gale/Cengage  
**File 636:Gale Group Newsletter DB(TM) 1987-2009/Apr 28**  
(c) 2009 Gale/Cengage  
**File 613:PR Newswire 1999-2009/May 19**  
(c) 2009 PR Newswire Association Inc  
**File 813:PR Newswire 1987-1999/Apr 30**  
(c) 1999 PR Newswire Association Inc  
**File 16:Gale Group PROMT(R) 1990-2009/Apr 28**  
(c) 2009 Gale/Cengage  
**File 160:Gale Group PROMT(R) 1972-1989**  
(c) 1999 The Gale Group  
**File 634:San Jose Mercury Jun 1985-2009/May 15**  
(c) 2009 San Jose Mercury News  
**File 148:Gale Group Trade & Industry DB 1976-2009/May 05**  
(c) 2009 Gale/Cengage

Set	Items	Description
S1	1977	(ALLERGEN? ? OR ALLERGIN? ? OR (INFLUENCING OR ATOPIC OR CAUSATIVE? ? OR CAUSING)() (AGENT? ? OR SUBSTANCE? ?) OR ALLERG?(N) (TRIGGER???) (5N) (POTENTIAL? OR CANDIDATE OR SUSPECT??? OR LIKELY OR PROBABLE)
S2	121	S1(5N) (PLURALITY OR GROUP? ? OR NUMBER OR COMBINATION? ? OR SEVERAL OR MANY OR LIST? ? OR MULTIPLE OR NUMEROUS OR MULTITUDE OR SET OR SETS)
S3	517502	(PATIENT OR PATIENTS OR SUBJECT OR SUBJECTS OR INPATIENT? ? OR OUTPATIENT? ? OR PERSON? ? OR INDIVIDUAL? ? OR USER? ?) (3-N) (EXPOSURE? ? OR EXPOSED OR EXPOSING OR EXPERIENC??? OR CONSUMPTION OR CONSUMED OR CONSUMING OR INHALE OR INHALES OR INHALING OR INHALATION OR INGEST??? OR EAT OR EATS OR EATING OR ATE)
S4	7925	(TRIGGER??? CAUSE? ? OR CAUSING OR CAUSAL OR (LEAD? ? OR LEADING OR LED)() TO OR RESULT???) (5N) (ALLERG? OR (PHYSICAL OR PHYSIOLOGICAL OR BODILY)() (REACTION? ? OR RESPONSE? ? OR EFFECT? ?) OR ATOPY OR ATOPIC OR HYPERSENSITIVITY OR ANAPHYLAXIS - OR ANAPHYLACT?)
S5	58077	((CORRELATION? ? OR STATISTICAL??) SIGNIFICAN??? OR PROBABILITY OR PROBABILITIES OR LIKELIHOOD OR CONFIDENCE OR (STRENGTH OR LINEAR OR MAGNITUDE OR DEGREE OR EXTENT OR MEASUR?) (2N) - (ASSOCIATION? ? OR RELATIONSHIP? ?) (3N) (COEFFICIENT? ? OR VALUE OR VALUES OR NUMBER? ? OR PERCENTAGE? ? OR SCORE? ?))
S6	4375	S5 (3N) (DETERMIN??? OR CALCULAT???? OR COMPUTE OR COMPUTES OR COMPUTING OR (FIGUR??? OR WORK)() OUT OR ASCERTAIN??? OR IDENTIF? ? OR ESTIMATE? ? OR ESTIMATING)
S7	197245	(CORRELATION? ? OR CONFIDENCE OR STATISTICAL??) SIGNIFICAN??? OR PROBABILITY OR PROBABILITIES OR LIKELIHOOD OR ASSOCIATION? ? OR RELATIONSHIP? ?) (5N) (DETERMIN? OR CALCULAT???? OR COMPUTE OR COMPUTES OR COMPUTED OR COMPUTING OR COMPUTATION? ?



OR (FIGUR??? OR WORK)()OUT OR ASCERTAIN??? OR IDENTIF? OR EST-  
IMATE? ? OR ESTIMATING)

S8 10960 S7 (3N)(COEFFICIENT? ? OR VALUE OR VALUES OR NUMBER? ? OR -  
PERCENTAGE? ? OR SCORE? ? OR SCORING)

S9 257 S4(5N)(IDENTIF? OR DIAGNOS? OR PINPOINT? OR PIN()POINT OR -  
ISOLATE OR ISOLATES OR ISOLATING OR DISTINGUISH??? OR PRONOUN-  
CE? ? OR PRONOUNCING OR INTERPRET???)

S10 9 (S5 OR S7)(20N)(FOOD? ? OR ALLERG?)(2N)(CHALLENGE()TEST???  
OR ELIMINATION()DIET? ? OR CAUSE(1W)EFFECT)

S11 14 (CORRELAT? OR PROBABILITY OR LIKELIHOOD OR CONFIDENCE)(5N)-  
(ALLERG? OR TRIGGER?)(5N)(REACTION? ? OR RESPONSE? ? OR HYPER-  
SENSITIVIT? OR ATOPY OR ATOPIC)(5N)(DIAGNOS? OR IDENTIF? OR P-  
INPOINT? OR ISOLAT?)

S12 0 S2 (10N) S3

S13 4 S2 (20N) S4

S14 0 S2 (20N) (S6 OR S8)

S15 0 S2 (20N) (S5 OR S7)

S16 0 S2 (20N) S9

S17 0 S2 AND S3 AND S4 AND (S5 OR S7)

S18 0 S2 AND S3 AND S9 AND (S5 OR S7)

S19 0 S2 (30N)(S6 OR S8)

S20 0 S2 (40N)(S5 OR S7)

S21 49 S1 (20N) S4

S22 0 S21 AND (S6 OR S8)

S23 0 S21 AND (S5 OR S7)

S24 2 S21 AND S9

S25 1 S21 AND S3

S26 23 (S10 OR S11 OR S13 OR S24 OR S25) NOT PY>2004

S27 17 RD (unique items)

S28 2 S2 AND S9

S29 5 S1 (30N) S9

S30 0 S1 (30N) (S6 OR S8)

S31 1 S1 AND (S6 OR S8)

S32 5 S1 (40N) (S5 OR S7)

S33 0 S9 AND (S6 OR S8)

S34 2 S9 AND (S5 OR S7)

S35 1 S4 (30N) (S6 OR S8)

S36 13 S4 (30N)(S5 OR S7)

S37 15 (S28-S36) NOT (S27 OR PY>2004)

S38 10 RD (unique items)

27/3,K/1 (Item 1 from file: 15)

DIALOG(R)File 15: ABI/Inform(R)

(c) 2009

ProQuest Info&Learning. All rights reserved.

01970158

47560866

**Asthma induced by  
alcoholic drinks: A new food allergy questionnaire**

Vally, Hassan; De Klerk, Nick;

Thompson, Philip J

Australian & New Zealand

Journal of Public Health

v23n6 pp: 590-594

Dec 1999

**ISSN: 1035-7319 Journal**

**Code: AUP**

**Word Count: 3336**

**Abstract:**

...extent of this problem is unclear. In this study, a new food allergy questionnaire was designed to specifically investigate the prevalence and characteristics of asthmatic **reactions triggered** by alcoholic drinks, as well as other **foods** and chemicals. **Responses** to the FAQ were found to **correlate** highly with assessment by clinical interview for all of the parameters assessed. Specifically, the FAQ **identified** reactions to alcoholic drinks with a coefficient of agreement of 88.9%, a sensitivity of 100%, and a specificity of 83.3%. Responses to the...

27/3,K/2 (Item 2 from file: 15)

DIALOG(R)File 15: ABI/Inform(R)

(c) 2009 ProQuest Info&Learning. All rights reserved.

01788459 04-39450

**Kick that habit (the virtual way)**

Brody, Herb

Technology Review v102n2 pp: 29

Mar/Apr 1999

**ISSN:** 1099-274X **Journal Code:** TCR

**Word Count:** 223

**Text:**

...immersive virtual reality rig. While a headset displays a video from a laser disc, sensors monitor respiration rate, pulse rate, perspiration and skin temperature; therapists **correlate** spikes in bodily **responses** to particular scenes from the videodisc. Once the **triggers** are **identified**, TRI subjects its clients to the most provocative scenes over and over again. By watching the instrumentation readouts, the subjects learn to suppress their cravings...

27/3,K/4 (Item 2 from file: 9)

DIALOG(R)File 9: Business &

Industry(R)

(c) 2009 Gale/Cengage. All rights reserved.

01251626

Supplier Number: 23849984 (USE FORMAT 7 OR 9

FOR FULLTEXT)

**Glove standard expected soon**

(Publication of European standards regarding the composition and labeling of natural rubber latex gloves is expected by end-1997 )

European Rubber Journal , v 179

, n 4 , p 21

April 1997

**Document Type:** Journal

**ISSN:** 0266-4151 ( United Kingdom )

**Language:**

English **Record Type:** Fulltext

**Word Count:**

721 (USE FORMAT 7 OR 9 FOR FULLTEXT)

**TEXT:**

...Measurements and Testing research programme, by a team from Vienna, with links to Erlangen, Copenhagen and Helsinki, said Lange.

Further work is needed here on **correlating allergic reactions** with residual protein and chemicals and on **diagnostic** methods hence Lange's WG 3 supports the various groups across Europe working on such projects and TC 205 will request financial support from the...

27/3,K/8 (Item 1 from file: 636)

DIALOG(R)File 636: Gale Group Newsletter

DB(TM)

(c) 2009 Gale/Cengage. All rights reserved.

02650463

**Supplier Number:** 45368704 (USE FORMAT 7  
FOR FULLTEXT)

**When Fishing for Allergies, Allergists  
Advise Casting a Wider Net**

Genesis Report-Dx

, v 4 , n 5 , p N/A

March , 1995

**Language:** English **Record Type:** Fulltext

**Document Type:** Newsletter ; Trade

**Word Count:**

349

-

...backs by prick skin testing are a more accurate indication of an allergy than a blood test for antibodies.

The detection of an antigen-antibody **reaction** by a blood test does not necessarily mean that an **allergy** exists. As one **diagnostic** industry authority said, "There isn't a one-to-one **correlation** between a positive **reaction** and an **allergy**

. Some people may have the antibodies present, but this doesn't mean that they'll become allergic. Sensitivities vary among people."

Prick skin tests are...

27/3,K/9 (Item 2 from file: 636)

DIALOG(R)File 636: Gale Group Newsletter

DB(TM)

(c) 2009 Gale/Cengage. All rights reserved.

02018398

**Supplier Number:** 43650102 (USE FORMAT 7  
FOR FULLTEXT)

**FOOD/DRUG DICHOTOMY IS PROBLEM FOR  
NUTRACEUTICALS INDUSTRY**

Food Chemical News

, v 34 , n 51 , p N/A

Feb 15 , 1993

**Language:** English **Record Type:** Fulltext

**Document Type:** Newsletter ; Trade

**Word Count:**

898

...chided De Felice. "But there's a whole other world out there -- like

fatigue, sleep, mood, arthritis, memory loss -- that I am quite certain **food** has a role in. You'd have to be a cretin not to believe it."

Amen urged the universities to focus on increased

**identification of cause and effect**

**relationships** leading to new **food** production opportunities.

"We can't everybody just home in on cardiovascular disease and cancer," he said. "There are a myriad of other diseases out there..."

27/3,K/10 (Item 1 from file: 813)

DIALOG(R)File 813: PR Newswire

(c) 1999

PR Newswire Association Inc. All rights reserved.

0390964 NY061

### **ASTHMA PATIENT ADVOCACY GROUP URGES CAUTION ON DRUG REPORTS**

**Date:** August 9, 1991

19:39 EDT **Word Count:** 55

#### **Correction:**

...journals, as the merits of the unpublished findings are impossible for physicians and other scientists to evaluate otherwise," said Martha White, M.D., a pediatric **allergist** and researcher at the National Institutes of Health.

"Retrospective epidemiological studies usually are not designed to **determine cause-and-effect relationships**," Dr.

White added.

The American College of **Allergy** and Immunology, in a statement released Thursday, said that beta-2 agonists "are safe and effective for the treatment of asthma, and patients taking the..."

27/3,K/12 (Item 2 from file: 16)

DIALOG(R)File 16: Gale Group

PROMT(R)

(c) 2009 Gale/Cengage. All rights reserved.

09798016

**Supplier Number:** 86138360 (USE FORMAT 7  
FOR FULLTEXT)

**Predisposition to atopic symptoms to  
inhaled antigens may protect from childhood type 1 diabetes.  
(Epidemiology/Health Services/Psychosocial Research).**

Mattila, Petri S.; Tarkkanen, Jussi; Saxen, Harri;

Pitkaniemi, Janne; Karvonen, Marjatta; Tuomilehto, Jaakko

Diabetes Care , v 25 , n 5 , p 865(4)

May , 2002

**Language:** English

**Record Type:** Fulltext

**Document Type:** Magazine/Journal;

Refereed ; Professional

**Word Count:** 2819

-

...by uniform criteria because it entitles the patient to a reimbursement for asthma medication granted by the Finnish Social Insurance Institute. The criteria for asthma **diagnosis** are based on the recommendations

of the American Thoracic Society.

Self-reported **atopic** symptoms may not always have a good **correlation** with objective findings of **atopy**, such as skin-prick tests or serum **allergen** specific or total IgE (9). Although symptoms of respiratory **allergy** have been shown to have a better **correlation** with serum **allergen** specific or total IgE than symptoms of **atopic** dermatitis (11), the evaluation of self-reported symptoms of allergy to inhaled antigens is restricted in that it may reflect a broader range of hypersensitivity...

27/3,K/13 (Item 3 from file: 16)

DIALOG(R)File 16: Gale Group

PROMT(R)

(c) 2009 Gale/Cengage. All rights reserved.

08682781

**Supplier Number: 75211510 (USE FORMAT 7 FOR FULLTEXT)**

**Reporting without repercussions.(health care industry safety)**

Morrissey, John

Modern Healthcare , v 31 , p 18

May 28 , 2001

**Language:** English

**Record Type:** Fulltext

**Document Type:** Magazine/Journal ;

Professional

**Word Count:** 2059

...a safe dose.

Targeting improvements

Using its sophisticated clinical information system and expertise from physicians on staff at LDS Hospital in Salt Lake City, Intermountain **identified** drugs that have the same basic therapeutic effect but vary in their **likelihood** to cause an **allergic reaction**. A computerized ordering system was programmed to alert physicians to the relatively dangerous drugs and suggest alternatives, James says. That was one way to decrease...

27/3,K/14 (Item 1 from file: 160)

DIALOG(R)File 160: Gale Group

PROMT(R)

(c) 1999 The Gale Group. All rights reserved.

00724843

**The Glutamate Assn, a group of manufactures, marketers and users of MSG and other glutamic acid salts, has denounced a study linking MSG to an asthmatic response in sensitive individuals as an unfounded food scare.**

Food Development

January, 1982 p. 10

...to such a delayed symptom. The research made no provision for a placebo effect from administration of MSG in capsules or to account for other **potential** asthma-causing **allergens** that **subjects** may have been **exposed** to in the 12 hrs following

ingestion of the capsules.

27/3,K/15 (Item 1 from file: 634)

DIALOG(R)File 634: San Jose Mercury

(c) 2009 San Jose Mercury News. All rights reserved.

05092234

**DIETARY SUPPLEMENT TIED TO BLOOD DISORDER**

SAN JOSE MERCURY NEWS ( SJ ) - Sunday, November 12, 1989

**By:** Associated Press

**Edition:** Morning Final Street **Section:** Front **Page:** 16A

**Word Count:** 230

**Text:**

...consumers to temporarily discontinue using the dietary supplement L-Tryptophan after numerous reports of a blood disorder associated with the over-the-counter drug.

The **Food** and Drug Administration, which issued the warning, said a joint investigation with the Centers for Disease Control has not **determined** a **cause-and-effect association** with the blood condition but ''affected persons in most of the cases have reported taking L-Tryptophan products before becoming ill.''

38/3,K/1 (Item 1 from file: 810)

DIALOG(R)File 810: Business Wire

(c)

1999 Business Wire . All rights reserved.

0576606 BW0145

**RPT IMMULOGIC :**

**REPEAT/ImmuLogic reports first quarter results and updates status of ALLERVAX CAT phase III clinical trial**

April

18, 1996

**Byline:** Business Editors

...plan for a complete scientific presentation of the data at appropriate medical meetings in the coming months."

Also during the quarter, the company reported positive **results** from its ALLERVAX RAGWEED 1995 **allergy** season trials. These **results** showed a **statistically significant**

reduction in symptom **scores** in the treatment group receiving four 750 ug. doses of ALLERVAX RAGWEED, compared to placebo. The company has recently designed a pivotal phase III trial...

38/3,K/3 (Item 1 from file: 621)

DIALOG(R)File 621: Gale Group New

Prod.Annou.(R)

(c) 2009 Gale/Cengage. All rights reserved.

03307493

**Supplier Number:** 94156054 (USE

**FORMAT 7 FOR FULLTEXT)**

**Study Suggests Cockroach**

**Sensitization Linked To Asthma Morbidity in Urban Elderly; Elderly Sensitized to Cockroach Allergens Experience Increased Airway Obstruction and Hyperinflation.**

PR Newswire , p DCTU02212112002

Nov 12 , 2002

**Language:**

English **Record Type:** Fulltext

**Document Type:**

News wire ; Trade

**Word Count:** 602

...to indoor allergens had decreased pulmonary function. No relationship was found between pulmonary function and outdoor allergen sensitization.

Spirometry and plethysmography tests were used to **determine** the **association** between pulmonary function and patients' sensitivity to CR **allergens**. **Results** showed that airflow, as measured by forced expiratory air volume, was significantly lower in patients with CR sensitivity (CR+) as compared to patients without CR...

38/3,K/7 (Item 1 from file: 813)

DIALOG(R)File 813: PR Newswire

(c) 1999

PR Newswire Association Inc. All rights reserved.

1418787 HSM088

**Journal of Allergy and Clinical Immunology: February 1999**

**Highlights**

**Date:** February 8, 1999

20:56 EST **Word Count:** 1,211

**Correction:**

...a gelatin-containing DTaP vaccine.

(From: "The Jell-O(R) story." J Allergy Clin Immunol 1999;103: 200-202; and " A clinical analysis of gelatin **allergy** and **determination** of its **causal relationship** to the previous administration of gelatin-containing acellular pertussis vaccine combined with the diphtheria and tetanus toxoids." J Allergy Clin Immunol 1999;103: 321-325...

38/3,K/8 (Item 1 from file: 16)

DIALOG(R)File 16: Gale Group PROMT(R)

(c)

2009 Gale/Cengage. All rights reserved.

10345966 **Supplier**

**Number:** 99272466 (USE FORMAT 7 FOR FULLTEXT)

**GA subset served: some granuloma annulare patients respond positively to Tx with tacrolimus ointment. (Clinical Dermatology).**

Stephenson, Michelle

Dermatology Times , v 24 , n 3 , p 37

March , 2003

**Language:** English

**Record Type:** Fulltext

**Document Type:** Magazine/Journal ;

Trade

**Word Count:** 668

...contraindicated, such as intertriginous regions. "This medication is very safe to use. In fact, it was initially studied and approved for pediatric patients who have **atopic** dermatitis," she said.

While these **results** are positive, the researchers feel that a larger study is necessary to **determine** with better **confidence** the **percentage** of patients likely to respond to this treatment.

38/3,K/9 (Item 2 from file: 16)

DIALOG(R)File 16: Gale Group PROMT(R)

(c)

2009 Gale/Cengage. All rights reserved.

07092088 **Supplier**

**Number:** 59278206 (USE FORMAT 7 FOR FULLTEXT)

**Home truths.(Brief Article)**

Chemist & Druggist , p I

Feb 5 , 2000

**Language:** English

**Record Type:** Fulltext

**Article Type:** Brief Article

**Document Type:** Magazine/Journal ; Professional Trade

**Word**

**Count:** 2840

-

...blockage, and can also be used for challenge tests to confirm whether an allergen causes rhinitis.

Clinical history

A good clinical history is vital for **diagnosis** of an **allergy**. False positive and negative **results** are possible, albeit rarely, but a thorough history combined with appropriate tests will confirm which allergens are responsible for an allergic disease. Blood tests performed...a protocol for questioning an allergy sufferer on their allergen. Develop a protocol each for asthma, allergic rhinitis and eczema.

2. In your practice workbook **list potential** avoidance action for different **allergens**. Are they reasonable enough for sufferers to adhere to them?

3. What treatment do you recommend for perennial allergies? Discuss these with your medicine counter...

38/3,K/10 (Item 1 from file: 148)

DIALOG(R)File 148: Gale Group Trade &

Industry DB

(c) 2009 Gale/Cengage. All rights reserved.

13206691

**Supplier Number:** 71632565 (USE  
FORMAT 7 OR 9 FOR FULL TEXT )

**Sensitisation, asthma, and a**

**modified Th2 response in children exposed to cat allergen: a population-based**



**cross-sectional study.**

Platts-Mills, Thomas;

Vaughan, John; Squillace, Susan; Woodfolk, Judith; Sporik, Richard

Lancet , 357 , 9258 , 752

March 10 , 2001

ISSN: 0099-5355

**Language:**

English

**Record Type:** Fulltext; Abstract

**Word Count:**

5766 **Line Count:** 00510

**Abstract:** The authors report on children's exposure to cat and mite allergens to **determine** the **relationship**, if any, to later development of asthma. They found that early exposure to these allergens, particularly cat allergen, can stimulate immunoglobulin responses without increasing sensitivity...

**Abstract:**

...were available from all of them. Assessment of sensitisation to cat or mite allergen was based on RAST or skin tests because we wished to **identify** all the children who were **allergic**. In accordance with previous **results**, sensitisation to mite increased with increasing exposure(1,7,22) (table 1). On examination the results and the published data we found that the difference...

## V. Additional Resources Searched

### A. Google:

House dust mite-induced histamine release from washed blood cells

Evaluation of effect parameters

H. MOSBECH<sup>1</sup> P. STAHL SKOV\*

<sup>1</sup> Allergy Unit, Medical Dept. TTA, State University Hospital \*Institute of Pharmacology, University of Copenhagen, Copenhagen, Denmark

Correspondence to H. Mosbech, M.D., Allergy Unit, Medical Dept. TTA, Rigshospitalet, 2200 Copenhagen N, Denmark

#### KEYWORDS

bronchial challenge • *Dermatophagoides pteronyssinus* • histamine release

#### ABSTRACT

In a selected group of 60 house dust mite allergic asthmatics, the correlation between the bronchial sensitivity to house dust mite and effect parameters of mite-induced histamine release from washed blood cells was evaluated. Using a sensitive glass microfibre-based method, a significant positive correlation ( $r = 0.60$ ;  $P < 0.001$ ) was found between bronchial allergen sensitivity and basophil cell sensitivity expressed as the house dust mite concentration necessary to give half the maximum histamine release. No correlation was found between bronchial sensitivity and other parameters of the histamine release response. This way of determining the histamine release from washed blood cells is a simple and valuable alternative to bronchial allergen challenge.

Accepted for publication 28 May 1987

#### DIGITAL OBJECT IDENTIFIER (DOI)

10.1111/j.1398-9995.1987.tb00382.x About DOI

---

### B. ProQuest

*TEXT(allerg\* w/3 (potential\* or candidate or suspect\* or likely or probable) w/5 (plurality or group or number or combination or several or many or list or multiple or numerous or multitude or several or set or sets)) AND TEXT((trigger\* or caus\*) w/5 ((allergic or adverse or physical or physiological or bodily) w/3 (reaction\* or response\* or effect\* or atopy or atopic of hypersensitivity))) AND TEXT((correlation\* or association or "statistical significance" or probability or probabilities or likelihood or relationship) w/5 (determin\* or calculat\* or compute or computes or computing or computed or identif\* or estimate or estimating)) AND TEXT(diagnos\* or pinpoint\* or isolat\* or pronouc\*) AND PDN(<3/30/2004)*

#### Prevalence of food allergies in young adults and their relationship to asthma, nasal allergies, and eczema

Rosalie K Woods, Frank Thien, Joan Raven, E Haydn Walters, Michael Abramson. Annals of Allergy, Asthma, and Immunology. Palatine: Feb 2002. Vol. 88, Iss. 2; pg. 183, 7 pgs

#### Abstract (Summary)

**BACKGROUND:** The true prevalence of food allergy in adults is generally thought to be uncommon. It is unknown whether there are any relationships between food allergy and atopic diseases. **OBJECTIVE:** To

determine the prevalence of probable immunoglobulin (Ig)E-mediated food allergy to peanut, shrimp, cow's milk, wheat, and egg as defined by a positive skin prick test result and relevant clinical history to the same food, and to explore the relationship with atopic diseases. **METHODS:** Cross-sectional epidemiologic study. One thousand one hundred forty-one randomly selected young adults (aged 20 to 45 years) underwent skin prick testing to five common food allergens (cow's milk, peanut, egg white, shrimp, and wheat), completed a detailed questionnaire, including validated items on respiratory symptoms, history of asthma and other allergic conditions, as well as undergoing lung function testing. **RESULTS:** Just over one percent (1.3%, n = 15) had probable IgE-mediated food allergy. The prevalence of probable IgE food allergy was: <0.27% for wheat, 0.09% (95% confidence interval = 0.0 to 0.49%) each for cow's milk and egg, 0.53% (0.21 to 1.09%) for shrimp, and 0.61% (0.25 to 1.26%) for peanut. Those with probable IgE peanut and shrimp allergy were significantly more likely to have current asthma and doctor-diagnosed asthma. Wheeze and history of eczema were also associated with peanut allergy, whereas nasal allergies were associated with shrimp allergy. **CONCLUSIONS:** The prevalence of probable IgE-mediated food reactions is rare in young adults. Some positive associations between probable IgE-mediated food allergy and allergic diseases were found, but larger study numbers are required to confirm these results.

### **Food allergy**

Hugh A Sampson. JAMA. Chicago: Dec 10, 1997. Vol. 278, Iss. 22; pg. 1888, 7 pgs

#### **Abstract (Summary)**

The evaluation of adverse reactions to foods involving abnormal immune responses to food allergens remains an important part of the practice of allergy and immunology. Approximately 5% of children younger than 3 years and 1.5% of the general population experience food allergic disorders, indicating that about 4 million Americans suffer from food allergies. The evaluation of adverse reactions to foods depends on a careful clinical history, diagnostic studies including appropriate skin testing or in vitro testing with food extracts, and/or endoscopy and biopsy. The mainstay of therapy remains avoidance of incriminated foods and education to deal with inadvertent exposures. Experience over the past decade suggests that the ready availability and early introduction of highly allergenic foods (eg, peanuts and nuts) into the diet will only increase the number of individuals suffering from hypersensitivity reactions to foods. Research has focused on the identification and characterization of allergenic proteins and the development of new therapeutic strategies, eg, plasmid DNA vaccines, to treat these disorders.

### **Primer on Allergic and Immunologic Diseases: Chapter 6--Food Allergies**

Sampson, Hugh A, Metcalfe, Dean D. JAMA. Chicago: Nov 25, 1992. Vol. 268, Iss. 20; pg. 2840, 5 pgs

#### **Abstract (Summary)**

Food allergies are diseases characterized by an abnormal response to specific food allergens and are divided into two categories--disorders that are mediated by IgE molecules and those that occur by non-IgE-mediated mechanisms. The diagnosis and treatment of food allergies are discussed.